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Chapter I.  General Introduction 
I. Adenylyl Cyclases  
1. General Introduction  
1.1 Mammalian Adenylyl Cyclases 
In intracellular signaling pathways adenosine 3’,5’-cyclic monophosphate (cAMP) is a 
key player as second messenger in the response to first messenger signaling 
molecules such as neurotransmitters, hormones, and odorants. Until recently, the 
signaling by this archetypal second messenger was considered to be understood and 
straightforward, but fifty years after its discovery by Earl Sutherland cAMP regulation 
has become very complex. By direct activation of nucleotide-gated ion channels and 
stimulation of protein phosphorylation via activation of protein kinase A (PKA), cAMP 
is known to be involved in modulation of membrane potential and the rate of cell 
division1,2,3. Independently of any phosphorylation, cAMP also induces protein-
protein interactions, e.g. in signaling of Rap1 proteins4,5. The high complexity of 
synthesis and degradation of the second messenger is also due to a multiplicity of 
phosphodiesterases and adenylyl cyclase (AC) isoforms.  
The modulation of AC activity is the key step in intracellular cAMP regulation by 
extracelluar stimuli. In mammals, the major ACs are integral plasma-membrane 
proteins; they catalyze the synthesis of cAMP and pyrophosphate (PPi) by 
conversion of adenosine 5’-triphosphate (ATP)6,7,8. ACs act as effector enzymes 
integrating extracelluar signals by G-protein coupled receptors (GPCRs) to a variety 
of intracellular signaling pathways9,10. The classic receptor-G-protein-AC signal 
transduction cascade is characterized by a large excess of G-proteins compared to 
receptor and effector molecules (Fig. 1). Therefore, G-proteins are the major 
amplification factor of the GPCR signal11,12 and the AC molecules are the limiting 
component for maximum second messenger production in response to hormone 
stimulation10,13. Although ACs do not contribute extensively to the amplification of 
intracellular signaling, they participate in diverse manners to integrate signaling 
pathways and cross-talks in different cell systems14,15.  
Once, in 1968, the signal cascade proposed by Robinson et al. was considered to be 
simple2, but today, the growth in knowledge about ACs and stoichiometric 
relationships between the membranous components leads to better understanding of 
this fundamental area of pharmacological research.  
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Fig. 1. Transmembrane signal transduction  
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Stoichiometric relationship of receptor-G-protein-effector molecules in the β-adrenergic-receptor 
mediated signal transduction was adapted based on the results of Post et. al.11,12. The basic 
transmembrane signal transduction cascade (GPCR – G-protein – AC) is shown by the receptor (2.1 x 
106 β-AR molecules/cell), Gsα in large excess (35 x 106 molecules/cell), and AC protein (6 x 106 AC 
molecules/cell). Based on these results similar ratios were hypothesized for other signaling systems12.  
Structure of adenylyl cyclases 
After the first cloning of a mammalian adenylyl cyclase gene by Krupinski et al., so 
far, nine closely related isoforms of membrane-bound ACs (mACs) and one soluble 
form (sAC) have been cloned and characterized in mammals15,16,17,18. Although each 
AC isoform exhibits its own tissue distribution and special biochemical properties, 
they all share the same three-dimensional structure with a large homology in their 
amino acid sequence8,19,20. All mACs consist of two hydrophobic stretches with six 
proposed α-helices each (M1 and M2) in the plasma membrane and of two 
cytoplasmatic domains C1 and C2 forming together the catalytical core of ACs 
(Fig. 2). These intracellular domains are further divided into “a” and “b” 
subdomains21. The units of C1a and C2a are responsible for ATP binding and 
catalysis as assessed by systematic mutational analysis19. Moreover, the ~230 amino 
acid long region of C1a and C2a shares 50 % to 90 % high sequence homology 
 2
Chapter I.  General Introduction 
among different AC isoforms. The subdomains C1b and C2b display less conserved 
regions among mammalian ACs. Recent studies may serve for better understanding 
of these subunits, proposing a role as isoform-specific regulatory domains, especially 
for C1b22. The knowledge about the transmembrane domains is still rather limited 
with the exception of their membrane anchoring function and coordination of C1/C2 
interaction6,23.  
It should be noted that the soluble AC isoform in mammals is structurally different 
from membranous ACs and related to cyanobacterial ACs15,24. Interestingly, inhibition 
of sAC may be useful as male contraceptives, because sAC is important for 
spermatocyte function25. 
Fig. 2. Structure of membranous adenylyl cyclases 
Schematic model of the proposed structure of membrane-bound adenylyl cyclase6,19,23 shows the N-
terminus (N), two hydrophobic domains (M1 and M2) with six transmembrane spans each, two 
cytosolic domains (C1 and C2) and the C-terminus (C). The intracellular domains are further divided 
into C1a/C1b and C2a/C2b. The catalytical core is formed by C1a and C2a. 
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Tissue distribution and (patho)physiological functions 
Due to low expression levels of mACs and the lack of high-quality antibodies, the 
exact determination of the tissue distribution of AC isoforms is difficult to assess. 
Although each mAC isoform exhibit its own unique form of tissue distribution in terms 
of mRNA, some overlap is observed. All mammalian AC isoforms are expressed in 
the central nervous system, and especially mACs 1, 2, and 8 are mainly expressed in 
the brain26 and implicated in synaptic plasticity, memory, learning, and long-term 
potentiation (LTP)27. Furthermore, AC2 is predominantly expressed in the lungs. For 
olfaction, the major AC isoform in the olfactory neuroepithelium is AC328. 
Interestingly, AC5 and AC6 are equally expressed in the heart at birth, but in 
adulthood AC5 becomes the major cardiac isoform29. Moreover, a further specific 
tissue distribution of AC5 and AC6 was observed in the kidney, mainly in the Medulla 
renalis30. The other mACs 4, 7, and 9 are widely expressed in several tissues, like 
brain, lung, kidney, or liver31.  
Knockout (KO) and transgenic animal models for AC research are feasible tools to 
assess the functional relevance of specific isoform expression in different tissues32. 
The results of KO-studies may be discussed controversially, i.e. AC1-KO mice 
showed impaired cerebellar LTP and somatosensory cortex development33. In 
contrast, the AC1-KO mice were protected against neuronal toxicity by ionotropic 
glutamate receptors34. Accordance is achieved to large extent for AC5-KO results. In 
a model of heart failure, AC5-KO improves heart function35. Furthermore, these mice 
were protected against stress and showed reduced chronic pain responses as well 
as increased longevity36. Thus, AC1/5 inhibitors may be useful drugs for the 
treatment of various age-related ailments including heart failure, neurodegenerative 
diseases, stroke and chronic pain37.  
Finally, experiments with AC3-KO mice indicated anosmia38 and AC8-KO mice 
revealed altered stress-induced anxiety responses39. So far, no experiments with 
AC4 and AC9 KO mice are reported. 
AC regulation mechanisms  
Overall, the regulation mechanisms of ACs are not simple and straightforward. In 
fact, in detail, the modulations are very diverse and complex due to the different 
regulatory properties of each AC isoform19,40. The best understood mechanism of AC 
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regulation is characterized by agonist activated GPCRs and subsequent stimulation 
of Gsα41. Although this signaling pathway is a common regulatory mechanism for 
activation of all AC isoforms, the affinity for Gsα is different for each isoform. A very 
potent and direct activator of mACs 1 – 8 is the diterpene forskolin (FS) from the 
roots of the Indian plant Coleus forskohlii40,42, but AC9 is not activated by FS43.  
G-proteins are also modulators for AC inhibition in an isozyme-specific manner, i.e. 
Giα inhibits AC5, AC6 and calmodulin-stimulated AC144. AC2 is not influenced by 
Giα45. The βγ-subunits of G-proteins exhibit an inhibitory effect on ACs 1, 5, and 6, 
but a stimulatory effect on ACs 2, 4, and 718. Protein kinases are a further instrument 
in AC regulation. Due to direct phosphorylation by cAMP-dependant protein kinase, 
AC5 and AC6 are inhibited. AC phosphorylation by PKA disrupts binding of Gsα to 
AC, causing inactivation46.  
In contrast to PKA, protein kinase C (PKC) activates several AC isoforms (ACs 1, 2, 
3, 5 and 7). The stimulatory effect of PKC-mediated phosphorylation on the activity of 
these specific ACs is synergistic with the stimulation by FS and Gsα15. However, the 
activity of Gsα-stimulated AC4 and AC6 is reduced by PKC47. Moreover, the divalent 
cations of Mg2+ and Mn2+ exhibit different stimulatory effects on all mAC isoforms48. 
Another important divalent cation, especially in complex with calmodulin (CaM), is 
Ca2+. The Ca2+/CaM complex directly activates AC isoforms 1, 3, and 8 by a putative 
binding site located closely to the catalytical core of ACs49 and integrates into a high 
synergism with Gsα stimulation50. In contrast, the closely related isoforms of AC5 and 
AC6 are inhibited by physiological concentrations of Ca2+-ions in submircomolar 
concentrations. All other AC isoforms are inhibited by supraphysiological Ca2+ levels 
(submillimolar concentrations)51. Because of the different patterns of regulation and 
specificity of the regulatory mechanism, individual AC isoforms are relevant in 
specific tissues and subcellular localization. Thus, the most abundant mAC isoforms 
in the brain are Ca2+/CaM-activated ACs facilitating distribution of signals mediated 
by cAMP. ACs 1 and 8 play an important role in memory function and LTP9,52. In 
comparison to CaM-activated ACs, AC5 and AC6, mainly expressed in the heart, are 
inhibited by Ca2+. AC activation is followed by activation of L-type Ca2+ channels and 
an increase of intracellular Ca2+ concentrations in the heart. This increase of Ca2+ 
displays a downstream and negative feedback in regulatory mechanism in AC 
catalysis.  
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Catalytic mechanism of mACs 
Crystallographic and mutational studies have shown the fundamental requirement of 
the cytosolic domains C1 and C2 for maximum AC catalysis in the presence of 
activators like FS and Gsα.(Fig. 3)53.  
Fig. 3. Crystal structure of catalytic domains VC1 and IIC2  
VC1 
FS binding site 
IIC2 
Gsα  
ATP binding site 
Crystallography of catalytic domains of C1 from AC5 (VC1) and C2 from AC2 (IIC2) together with Gsα 
adapted from Mou et al.53. The VC1 and IIC2 domains are colored tan and mauve, Gsα is shown as a 
red cylinder. FS and the ATP substrate analog MANT-GTP are drawn as stick models. The two Mn2+ 
ions are shown as metallic orange spheres.  
Although the two domains C1 and C2 are very homologous to each other, they 
possess different functional properties54. The interface between C1/C2 domains is 
formed by interacting polar and charged regions. In the C2 domain asparagine 1025 
and aspartic acid 1029 are the two most crucial amino acid residues for catalysis 
identified by mutagenesis and kinetic studies. However, these two amino acids are 
not conserved in the C1 domain, e.g. exchange by tyrosine for Asp102555. Mutation 
of Asp354 in AC1 leads to almost complete loss of catalytical activity19. In addition, 
Lys1067 (AC2) located in the carboxyl-terminal region, is a further crucial amino acid 
and confers specificity to adenine56. Recent studies illustrate that mutations of some 
 6
Chapter I.  General Introduction 
residues at C2 (Ile1010Met, Lys1014Asn, Pro1015Glu, AC5) leading to constitutive 
activation of AC and increased association of C1/C257,58. The precise alignment of 
these residues forming the catalytic core is required for substrate binding (ATP) and 
catalysis (cAMP formation). Thus, different AC regulators change the relative 
orientation of C1/C2 and the position of these active site residues within the 
catalytical binding pocket. A model for the enzymatic mechanism of AC was firstly 
proposed by Tang and Hurley8. They hypothesized that AC cycles between several 
conformational states (Fig. 4).  
Fig. 4. Proposed model of the catalytic cycle of AC 
A schematic representation of the proposed catalytic cycle of AC adapted from Tang and Hurley is 
shown8. Activators cause conformational change in the enzyme to go from the inactive (AC) to the 
substrate-free activated state (AC*). In its active state, the enzyme is inactive for catalysis, but open 
for the substrate ATP. ATP binding leads to further conformational changes. Now, this active 
substrate-bound state (AC**-ATP) allows the catalytic reaction to cAMP and pyrophosphate (PPi) 
(AC** - cAMP, PPi) in the closed conformation. After catalysis and release of the products (cAMP 
followed by PPi) AC returns to the substrate-free activated state (AC** and AC*) and eventually to its 
ground state (AC). 
The model includes at least three conformational states, i.e. an inactive state (AC), a 
substrate-free activated state (AC*), and a substrate/product-bound state (AC**-ATP 
and AC**-cAMP, PPi). ACs convert ATP to cAMP without a covalently enzyme-bound 
intermediate with turnover numbers of 1 to 100 sec-1 59. The enzymatic reaction is 
sequential and bireactant requiring Mg2+-ATP and free Mg2+ 60. The key step in the 
reaction mechanism proceeds by the inversion of configuration at the α-phosphate, 
consistent with a direct in-line displacement of pyrophosphate by attack of the 3’-OH 
on the α-phosphate59. The catalytic cycle is proposed as follows: the catalytic region 
(C1/C2) of AC undergoes a conformational transition (AC→AC*) that is promoted by 
AC AC* AC** cAMP,PPi AC** ATP
AC** AC** PPi 
cAMP 
PPi 
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activators like FS or Gsα, or is blocked by inhibitors like Giα. Although with ~10-fold 
lower affinity than for ATP, AC binds to GTP, but it is not used as a substrate. 
Therefore, substrate binding (ATP) has to induce a further conformational change 
(AC*→AC**) which enables the enzyme to confirm its substrate (proof reading) and 
proceed through catalysis. After the conversion, the AC* state could reform either 
before or after release of the product. The release of cAMP first may be favorable. 
Further structural characterization of the conformational changes on activation and 
during the enzyme reaction cycle will be critically important.  
Furthermore, AC may exist in different catalytic, inactive, and transitional states of 
conformation8,58. Stabilization of different conformations of AC may significantly 
change the binding mode of ATP and in consequence the catalytic activity of AC in 
an isozyme-specific manner. Nevertheless, the precise molecular mechanism of AC 
catalysis is still incomplete understood, due to the lack of crystallographic structures 
of holo ACs with substrate or substrate analogs. 
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1.2 Bacterial Adenylyl Cyclases 
Exotoxin AC of Bordetella pertussis (CyaA) 
Expression of ACs is not limited to mammals and extended to other organisms like 
bacteria8. Interestingly, mammalian sAC exhibit high homology to AC of 
cyanobacteria15,24. In the evolutionary perspective, ACs of bacteria are the ancestors 
of mammalian second messenger signaling systems. Especially, cyanobacteria and 
their precursors are known to be one of the oldest species populated on Earth, dating 
back to more than three billion years61. Beside the appearance of intracellular ACs in 
bacteria, secretions of some bacteria contain exotoxin ACs as well. One 
representative AC exotoxin is CyaA of Bordetella pertussis, the bacterium causing 
whooping cough, a highly contagious acute disease of the respiratory tract62,63.  
Whooping cough (or pertussis) is both, the name and the most dominant symptom of 
this illness affecting young infants most severely. According to the literature, the first 
description of a whooping cough epidemic in France was in 1578 by Guillaume de 
Baillou64. Other descriptions like the Perinthus cough go back to Hippocrates (around 
400 B.C.) and may also indicate whooping cough65. The clinical course is divided into 
three stages. After the incubation period (5 to 10 days) the illness starts with the 
catarrhal phase and lasts usually 1 to 2 weeks characterized by low-grade fever, 
rhinorrhea and progressive cough. The subsequent stage is determined by the 
paroxysmal phase (several weeks), causing severe spasmodic cough episodes with 
a characteristic whoop with cyanosis and vomiting. In between the attacks the 
patients often perform normally. Paroxysmal attacks occur more frequently at night 
with an average of 15 attacks per 24 hours. Although young infants (under 6 months 
of age) may not have the strength to whoop, they could exhibit paroxysms of 
coughing. A further risk of an absent cough is displayed by spells of apnoea66. The 
third and last phase of reconvalescence (1 to 3 weeks) is characterized by a 
continuous decline of the cough before the patient returns to normal. However, 
paroxysms could recur with subsequent respiratory infections for many months after 
the onset of pertussis. In general, fever only occurs minimally in the course of 
infection.  
Infection results in colonization and rapid multiplication of Bordetella pertussis on the 
mucous membranes of the respiratory tract. The immobile and aerobic bacterium 
produces a number of virulence factors, which includes adenylyl cyclase toxin 
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(CyaA), pertussis toxin, filamentous haemagglutinin, fimbriae, tracheal cytotoxin, 
pertactin and dermonecrotic toxin. The bvg locus regulates the expression of these 
factors and assures the compound synthesis in response to certain environmental 
stimuli67.  
The key virulence factor of Bordetella pertussis is represented by the adenylyl 
cyclase toxin CyaA62,63. The exotoxin consists of 1706 amino acids and is divided into 
two functional parts. The N-terminal domain (400 amino acids) contains the active 
center for catalysis and the 1300 amino acid C-terminal domain interacts with 
eukaryotic host cells for delivery of the catalytic domain into the cytosol68. Moreover, 
the C-terminal residue possesses low hemolytic activity63. The endogenous calcium 
sensor calmodulin (CaM) activates CyaA toxin with high affinity by forming salt 
bridges, hydrogen bonds, and hydrophobic interactions69. After activation of the 
bacterial adenylyl cyclase a massive production of the second messenger cAMP from 
ATP is catalyzed70. The supraphysiological level of cAMP disrupts the endogenous 
signal transduction, inhibits phagocyte function, and facilitates respiratory tract 
infection by Bordetella pertussis71. Substrate analogs of ATP may be used to inhibit 
the catalytic activity of CyaA72 and prophylaxis of Bordetella pertussis infection. 
20 – 40 million cases of pertussis infections are diagnosed per year world-wide, with 
a 90% ratio of occurrence in developing countries and estimated 200,000 – 400,000 
fatalities each year73. However, over the last decade many industrial nations observe 
a re-emergence of whooping cough, even in countries with high vaccination 
coverage. Older children and adults are susceptible to be infected again because of 
waning naturally derived and vaccine-induced immunity. Thus, infection frequency is 
probably highest in adolescents and adults and in consequence those age groups 
are the main source of infection for infants62. In combination with an increase in 
tiredness for primary vaccination of infants and secondary vaccination of adults, this 
fact is alarming74. For classical antibiotic therapy drugs like azithromycin and 
clarithromycin are recommended. 
Nevertheless, toxemia and antibiotic-resistant strains of conventional antibiotic 
treatment set application limits, demanding more effective drugs for the prophylaxis 
of whooping cough.  
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Exotoxin AC of Bacillus anthracis (Edema factor) 
Another interesting field of research is the AC exotoxin edema factor (EF) of the 
bacterium Bacillus anthracis75. This bacterium causes the infectious disease of 
anthrax in humans and animals76. Bacillus anthracis is one of only a few bacteria 
forming long-lived spores75, which could survive for many decades or even centuries 
in a hostile environment. Thus, herbivorous mammals like cloven-hoofed animals are 
probably infected by ingesting or inhaling the spores while eating grass. Humans can 
also be infected by the bacilli by three different modes (ingestion, inhalation, 
cutaneous lesions), causing distinct clinical symptoms based on its site of entry. If 
bacteria enter a cut or abrasion on the skin, cutaneous anthrax (the most common 
type) includes symptoms of a raised, itchy blister which eventually becomes a 
painless necrotic ulcer. This type of anthrax responds well to early therapy with 
antibiotics. Gastrointestinal anthrax is rare, but humans can acquire this form from 
eating meat contaminated with Bacillus anthracis or their spores. Typical symptoms 
are stomach pain, bloody diarrhea, nausea, and blood vomit. After the invasion of the 
bowel system the bacteria spread through the bloodstream throughout the body. 
Compared to cutaneous anthrax, gastrointestinal anthrax therapy is less successful 
and results in a mortality rate of 25 % to 60 %. The least common but most 
threatening infection pathway is by inhalation. This type of anthrax has also been 
called wool sorter’s disease because it is an occupational hazard for people who sort 
wool, inhaling spore-bearing dust. Spores are further transported through the air 
passages into the alveoli in the lungs. Picked up by macrophages, the bacilli enter 
the lymph nodes in the central chest cavity, where the spores transform into active 
reproducing bacteria. The respiratory infection with cold or flu-like symptoms is rarely 
treated efficiently, causing death rate of nearly 100 %77. A lethal infection is reported 
by inhalation of about 2,500 – 55,000 spores78, depending on the host species. 
Moreover, this type of infection is disreputably used in biological warfare79 and in 
terroristic attacks80.  
The discovery of Bacillus anthracis is based on the research of the German physician 
Robert Koch in the 1870s, who was the first to draw the conclusion that a bacterium 
causes a disease in mammals. The scientist cultivated the anthrax organisms taken 
from dead farm animals on microscopic slides and demonstrated the relation 
between bacillus and disease by the growing bacteria into long filaments.  
The gram-positive Bacillus anthracis exerts its deleterious effects by production of 
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three major exotoxins: EF, protective antigen, and lethal factor75. EF and lethal factor 
enter host cells via a complex with membrane-associated protective antigen, which 
acts as a pH-dependent protein transporter. Lethal factor, a specific zinc-
metalloprotease, inactivates mitogen-activated protein kinase81. EF possesses ~800 
amino acid residues and an apparent molecular mass of ~89 kDa and is a CaM-
dependent AC82. After entering host cells, EF forms a complex with CaM, the 
mammalian regulatory protein, (as described before with CyaA toxin), that mediates 
many aspects of calcium-regulated signaling83. The binding of CaM induces a major 
conformational change in the catalytic domain of EF82. This rearrangement renders 
EF highly efficient at catalyzing the conversion of ATP into cAMP, disrupting 
intracellular signaling pathways through excessive activation of cAMP-dependent 
signaling pathways84. Thus, EF mediates the efflux of water out of the cells, resulting 
in edema (explanation for the name: edema factor).  
In spite of limitations in antibiotic treatment the disruption of the infection cascade by 
inhibition of EF72b is a feasible tool to prevent the massive onset of anthrax. The 
impairment of the second messenger signaling is an entirely new approach in finding 
new drugs against exotoxins like EF. 
1.3  Research aims in this thesis 
The aim of our studies presented in this thesis was initially the synthesis of ATP 
substrate analogs based on methylanthraniloyl-derived nucleotides as high potent 
AC inhibitors. Moreover, newly synthesized compounds were characterized on 
mammalian ACs 1, 2 and 5 and bacterial AC toxin CyaA, regarding inhibition potency 
and selectivity by pharmacological AC assays to validate this enzymes as potential 
drug targets. For better understanding of the catalytic site and mode of action for AC 
inhibition, fluorescence spectroscopy, crystallography and molecular modeling 
support our investigations.  
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Chapter II.  Introduction 
II. Potent inhibition of mammalian adenylyl cyclases by 
anthraniloyl-derived nucleotidesϕζ 
1. Introduction 
Mammals express nine membranous AC isoforms that play an important role in 
signal transduction1,2. ACs are activated by the G-protein Gs via receptors for 
hormones and neurotransmitters and catalyze the production of the second 
messenger cAMP.  
ACs 1-8 are also activated by the diterpene, forskolin (FS)1-3. The analysis of AC 
knock-out mice provided important insights into the function of specific AC isoforms 
and potential therapeutic applications of AC inhibitors2b. Currently, there is much 
interest in ACs 1 and 5. Specifically, AC1 knock-out mice are protected against 
neuronal toxicity mediated by ionotropic glutamate receptors4,5. AC5 knock-out mice 
are protected against heart failure and stress and show reduced chronic pain 
responses as well as increased longevity6,7,8. Thus, AC1/5 inhibitors may be useful 
drugs for the treatment of various age-related ailments including heart failure, 
neurodegenerative diseases, stroke and chronic pain6,9,10. 2’,3’-O-(N-
Methylanthraniloyl) (MANT)-substituted nucleotides are competitive AC 
inhibitors11,12. ACs 1 and 5 are more sensitive to inhibition by MANT-nucleotides than 
AC212. MANT-GTPγS inhibits recombinant ACs 1 and 5 expressed in Sf9 insect cells 
with Ki values of ~30 – 60 nM12 and blocks activation of voltage-dependent calcium 
channels in cardiomyocytes via AC510.  
                                                          
Moreover, MANT-nucleotides are fluorescence probes13. In the presence of forskolin, 
MANT-nucleotides promote assembly of the purified catalytic subunits of mammalian 
AC (C1 subunit of AC5 (VC1) and C2 subunit of AC2 (IIC2)), giving rise to a direct 
MANT-nucleotide fluorescence increase and FRET between Trp1020 in IIC2 and the 
MANT-group14,15. Enzymatic, fluorescence, crystallographic and molecular modeling 
studies showed that ACs exhibit a high degree of conformational flexibility, allowing 
the catalytic site to accommodate structurally diverse bases12,16,17. 
The aim of the present study was to identify even more potent AC1/5 inhibitors than 
ϕ  This chapter is in revision for publication in Molecular Pharmacology, 2009 
ζ  Crystallographic study was carried out by Melanie Hübner, Department of Pharmacology and Toxicology, 
University of Regensburg, Germany; Studies of AC subunits of C1/C2 were carried out by Dr. Cibele Pinto, 
Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA. 
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MANT-GTPγS and to better understand their mechanism of action. To achieve the 
aim, we examined the effects of 21 (M)ANT-nucleotides on recombinant ACs 1, 2, 
and 5 expressed in Sf9 insect cells (Fig. 1). 
In addition, we examined the interactions of (M)ANT-nucleotides with VC1/IIC2 in 
terms of enzyme inhibition, co-crystallography, and fluorescence spectroscopy. It 
would have been desirable to examine the homologous C1 and C2 subunits from 
ACs 1, 2 and 5, but to this end, we have not yet achieved this ambitious goal (data 
not shown). Nonetheless, in view of the high degree of homology of the catalytic C1 
and C2 subunits of ACs 1, 2 and 5, respectively1,14, the VC1/IIC2 system is a valid 
general model for membranous ACs. 
In 2’,3’-MANT-nucleotides, the MANT-group spontaneously isomerizes between the 
2’- and 3’-position of the ribosyl residue13. Therefore, we also studied the defined 3’-
MANT-2’-d- and 2’-MANT-3’-d-isomers of MANT-GTP (2 and 3) and MANT-ATP (6 
and 7). Moreover, given the high affinity of MANT-ITPγS (9) for AC5 (Ki = 31 nM)12, 
we studied MANT-ITP (8), differing from MANT-GTP (1) only by the lack of a NH2-
group at C2 of the purine ring. For comparison, we studied MANT-XTP (10) which 
inhibits VC1/IIC2 (also briefly referred to as C1/C2) much less potently than MANT-
GTP14. Considering the relatively high potency of 2’,3’-O-(2,4,6-trinitrophenyl)-UTP 
and 2’,3’-O-(2,4,6-trinitrophenyl)-CTP for VC1/IIC2 (Ki ~100 – 300 nM)15, we 
examined the interaction of C1/C2 with MANT-UTP (11) and MANT-CTP (12) as well. 
ANT-nucleotides differ from MANT-nucleotides by the lack of the methyl group at the 
anthraniloyl residue and were used for the fluorescence analysis of various 
proteins13. Therefore, we included various ANT-nucleotides (14 and 15, 21) into our 
studies. Finally, the length of the polyphosphate tail critically determines the affinity of 
AC for 2’,3’-substituted nucleotides12. Thus, we examined several (M)ANT-NDPs 
(15 – 19) and (M)ANT-NMPs (20, 21), too.  
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Fig. 1. General structure of 2’,3’-ribosyl modified nucleotides 
 (M)ANT- nucleotide R1 R2 base
OOPOPHO
O
OH
O
OH
0   2
R2R1
1'
2'3'
4'
5'
S
 
1 MANT-GTP MANT / OH 
 2 3’-MANT-2’-d-GTP MANT H 
 3 2’-MANT-3’-d-GTP H MANT 
4 MANT-GTPγS MANT / OH  
N
NN
N
NH2
adenine
uracil
NH
N
O
O
NH
NN
N
O
hypoxanthine
cytosine
N
N
NH2
O
NH
NN
N
O
guanine
NH2
Bases:
2 2
NH
N
H
N
N
O
xanthine
2
O
5 MANT-ATP MANT / OH 
 
6 3’-MANT-2’-d-ATP MANT H 
 7 2’-MANT-3’-d-ATP H MANT 
 8 MANT-ITP MANT / OH 
9 MANT-ITPγS MANT / OH  
10 MANT-XTP MANT / OH 
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11 MANT-UTP MANT / OH 
 12 MANT-CTP MANT / OH 
 14 ANT-ATP ANT / OH 
15 ANT-ADP ANT / OH  
16 MANT-ADP MANT / OH 
 17 MANT-IDP MANT / OH 
 
NHCH3
O
O
MANT:
NH2
O
O
ANT: 18 MANT-UDP MANT / OH 
 19 MANT-CDP MANT / OH 
20 MANT-IMP MANT / OH  
21 ANT-IMP ANT / OH 
 
Represented are the three pharmacophores contributing to the inhibitor potencies of these nucleotides, i.e. the base, the phosphate chain and the (M)ANT-
group. Nucleotides differed from each other in the base (guanine, hypoxanthine, xanthine, adenine, uracil and cytidine), γ-phosphate chain substitution 
(phosphate or thiophosphate), phosphate chain length (5’-triphosphate, 5’-diphosphate, 5’-monophosphate analogs), ribosyl substituent (MANT or ANT), 
and in the position of the MANT-group (2’- and 3’-MANT). 
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2. Materials and Methods 
2.1. Materials 
Mono-substituted (M)ANT-NTPs of MANT-ATP (5), MANT-ITP (8), MANT-UTP (11), 
MANT-CTP (12), ANT-ATP (14), and MANT-NDPs of ANT-ADP (15), MANT-ADP 
(16), MANT-IDP (17), MANT-UDP (18), MANT-CDP (19), and MANT-NMPs of 
MANT-IMP (20), ANT-IMP (21) were synthesized according to Hiratsuka18 as 
previously described19,20. Under the basic reaction conditions (M)ANT-NTP 
derivatives were partially decomposed to its corresponding diphosphates. Because of 
their putative inhibitory effects they were isolated as well. For detailed description of 
synthesis and purification see Experimental section.  
MANT-GTP (1), 3’-MANT-2’-d-GTP (2), 2’-MANT-3’-d-GTP (3), MANT-GTPγS (4), 3’-
MANT-2’-d-ATP (6), 2’-MANT-3’-d-ATP (7), MANT-ITPγS (9), MANT-XTP (10), and 
ANT-GTP (14) were obtained from Jena Bioscience, Jena, Germany. Methylisatoic 
anhydride, isatoic anhydride, ATP, ITP, CTP, UTP, IMP and bovine serum albumin, 
fraction V, highest quality, were purchased from Sigma-Aldrich (Seelze, Germany). 
MnCl2 tetrahydrate (highest quality) and Aluminum oxide 90 active, (neutral, activity 
1; particle size, 0.06 - 0.2 mm) were from MP Biomedicals (Eschwege, Germany). [α-
32P]ATP (800 Ci/mmol) was purchased from PerkinElmer, Rodgau Jügesheim, 
Germany. Forskolin was supplied by LC Laboratories (Woburn, MA). For all 
experiments double-distilled water was used. Catalytic AC subunits VC1 and IIC2 
and GTPγS activated Gsα (Gsα-GTPγS) were expressed and purified as described21.  
2.2 Cell culture and membrane preparation 
Cell culture and membrane preparation were performed as previously described22. 
Briefly, Sf9 cells were cultured in SF 900 II medium supplemented with 5 % (vol/vol) 
fetal bovine serum and 0.1 mg/ml gentamicin. High-titer baculoviruses for ACs 1, 2 
and 5 were generated through two sequential amplification steps as previously 
described12,22. In each amplification step the supernatant fluid was harvested and 
stored under light protection at 4 °C. For membrane preparation Sf9 cells (3.0 x 106 
cells/ml) were infected with corresponding baculovirus encoding different mammalian 
ACs (1:100 dilutions of high-titer virus) and cultured for 48 hours. Membranes 
expressing each construct and membranes from uninfected Sf9 cells were prepared 
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as described22. Briefly, cells were harvested and cell suspensions were centrifuged 
for 10 min at 1,000 x g at 4 °C. Pellets were resuspended in 10 ml of lysis buffer 
(1 mM EDTA, 0.2 mM phenylmethylsulfonylfluoride, 10 µg/ml leupeptine and 10 
µg/ml benzamide, pH 7.4). Thereafter, cells were lyzed with 20 – 25 strokes using a 
Dounce homogenizer. The resultant cell fragment suspension was centrifuged for 5 
min at 500 x g and 4 °C to sediment nuclei. The cell membrane-containing 
supernatant suspension was transferred into 30 ml tubes and centrifuged for 20 min 
at 30,000 x g and 4 °C. The supernatant fluid was discarded and cell pellets were 
discarded and cell pellets were resuspended in buffer consisting of 75 mM Tris/HCl, 
12.5 mM MgCl2, and 1mM EDTA, pH 7.4. Membrane aliquots of 1 ml were prepared, 
stored at -80 °C and protein concentration for each membrane preparation was 
determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA).  
2.3 AC activity assay 
AC activity in Sf9 membranes expressing ACs 1, 2 or 5 was determined essentially 
as described in the literature12. Before starting experiments, membranes were 
sedimented by a 15 min centrifugation at 4 °C and 15,000 x g and resuspended in 
75 mM Tris/HCl, pH 7.4. Reaction mixtures (50 μl, final volume) contained 20 – 40 μg 
of membrane protein, 40 μM ATP/Mn2+ plus 5 mM MnCl2, 100 μM FS, 10 μM GTPγS 
and (M)ANT-nucleotides at concentrations from 0.1 nM to 1 mM as appropriate to 
obtain saturated inhibition curves. Following a 2 min pre-incubation at 37 °C, 
reactions were initiated by adding 20 μl of reaction mixture containing (final) 1.0 -
 1.5 μCi/tube [α-32P]ATP and 0.1 mM cAMP. AC assays were conducted in the 
absence of an NTP-regenerating system to allow for the analysis of (M)ANT-NDPs 
that could otherwise be phosphorylated to the corresponding (M)ANT-NTPs12. For 
the determination of Km values, reactions mixtures contained 20 µM – 1 mM 
ATP/Mn2+ as substrate12. Reactions were conducted for 20 min at 37 °C and were 
terminated by adding 20 μl of 2.2 N HCl. Denatured protein was precipitated by a 
1 min centrifugation at 25 °C and 15,000 x g. Sixty μl of the supernatant fluid were 
applied onto disposable columns filled with 1.3 g neutral alumina. [32P]cAMP was 
separated from [α-32P]ATP by elution of [32P]cAMP with 4 ml of 0.1 M ammonium 
acetate, pH 7.0. Recovery of [32P]cAMP was ~80 % as assessed with [3H]cAMP as 
standard. Blank values were approximately 0.02 % of the total added amount of [α-
32P]ATP; substrate turnover was < 3 % of the total added [α-32P]ATP. Samples 
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collected in scintillation vials were filled up with 10 ml of double-distilled water and 
Čerenkov radiation was measured in a Tri-Carb 2800TR liquid scintillation analyzer 
(PerkinElmer Life and Analytical Sciences).  
For experiments with purified catalytic AC subunits, reaction mixtures contained 
100 μM ATP/Mn2+, 10 mM MnCl2 and (M)ANT-nucleotides at concentrations from 0.1 
nM to 1 mM as appropriate to obtain saturated inhibition curves. For experiments with 
Gsα-GTPγS, assay tubes contained VC1 (3 nM), IIC2 (15 nM) and Gsα-GTPγS (51 nM). 
Reactions were conducted in the presence of 100 μM FS. Following a 2 min pre-
incubation at 30 °C, reactions were initiated by adding 20 μl of reaction mixture 
containing (final) 1.0 μCi/tube [α-32P]ATP, 0.1 mM cAMP and 100 mM KCl in 25 mM 
HEPES/NaOH, pH 7.4. AC assays were conducted in the absence of an NTP-
regenerating system to allow for the analysis of 2’,3’-substituted (M)ANT-NDPs that 
could otherwise be phosphorylated to the corresponding (M)ANT-NTPs12. Reactions 
were conducted for 10 – 20 min at 30 °C.  
Free concentrations of divalent cations were calculated with Win-MaxC 
(http://www.stanford.edu/_cpatton/maxc.html). Competition isotherms were analyzed 
by non-linear regression using the Prism 4.0 software (GraphPad, San Diego, CA). 
Km values were 120 µM (AC1), 100 µM (AC2), 70 µM (AC5) and were taken from 
Gille et al.12 for mAC. Km value for catalytic subdomains VC1/IIC2 was 430 µM 
(Mn2++FS+Gsα-GTPγS), determined in a previous study14. 
2.4 Crystallographic studies 
In analogy to previous crystallographic studies with catalytical subunits of VC1/IIC2 
with MANT-GTP14 as ATP substrate analog, we investigated in a further co-crystal 
with MANT-ITP to explain its high potency for AC inhibition. For this thesis the 
crystallographic data is only presented in the discussion part (4. Discussion and 
Conclusion; page 30). For details of generating the crystallographic data please 
contact Melanie Hübner, Department of Pharmacology and Toxicology, University of 
Regensburg, Germany.  
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3.  Results 
3.1 Inhibition of the catalytic activity of recombinant ACs 1, 2 and 5 by 
(M)ANT-nucleotides 
In agreement with previous data12, MANT-GTPγS (4) and MANT-ITPγS (9) were 
similarly potent AC5 inhibitors (Table 1). Whereas substitution of the γ-thiophosphate 
by a γ-phosphate decreased potency in case of guanine nucleotide (4→1), this 
substitution increased potency in case of inosine nucleotides (9→8) by more than 25-
fold, yielding MANT-ITP.  
MANT-UTP was similarly potent as MANT-GTP, whereas introduction of adenine (5) 
or cytosine (12) decreased affinity for AC5 by 3- to 5-fold relative to guanine (1). 
Among all bases studied, xanthine (10) conferred the lowest inhibitor potency to 
MANT-NTPs. In case of guanine, both the 3’-MANT-2’-d-substitution (2) and the 2’-
MANT-3’-d-substitution (3) substantially reduced inhibitor potency, whereas in case 
of adenine, only the 3’-MANT-2’-d-substitution (6) decreased inhibitor potency. 
Exchange of the MANT-group for an ANT-group had little effect on inhibitor potency 
(5→14, 15→16 and 20→21). Deletion of the γ-phosphate reduced inhibitor affinity 5- 
to 30-fold (5→16, 8→17, 11→18 and 12→19) and deletion of the β-phosphate 
reduced inhibitor affinity almost 150-fold (17→20). Overall, with the exception of 2’-
MANT-3’-d-ATP (7), inhibitor affinities at AC1 resembled those at AC5. Inhibitor 
affinities at AC2 were all lower than at ACs 1 and 5. 
Most importantly, MANT-ITP (8) inhibited AC2 ~5- to 10-fold less potently than ACs 1 
and 5. The generally lower affinities of (M)ANT-nucleotides at AC2 compared to ACs 
1 and 5 are in agreement with previous observations12 and are explained by 
Ala409Pro- and Val1108Ile exchanges in ACs 1 and 5 versus AC214. 
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 Table 1. Inhibition of catalytic activity of recombinant ACs 1, 2, 5 and catalytic subunits of VC1/IIC2 by (M)ANT-nucleotides 
 (M)ANT-nucleotide AC 1 (nM) AC 2 (nM) AC 5 (nM) VC1/IIC2 (nM) 
1 MANT-GTP  90 ± 18  610 ± 70  53 ± 12  18 ± 6 
2 3’-MANT-2’-d-GTP  270 ± 30  1,300 ± 210  410 ± 35  180 ± 6 
3 2’-MANT-3’-d-GTP  1,800 ± 70  8,700 ± 1,800  1,800 ± 100  350 ± 40 
4 MANT-GTPγS  63 ± 17  370 ± 80  34 ± 8  24 ± 4 
5 MANT-ATP  150 ± 40  330 ± 80  100 ± 30  16 ± 6 
6 3’-MANT-2’-d-ATP  320 ± 20  4,800 ± 560  360 ± 54  190 ± 3 
7 2’-MANT-3’-d-ATP  470 ± 20  540 ± 20  65 ± 5  90 ± 2 
8 MANT-ITP  2.8 ± 0.9  13.5 ± 0.5  1.2 ± 0.1  0.7 ± 0.1 
9 MANT-ITPγS  40 ± 11  120 ± 23  32 ± 8  19 ± 3 
10 MANT-XTP  1,100 ± 100  3,000 ± 200  1,300 ± 400  1,200 ± 370 
11 MANT-UTP  46 ± 4  460 ± 60  32 ± 2  6.1 ± 1.3 27
12 MANT-CTP  150 ± 30  690 ± 20  150 ± 30  9.2 ± 1.5 
14 ANT-ATP   130 ± 20  640 ± 70  120 ± 20  17 ± 2.4 
15 ANT-ADP  860 ± 10   2,900 ± 300   640 ± 70  250 ± 12 
16 MANT-ADP  1,300 ± 400  2,900 ± 500  790 ± 180  260 ± 40 
17 MANT-IDP  39 ± 12  86 ± 9  31 ± 12  n. d. 
18 MANT-UDP  390 ± 50  2,700 ± 300  340 ± 10  170 ± 27 
19 MANT-CDP  580 ± 10  3,700 ± 400  740 ± 30  140 ± 22      20 MANT-IMP  4,600 ± 400  8,200 ± 800  3,400 ± 200  n. d.  
21 ANT-IMP  7,400 ± 1,200  7,500 ± 1,400  4,300 ± 600  n. d.  
     
 
AC activity in Sf9 membranes and of catalytic subunits of VC1/IIC2 were determined as described in “Materials and Methods”. Non-linear regression analysis 
was used for calculation of Ki values from IC50 values. Ki values are given in nanomolar and are the mean values ± SD of 4 – 5 independent experiments 
performed in triplicates with at least two different membrane preparations (mACs) or two different batches of protein (C1/C2). n. d.; not determined. 
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3.2  Inhibition of the catalytic activity of VC1/IIC2 by (M)ANT-nucleotides 
Additionally, the inhibitory effects of selected (M)ANT-nucleotides were determined 
on the catalytic activity of VC1/IIC2 (Table 1). 3’-O and 2’-O-isomers of both MANT-
GTP (2, 3) and MANT-ATP (6, 7) exhibited 5- to 20-fold lower inhibitory potencies for 
the maximally stimulated VC1/IIC2 than MANT-GTP (1) and MANT-ATP (5), 
respectively. These results are in accordance with crystallographic and molecular 
modelling studies showing that MANT-GTP binds to VC1/IIC2 preferentially as 3’- 
MANT-isomer and that the 2’-hydroxyl group forms a hydrogen bond with the 
backbone nitrogen of Asn1025 of IIC214,15,17. Thus, this missing H-bond may explain 
the lower affinity of 2, 3, 6 and 7 relative to 1 and 5, respectively, for VC1/IIC2. 
However, hydrophobic interaction between the MANT-group and Ala409, Trp1020, 
Val413, Leu412, Ala404, and Phe40012,14,15 in the interface of VC1/IIC2 still confer 
high-affinity interactions. 
2’-MANT-3’-d-GTP (3) was 2-fold less potent than the 3’-MANT-2’-d-derivative (2). 
This finding is in accordance with crystallographic data showing that 3’-MANT-GTP is 
the preferred isomer for binding to VC1/IIC214. Thus, the orientation of the 2’-MANT-
derivative into the hydrophobic pocket may be less favorable, resulting in slightly 
reduced affinity compared with 3’-MANT-GTP. Although previous studies showed 
that MANT-ATP also binds to VC1/IIC2 preferably as 3’-isomer15, contrary to MANT-
guanine nucleotides 1 – 3 , 3’-MANT-2’-d-ATP (6) was less potent than the 2’-MANT-
derivative (7) at inhibiting VC1/IIC2 catalytic activity. This suggests that in case of a 
missing hydrogen bond of the free ribosyl hydroxyl group, the adenine nucleotide 
gains flexibility so that the 2’-MANT-derivative fits into the hydrophobic pocket more 
favorably than the 3’-MANT-derivative. 
MANT-UTP (11) and MANT-CTP (12) exhibited 2- to 3-fold higher inhibitory 
potencies at VC1/IIC2 than MANT-GTP (1) and MANT-ATP (5) under maximally 
stimulatory conditions. Previous studies showed that MANT-GTP (1), MANT-GTPγS 
(4) and MANT-ITPγS (9) are similarly potent VC1/IIC2 inhibitors12. This study 
confirms the previous data. In contrast to the MANT-GTP/MANT-GTPγS pair, 
exchange of the γ-thiophosphate by a phosphate in hypoxanthine nucleotides 
increased the inhibitory potency by almost 30-fold (9→8). Introduction of a keto group 
at the C2 carbon atom of the purine ring (8→10) decreased inhibitor potency several 
100-fold which is explained by unfavorable electrostatic repulsion of the keto group 
with the carbonyl oxygen in Ile101914. The exceptionally high inhibitory potency of 
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MANT-ITP at VC1/IIC2 fits excellently to the potency of the compound at ACs 1 and 
5 (Table 1). Deletion of the methyl group from the fluorophore at the 2’,3’-O-ribosyl 
substituent in NTPs (compare 5 and 14) did not largely change their affinity for 
VC1/IIC2. These data suggest that ANT and MANT-substituted NTPs interact 
similarly with the hydrophobic pocket in the interface of VC1/IIC2. 
Deletion of the γ-phosphate reduced the inhibitory potency of (M)ANT-NDPs ~10- to 
80-fold compared to the corresponding (M)ANT-NTPs (compare 14 and 15, 5 and 16, 
11 and 18, 12 and 19). These data are in accordance with crystallographic data 
demonstrating that the Mn2+-ion in the B-site coordinates with the γ-phosphate of 
MANT-nucleotides and that deletion of the γ-phosphate destabilizes the 
polyphosphate chain in its binding site14,15.  
4.  Discussion and Conclusion 
Recent data from experiments with knock-out animals suggest that dual AC1/5 
inhibitors may be useful drugs for several age-related ailments including heart failure 
and neurodegeneration6,7,8,23. In a previous study with 18 MANT-nucleotides we 
identified MANT-GTP, MANT-GTPγS and MANT-ITPγS as similarly potent AC1/5 
inhibitors with Ki values in the 30 – 90 nM range12. In the present study, we confirmed 
those data and studied 14 additional (M)ANT-nucleotides. We identified MANT-ITP 
as the most potent AC1/5 inhibitor known so far with a Ki value in the 1 – 3 nM range 
(Table 1). MANT-ITP is also a highly potent inhibitor of the purified catalytic AC 
subunits VC1/IIC2. Possibly, the apparent Ki value of MANT-ITP at VC1/IIC2 is an 
underestimation of the true Ki value since the enzyme concentration was well above 
the Ki value of the inhibitor (see Materials and Methods). However, we do not know 
what fraction of the VC1/IIC2 subunits added to the assay was actually functionally 
active. The identification of MANT-ITP as a highly potent inhibitor of ACs 1 and 5 
provides the basis for the development of a sensitive AC1/5 radioligand binding 
assay that will facilitate the identification of other potent AC1/5 inhibitors in 
competition experiments. Hopefully, new inhibitors will exhibit greater selectivity 
towards other AC isoforms than MANT-ITP, i.e. MANT-ITP is just 5-fold less potent at 
inhibiting AC2 than AC1. 
We were particularly interested in learning more about the mechanisms underlying 
AC inhibition by (M)ANT-nucleotides. Previous studies from our laboratory already
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showed that the catalytic site of AC is quite flexible, allowing for the binding of 
structurally diverse nucleotides12,14,17. Therefore, the structure/activity relationships of 
a series of ribosyl-modified nucleotides were analyzed in terms of VC1/IIC2 inhibition. 
The nucleotides studied herein varied form each other in their base (purine and 
pyrimidine), MANT-position (2’,3’-isomerization versus 3’-MANT-2’-d-substitution and 
2’-MANT-3’-d-substitution), type  of the fluorophore (MANT and ANT), as well as the 
length of the polyphosphate chain (triphosphates, diphosphates and 
monophosphates) (Fig. 1). Finally, the exchange of γ-phosphate against γ-
thiophosphate was studied. Most of the nucleotides had not yet been analyzed at 
mammalian ACs in terms of enzyme inhibition. Several nucleotides were synthesized 
as part of a recently initiated in-house AC inhibitor synthesis program (5, 8, 11, 12, 14 
– 21) 19,20. 
The enzymatic data show that several MANT-purine and pyrimidine nucleotides 
exhibit high inhibitory potencies at recombinant ACs 1, 2 and 5 and VC1/IIC2. In fact, 
some pyrimidine nucleotides readily surpass purine nucleotides in terms of potency 
(Table 1). These results substantiate the recently elaborated concept15,17 that due to 
the conformational flexibility of the catalytic site of VC1/IIC2, ACs can accommodate 
large chemical alterations in nucleotide inhibitors with regard to the base (Fig. 1). As 
a general rule, the base substituent has relatively little impact on nucleotide-affinity 
for ACs, i.e. both purines and pyrimidines are well tolerated. However, as a most 
notable exception, an apparently “minor” structural change, namely the deletion of 
the NH2 group at C2 of the guanine ring, yielding hypoxanthine, resulted in up to 50-
fold increases in potency of MANT-ITP compared to MANT-GTP. For better 
understanding of these findings we investigated in crystallographic experiments14 and 
succeed in obtaining the co-crystal of MANT-ITP in complex with the catalytic 
subunits of VC1/IIC2 and Gsα (Fig. 2).  
We expected a different binding mode of MANT-ITP to explain its higher potency, 
compared to previous crystallographic studies with MANT-GTP14. After 
superimposing both structures the overall placement of VC1 and IIC2 did not differ 
extensively from each other (Fig. 2C), the protein residues revealed similar hydrogen 
bond interactions as well as metal ion interactions with the purine and polyphosphate 
residues for MANT-ITP in the identical 3’-O-isomer conformation (Fig. 2 B and D). 
The overall binding constraint of the purine binding pocket may be less favorable for 
MANT-ITP, due to the lack of hydrogen bonding with Ile1019 (missing NH2-group in 
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Fig. 2. Crystal structure of catalytic subunits VC1/IIC2 with MANT-ITP 
MANT-ITP and two metal ions are bound in the cleft between the soluble C1a and C2a domains. VC1 
and IIC2 are colored wheat and violet (A – D). MANT-ITP is shown as stick model, colors of atoms, 
unless otherwise indicated: lightblue, carbon; darkblue, nitrogen; red, oxygen; green, phosphorus. The 
two Mn2+ ions are shown as orange spheres. A, overview of VC1/IIC2 with electron density for 3’-O-
MANT-ITP and Mn2+. The secondary structure elements of the complex are labeled as defined 
previously24. B, Detailed view of substrate binding site of VC1/IIC2 with MANT-ITP, two Mn2+ ions, and 
the protein residue, responsible for ligand interaction. The interaction among protein residues and 
MANT-ITP, Mn2+ are shown as gray dashed lines. C, Superimposed crystal structures of 3’-O-MANT-
ITP and 3’-O-MANT-GTP. The derived MANT-ITP crystal structure was superimposed and compared 
with the crystal structure of MANT-GTP, shown as a transparent yellow stick model (Protein Data 
Bank code 1TL7)14. The protein residues are in almost identical conformation and the inhibitors are 
situated in the substrate binding pocket in a similar fashion. D, Superimposed purine binding site of 3’-
O-MANT-ITP and 3’-O-MANT-GTP. The interaction of the hypoxanthine ring and guanine ring of 
MANT-ITP and MANT-GTP are shown as black and olive green dashed lines. The distances of 
hydrogen bond between the hypoxanthine ring and surrounding protein residues of MANT-ITP are 
indicated in Å. The hydrogen bond between Ile1019 and the amino group of MANT-GTP is missing in 
the MANT-ITP structure. Lys938 and the keto function of the hypoxanthine ring are further apart. The 
hypoxanthine ring has less binding constraint in the purine binding pocket, compared to the guanine 
ring of MANT-ITP. 
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the purine residue for MANT-ITP). Moreover, the hydrogen-bond between the keto 
function of the hypoxanthine ring and Lys938 are further apart (> 3.2 Å). Thus, the 
catalytic binding pocket offers MANT-ITP more degrees of freedom with less 
restriction in the binding mode. The higher inhibitor potency of MANT-ITP cannot be 
readily explained by obvious protein-ligand interactions alone. Residual mobility of 
the ligand and partial solvation of the binding pocket suggest entropic actions25,26 as 
the tip on the scale. Due to the resolution of our crystal structure (3.1 Å), water 
molecules could not all be assessed by diffraction. Thus, we hypothesize that water 
molecules could play a crucial role in high affinity binding of MANT-ITP. High 
resolution crystal structures and isothermal calorimetric titrations may support our 
hypothesis. 
It should be noted that a similarly “minor” structural change in the purine ring as 
deletion of a NH2 group, namely exchange against a keto group at C2, yielding 
xanthine, reduced MANT-nucleotide affinity for ACs and VC1/IIC2 assembly 
dramatically through impairment of hydrogen bonding and repulsion force within the 
catalytic site14. Modifications of the position of the 2’,3’-O-ribosyl substituent affected 
the inhibitory potencies of the ribosyl-modified nucleotides at holo-ACs and VC1/IIC2. 
Overall, as expected from crystallographic data14,15, the 3’-MANT-2’-d- and 2’-MANT-
3’-d-substitutions of both guanine and adenine nucleotides showed lower inhibitory 
potencies than their respective 2’,3’-MANT-nucleotides (MANT-GTP and MANT-ATP, 
respectively). However, the impact of the position of the MANT-group (2’,3’ vs. 3’-
MANT-2’-d- and 2’-MANT-3’-d-substitution) depended on the base (guanine vs. 
adenine). The enzymatic data showed that based on the overall potency (MANT-GTP 
>> 3’-MANT-2’-d-GTP > 2’-MANT-3’-d-GTP and MANT-ATP >> 2’-MANT-3’-d-ATP > 
3’-MANT-2’-d-ATP) MANT-GTP binds to VC1/IIC2 preferably as 3’-MANT-isomer14,17. 
In contrast, MANT-ATP analogs may favor the 2’-MANT position rather than the 3’-
MANT position if hydrogen bonding of the ribosyl hydroxyl group cannot take place. 
In conclusion, MANT-ITP is the most potent inhibitor of ACs 1, 2 and 5 and VC1/IIC2 
identified so far. MANT-ITP can be used as starting point for the preparation of AC 
radioligands and the synthesis of even more potent and possibly AC isoform-
selective inhibitors. Based on our present data, modification of the purine base and 
introduction of new 2’,3’-ribosyl substituents constitute promising future avenues of 
research to obtain even more potent and selective AC inhibitors. 
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5. Experimental section 
5.1 Synthesis procedure 
General protocol of (M)ANT-nucleotide synthesis 
(M)ANT-nucleotides were synthesized according to Hiratsuka18 with modifications. 
The nucleotide (0.33 mmol, 1 eq) was propounded in a small two-neck round flask 
and dissolved in a minimum amount of water (3 ml). Under continuous stirring a 
crystalline preparation of (methyl)isatoic anhydride (0.5 mmol, 1.5 eq) was added. 
After heating to 38 °C the pH-value was adjusted to 8.6 and maintained by titration of 
1 N NaOH solution for 2 hours. The reaction mixture was extracted three times by 
chloroform (3 x 20 ml; only for MANT-nucleotides). The aqueous phase was dry-
frozen. The received foam showed white to brown color and was applied to a long 
Sephadex® LH-20 column (85 x 2 cm) and subsequently eluted with double-distilled 
water. The desired product could be detected directly by its blue fluorescence in the 
collection tubes at λex of 366 nm and by TLC. For further purification, reversed-phase 
preparative HPLC was required to separate (M)ANT-NTP from (M)ANT-NDP. In case 
of monophosphate derivatives only size-exclusion chromatography was required. 
After final dry-freezing white solid compounds (purity > 99%) were obtained. For the 
polyphosphate derivatives yields were determined by analytical HPLC measurements 
of crude reaction mixtures and correlate with the maximal accessible yield. Because 
of the time consuming and costly preparative HPLC isolation was stopped after 
obtaining approximate 5 mg pure compound. 
5.2 Analytical procedures 
HPLC analysis of (M)ANT-nucleotides 
The samples were filtered using a PTFE filter (Chromafil, O-20/15, organic, pore size 
0.2 mm; Machery-Nagel, Düren, Germany). A 10 μL sample was analyzed using a 
HPLC model 1100 (Agilent Technologies, Waldbronn, Germany) fitted with a C18 
analytical column (Phenomenex Luna, particle size 3 μm, 150 x 4.60 mm, 
Aschaffenburg, Germany) and DAD. Data were analyzed using a HPLC-3D 
ChemStation Rev. A.10.01 [1635]. Gradient elution was performed with 0.05 M 
ammonium acetate (solvent A) and acetonitrile (solvent B) at a constant flow rate of 
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1.0 ml/min. A gradient profile with the following proportions of solvent B was applied [t 
(min), % B]: [0, 5], [10, 5], [30, 45], [40, 80]. The chromatograms were monitored at 
220 and 254 nm. In addition, a fluorescence detector was used for the analysis of the 
fluorescent anthraniloylic compounds at λex of 350 nm and λem of 450 nm. 
LC/MS online coupling 
All samples were filtered using a PTFE filter and injected into a HPLC model 1100 
(Hewlett-Packard, Waldbronn, Germany). The compound to be analyzed was 
separated by a C18 column (Phenomenex luna, particle size 3 μm, 150 x 2 mm, 
Aschaffenburg, Germany). A binary eluent mixture consisting of water (10 mM 
ammonium acetate) (eluent A) and acetonitrile (eluent B) was pumped with a 
constant flow of 0.3 ml/min. The following gradient profile was used t [min], % B: [0, 
5], [10, 5], [30, 45], [40, 80]. The injected volume was 3 μl. The mass of the 
respective compound was determined with the use of a triple stage mass 
spectrometer (Finnigan TSQ 7000; Thermo Fisher Scientific, Waltham, MA).  
Preparative HPLC 
Compound mixtures were dissolved in water (concentration: 30 – 50 mg/ml) and 
filtered using a PTFE filter. Compounds were separated using a HPLC model 1100 
(Agilent Technologies, Waldbronn, Germany) fitted with a C18 preparative column 
(Phenomenex Luna, particle size 10 μm, 250 x 21.2 mm). Gradient elution was 
performed with 0.05 M ammonium acetate (solvent A) and acetonitrile (solvent B) at 
a constant flow rate of 21 ml/min. Due to the goodness of separation injection 
volumes differed from 10 µl to 60 µl for a run. The chromatograms were monitored at 
220 and 254 nm. 
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5.3 Synthesized compounds 
OOPO
OH
O
P
O
O
OH
PHO
OH
O
O OH
O
NHCH3
N
NN
N
NH2
 
MANT-ATP 
MANT-ATP (N-methyl-2’(3’)-O-anthraniloyl-adenosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-phosphono-
oxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-methylaminobenzoate (5). 
For the procedure see general prescription. 200 mg introduced disodium salt of ATP 
led over all purification steps to 41 mg (64 μmol, 19 %) pure product. Rf = 0.26 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 20.18 min, 20.37 min; 
k = 12.83, 12.96; LC/MS (ESI, H2O/CH3CN): m/z = 658.2 [M+NH4+] 
(Rt = 21.61 min, 21.82 min, 100 %); (-ESI, H2O/CH3CN): m/z = 639.2 [M-H-] 
(Rt = 21.60 min, 21.81 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 
14], [20, 14], [30, 80]): Rt = 10.20 min, 11.46 min; empirical formula: C18H23N7O15P3; 
MW = 640.33 
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OOPO
OH
O
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O
O
OH
PHO
OH
O
O OH
O
NHCH3
NH
NN
N
O
 
MANT-ITP 
MANT-ITP (N-methyl-2’(3’)-O-anthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-
methylaminobenzoate (8). 
189 mg introduced trisodium salt of ITP yielded over all purification steps 39 mg (61 
μmol, 18 %) pure product. Rf = 0.31 (1-propanol:H2O: NH3 (32 %) = 2:1:1). HPLC 
(analytic): Rt = 19.74 min, 19.86 min; k = 12.65, 12.73; LC/MS (ESI, H2O/CH3CN): 
m/z = 676.2 [M-H+2NH4+] (Rt = 20.92 min, 100 %), 659.2 [M+NH4+] (Rt = 20.92 min, 
80 %); (-ESI, H2O/CH3CN): m/z = 640.2 [M-H-] (Rt = 20.92 min, 100%); HPLC 
(preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 80]): Rt = 8.03 min, 8.23 
min; empirical formula: C18H22N5O15P3; MW = 641.31 
OOPO
OH
O
P
O
O
OH
PHO
OH
O
O OH
O
NHCH3
NH
N
O
O
 
MANT-UTP 
MANT-UTP (N-methyl-2’(3’)-O-anthraniloyl-uridine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-
methylaminobenzoate (11).  
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182 mg introduced disodium salt of UTP yielded over all purification steps 32 mg (52 
μmol, 15 %) pure product. Rf = 0.21 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
(analytic): Rt = 18.78 min, 19.15 min; k = 12.49, 12.75; LC/MS (ESI, H2O/CH3CN): 
m/z = 635.2 [M+NH4+] (Rt = 19.69 min, 19.88 min, 100 %), 652.2 [M-H+2NH4+] (Rt = 
20.15 min, 100 %); (-ESI, H2O/CH3CN): m/z = 616.2 [M-H-] (Rt = 19.53 min, 20.01 
min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 80]): Rt 
= 6.07 min, 6.79 min; empirical formula: C17H22N3O16P3; MW = 617.29 
OOPO
OH
O
P
O
O
OH
PHO
OH
O
O OH
O
NHCH3
N
N
NH2
O
 
MANT-CTP 
MANT-CTP (N-methyl-2’(3’)-O-anthraniloyl-cytosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-
methylaminobenzoate (12).  
200 mg introduced trisodium salt of CTP yielded over all purification steps 30 mg (48 
μmol, 14 %) pure product. Rf = 0.24 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
(analytic): Rt = 16.86 min, 17.60 min; k = 11.17, 11.70; LC/MS (ESI, H2O/CH3CN): 
m/z = 634.2 [M+NH4+] (Rt = 12.98 min, 16.98 min, 100 %); (-ESI, H2O/CH3CN): m/z = 
615.2 [M-H-] (Rt = 13.75 min, 17.24 min, 100 %); HPLC (preparative), gradient (t 
[min], % B: [0, 14], [20, 14], [30, 80]): Rt = 4.08 min, 4.61 min; empirical formula: 
C17H23N4O15P3; MW = 616.30 
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PHO
OH
O
O OH
O
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N
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N
NH2
 
ANT-ATP 
ANT-ATP (2’(3’)-O-anthraniloyl-adenosine-5’-triphosphate) or [(2R,3S,4R, 5R)-5-(6-
aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-aminobenzoate (14). 
189 mg introduced disodium salt of ATP yielded over all purification steps 59 mg (94 
μmol, 26 %) pure product. Rf = 0.24 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
(analytic): Rt = 17.44 min; k = 10.07; LC/MS (ESI, H2O/CH3CN): m/z = 661.3 [M-
H+2NH4+] (Rt = 18.12 min, 18.32 min, 100 %), 644.2 [M+NH4+] (Rt = 18.12 min, 18.32 
min, 80 %); (-ESI, H2O/CH3CN): m/z = 625.2 [M-H-] (Rt = 18.12 min, 18.33 min, 
100 %); HPLC (preparative), gradient (t [min], % B: [0, 11], [9, 11], [19, 80]): Rt = 7.07 
min, 7.51 min; empirical formula: C17H21N6O14P3; MW = 626.30 
OOPO
OH
O
P
O
HO
OH
O OH
O
NH2
N
NN
N
NH2
 
ANT-ADP 
ANT-ADP (2’(3’)-O-anthraniloyl-adenosine-5’-diphosphate) or [(2R,3S,4R,5R)-5-(6-
aminopurin-9-yl)-4(3)-hydroxy-2-[(hydroxy-phosphonooxyphosphoryl)oxymethyl] 
oxolan-3(4)-yl]2-aminobenzoate (15). 
200 mg introduced disodium salt of ADP yielded over all purification steps 8 mg (15 
μmol, 4 %) pure product. Rf = 0.27 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
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(analytic): Rt = 18.09 min; k = 10.73; LC/MS (ESI, H2O/CH3CN): m/z = 564.3 
[M+NH4+] (Rt = 18.81 min, 19.04 min, 100 %); (-ESI, H2O/CH3CN): m/z = 545.2 [M-H-] 
(Rt = 18.81 min, 19.04 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 
11], [9, 11], [19, 80]): Rt = 8.99 min; empirical formula: C17H20N6O11P2; MW = 546.32 
OOPO
OH
O
P
O
HO
OH
O OH
O
NHCH3
N
NN
N
NH2
 
MANT-ADP
MANT-ADP (N-methyl-2’(3’)-O-anthraniloyl-adenosine-5’-diphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[(hydroxy-phosphonooxy 
phosphoryl)-oxymethyl]oxolan-3(4)-yl]2-methylaminobenzoate (16).  
For the procedure see general prescription. 200 mg introduced disodium salt of ATP 
led over all purification steps to 4.7 mg (8.4 μmol, 2.2 %) pure product. Rf = 0.29 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 20.56 min, 20.79 min; 
k = 13.09, 13.25; LC/MS (ESI, H2O/CH3CN): m/z = 561.2 [M+H+] (Rt = 22.24 min, 
22.41 min, 100 %); (-ESI, H2O/CH3CN): m/z = 559.2 [M-H-] (Rt = 22.23 min, 
22.41 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 
80]): Rt = 14.56 min, 15.54 min; empirical formula: C18H22N6O11P2; MW = 560.35 
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O OH
O
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MANT-IDP 
MANT-IDP (N-methyl-2’(3’)-O-anthraniloyl-inosine-5’-diphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[(hydroxy-phosphonooxy 
phosphoryl)oxymethyl]oxolan-3(4)-yl]2-methylaminobenzoate (17).  
189 mg introduced disodium salt of IDP yielded over all purification steps 15 mg 
(27 μmol, 7 %) pure product. Rf = 0.35 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
(analytic): Rt = 20.34 min, 20.58 min; k = 13.07, 13.23; LC/MS (ESI, H2O/CH3CN): 
m/z = 596.3 [M-H+2NH4+] (Rt = 21.38 min, 100 %), 579.3 [M+NH4+] (Rt = 21.38 min, 
70 %); (-ESI, H2O/CH3CN): m/z = 560.2 [M-H-] (Rt = 21.39 min, 21.55 min, 100 %); 
HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 80]): Rt = 10.62 min, 
11.36 min; empirical formula: C18H21N5O12P2; MW = 561.33 
OOPO
OH
O
P
O
HO
OH
O OH
O
NHCH3
NH
N
O
O
 
MANT-UDP 
MANT-UDP (N-methyl-2’(3’)-O-anthraniloyl-uridine-5’-diphosphate) or 
[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4(3)-hydroxy-2-[(hydroxy-
phosphonooxyphosphoryl)oxymethyl]oxolan-3(4)-yl]2-methylaminobenzoate (18).  
182 mg introduced disodium salt of UDP yielded over all purification steps 8 mg (15 
μmol, 3.8 %) pure product. Rf = 0.25 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
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(analytic): Rt = 19.75 min, 19.93 min; k = 13.19, 13.32; LC/MS (ESI, H2O/CH3CN): 
m/z = 555.2 [M+NH4+] (Rt = 20.64 min, 20.94 min, 100 %), 572.2 [M-H+2NH4+] (Rt = 
20.64 min, 20.94 min, 40 %); (-ESI, H2O/CH3CN): m/z = 536.2 [M-H-] (Rt = 20.50 min, 
20.78 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 
80]): Rt = 8.79 min, 9.49 min; empirical formula: C17H21N3O13P2; MW = 537.31 
OOPO
OH
O
P
O
HO
OH
O OH
O
NHCH3
N
N
NH2
O
 
MANT-CDP 
MANT-CDP (N-methyl-2’(3’)-O-anthraniloyl-cytosine-5’-diphosphate) or 
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4(3)-hydroxy-2-[(hydroxy-
phosphonooxyphosphoryl)oxymethyl]oxolan-3(4)-yl]2-methylaminobenzoate (19).  
200 mg introduced disodium salt of CDP yielded over all purification steps 2 mg 
(3.7 μmol, 1 %) pure product. Rf = 0.28 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC 
(analytic): Rt =18.38 min; k = 12.27; LC/MS (ESI, H2O/CH3CN): m/z = 554.2 
[M+NH4+] (Rt = 18.55 min, 100 %); (-ESI, H2O/CH3CN): m/z = 535.2 [M-H-] 
(Rt = 18.66 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], 
[30, 80]): Rt = 5.80 min; empirical formula: C17H22N4O12P2; MW = 536.32 
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MANT-IMP 
MANT-IMP (N-methyl-2’(3’)-O-anthraniloyl-inosine-5’-monophosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[phosphonooxymethyl] 
oxolan-3(4)-yl]2-methylaminobenzoate (20). 
The disodium salt of IMP (100 mg, 0.26 mmol) yielded 34 mg (71 μmol, 27 %) pure 
product after size-exclusion chromatography. Rf = 0.22 (1-propanol:H2O:NH3 (32 %) 
= 2:1:1). HPLC (analytic): Rt = 21.36 min, 22.08 min; k = 12.68, 13.15; LC/MS (ESI, 
H2O/CH3CN): m/z = 499.2 [M+NH4+] (Rt = 22.07 min, 22.78 min, 100 %); (-ESI, 
H2O/CH3CN): m/z = 480.2 [M-H-] (Rt = 22.06 min, 22.77 min, 80 %), 540.2 
[M+CH3COO-] (Rt = 22.06 min, 22.77 min, 100 %); empirical formula: C18H20N5O9P; 
MW = 481.35 
OOPHO
OH
O
O OH
O
NH2
NH
NN
N
O
 
ANT-IMP 
ANT-IMP (2’(3’)-O-anthraniloyl-inosine-5’-monophosphate) or [(2R,3S,4R,5R)-5-(6-
oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[phosphonooxymethyl]oxolan-3(4)-yl]2-
aminobenzoate (21).  
The disodium salt of IMP (100 mg, 0.26 mmol) yielded 30 mg (65 μmol, 25 %) pure 
product after size-exclusion chromatography. Rf = 0.20 (1-propanol:H2O:NH3 (32 %) 
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= 2:1:1). HPLC (analytic): Rt = 17.88 min, 18.82 min; k = 10.72, 11.34; LC/MS (ESI, 
H2O/CH3CN): m/z = 485.1 [M+NH4+] (Rt = 17.75 min, 19.13 min, 100 %); (-ESI, 
H2O/CH3CN): m/z = 466.1 [M-H-] (Rt = 17.75 min, 19.13 min, 40 %), 526.2 
[M+CH3COO-] (Rt = 17.75 min, 19.13 min, 100 %); empirical formula: C17H18N5O9P; 
MW = 467.33 
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0BIII. Bis-substituted anthraniloyl-derived nucleotides as 
potent and selective adenylyl cyclase inhibitorsFψFFξ 
1B . Introduction 
Whooping cough is a highly contagious acute disease of the respiratory tract caused 
by the gram-negative bacterium Bordetella pertussisD1D,D2D. The immobile and aerobic 
bacterium Bordetella pertussis secretes the key virulence factor, the adenylyl cyclase 
toxin CyaA. The exotoxin consists of 1706 amino acids. The N-terminal domain (400 
amino acids) contains the active center for catalysis and the 1300 amino acid C-
terminal domain interacts with eukaryotic host cells for delivery of the catalytic 
domain into the cytosolD3D,D4D,D5D. Moreover, the C-terminal residue possesses low 
hemolytic activityX2 X.  
The endogenous calcium sensor calmodulin (CaM) activates CyaA toxin with high 
affinity (Kd = 0.2 nM) by forming a large number of salt bridges, hydrogen bonds, and 
hydrophobic interactions X29 X. After activation of the bacterial adenylyl cyclase a 
massive production of the second messenger cAMP from ATP is catalyzedD6D, X16 X. The 
supraphysiological level of cAMP disrupts the endogenous signal transduction, 
inhibits phagocyte function, and facilitates respiratory tract infection by Bordetella 
pertussisD7D. Substrate analogs of ATP may be used to inhibit the catalytic activity of 
CyaAD8D, X18 X, X32 X and prophylaxis of Bordetella pertussis infection (Fig. 1). We have 
discovered N-methylanthraniloyl (MANT) substituted nucleotides as competitive 
inhibitors of mammalian and bacterial ACs, including CyaA X15 X, X18 X, X37 X. In addition, 2’,3’-
(2,4,6-trinitrophenyl) (TNP)-substituted NTPs are valuable compounds for the 
inhibition and conformational characterization of mammalian X28 X and bacterial X15 X ACs. 
Furthermore, adefovir, a drug for the treatment of chronic hepatitis B virus infection, 
is a potent CyaA inhibitorX16 X. 
In mammals nine closely related membranous AC isoforms (AC1-9) and one soluble 
AC are expressedD9D. We have employed the cytosolic domains C1 of type 5 AC and 
C2 of type 2 AC for molecular AC analysis X18 X, X27 X, X28 X. We have also reported the crystal 
structure of CyaA in complex with CaM and 9-[2-(phosphonomethoxy)ethyl]adenine 
diphosphate (PMEApp) X29 X, the active metabolite of adefovir. By the combination of 
                                                          
ψ The results of this chapter are in preparation for publication. 
ξ  Molecular modeling was carried out by Prof. Dr. Stefan Dove, University of Regensburg, Germany. 
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Fig. 1. Representative AC inhibitors of ATP analogs 
Structures of MANT-ATP (A), TNP-ATP (B), Bis-MANT-IMP (C), PMEApp (D) are shown as 
representative AC inhibitors. The MANT-group of MANT-ATP is not fixed and undergoes spontaneous 
isomerization between 2’- and 3’-ribosyl position under physiological pHX23X. For TNP-ATP the TNP-
group is fixed to the ribosyl ring via the 2’- and 3’-position, isomerization does not occur at neutral or 
basic pHD10D. 
crystallographic and molecular modeling approaches, we investigated in the binding 
motive of MANT-nucleotides, developing a three-site pharmacophore model for mAC 
and CyaA with domains for the base, the MANT-group and the polyphosphate 
chainD11D,D12D, X15 X, X28 X. Several complementary approaches can be employed for monitoring 
nucleotide binding to, and conformational changes in, CyaA. MANT- and ANT-
nucleotides are environmentally sensitive fluorescent probes displaying increased 
fluorescence and blue shift of the emission maximum upon exposure to a 
hydrophobic environment X23 X, X43 X. In accordance to the CyaA crystal structure in complex 
with PMEApp X29 X the catalytic site contains the hydrophobic amino acid phenylalanine 
306. Nucleotide binding to CyaA allows hydrophobic interactions between the 
(M)ANT-group and Phe306, resulting in an increased fluorescence signalD13D, X29 X. This 
observation is supported by the fact that CyaA-Phe306Ala does not increase the 
fluorescence signal of 3’-ANT-2’d-ATPX29 X. 
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Enzymatic, fluorescence, crystallographic and molecular modeling studies showed 
that the catalytic site of mAC and CyaA exhibit substantial conformational flexibility, 
accommodating both purine and pyrimidine nucleotides. Nonetheless, the 
structure/activity relationships of MANT-nucleotides at mAC and CyaA are quite 
different, offering the opportunity to design potent and selective AC inhibitorsX11 X, X12 X, X28 X. 
In our recent study X15 X, we have shown that the spacious catalytic site of CyaA 
accommodates a broad variety of 2’,3’-substituted nucleotides, even a bis- 
substituted MANT-nucleotide. Interestingly, Bis-MANT-IMP exhibited higher potency 
in comparison to the corresponding mono-substituted MANT-nucleotide. This finding 
was an excellent starting point for the new synthesis of bis-substituted MANT-
nucleoside 5’-triphosphates, expecting even higher inhibition potency by the 
elongation of the polyphosphate tail. The number of phosphate groups critically 
determines the affinity of AC for 2’,3’-substituted nucleotidesX11 X, X15 X.  
To the best of our knowledge, bis-substituted (M)ANT-nucleotides have not yet been 
explicitly described in the literature, although they apparently occurred as side 
products in the regular synthesis X43 X of MANT-nucleotides. In the present study, we 
expanded the synthesis of bis-substituted (M)ANT-nucleotides (compounds: 17, 18, 
19, 28, 29, 32) and synthesized new mono- and bis-substituted anthraniloyl-group 
derived purine nucleotides (Fig. 2). The anthraniloyl (ANT) moiety differ by halogens 
of chlorine and bromine (4 – 7, 14, 20 – 23, 30) and acetylated amino group (10, 11, 
26, 27) in 5 position of the phenyl ring system. Moreover, substitution at the amino 
function of the ANT-group lead to propyl (Pr-ANT) derivatives (8, 9, 24, 25). 
Overall, we prepared 32 compounds in our study to compare 16 pairs of mono- and 
bis-substituted (M)ANT-nucleotides for their potencies at inhibiting CyaA and mACs 
and to regard selectivity between mammalian and bacterial AC. So far, highly potent 
CyaA inhibitors with selectivity towards mammalian ACs are unknown. The insertion 
of a second fluorophore may result in unexpected fluorescence properties, why we 
also investigated fluorescence spectroscopy. In addition, the binding mode of 
representative derivatives was explored by modeling studies. 
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2B . Materials and Methods 
7B2.1. Materials 
Mono-substituted (M)ANT-NTPs of MANT-ATP (1), MANT-ITP (2), MANT-CTP (3), 
MANT-NDPs of MANT-ADP (12), MANT-IDP (13) and MANT-NMPs of MANT-IMP 
(15), ANT-IMP (16) were synthesized as describedD14D,D15D.  
Synthesis of new compounds of mono- and bis-substituted (M)ANT nucleotides 
followed the general reaction scheme (Fig. 2) to achieve halogen anthraniloylic 
derived residues of (Bis-)Cl-ANT-ATP (4, 20), (Bis-)Cl-ANT-ITP (5, 21), (Bis-)Br-ANT-
ATP (6, 22), (Bis-)Br-ANT-ITP (7, 23), (Bis-)Br-ANT-ADP (14, 30) and propyl 
anthraniloylic derived residues of (Bis-)Pr-ANT-ATP (8, 24), (Bis-)Pr-ANT-ITP (9, 25) 
and acetylated amino anthraniloylic derived residues of (Bis-)Ac-NH-ANT-ATP (10, 
26), (Bis-)Ac-NH-ANT-ITP (11, 27). Furthermore we generated the bis-substituted 
derivatives of the known (M)ANT-nucleotides of Bis-MANT-ATP (17), Bis-MANT-ITP 
(18), Bis-MANT-CTP (19), Bis-MANT-ADP (28), Bis-MANT-ADP (29), Bis-MANT-IMP 
(31), and Bis-ANT-IMP (32).  
Under the basic reaction conditions mono- and bis-(M)ANT-NTP derivatives were 
partially decomposed to its corresponding diphosphates. Because of their putative 
inhibitory effects they were isolated as well. For more details see Experimental 
section. Methylisatoic anhydride, isatoic anhydride, chloroisatoic anhydride, 
bromoisatoic anhydride, aminoisatoic anhydride, ATP, ITP, CTP, IMP and bovine 
serum albumin, fraction V, highest quality, were purchased from Sigma-Aldrich 
(Seelze, Germany). MnCl2 tetrahydrate (highest quality) and Aluminum oxide 90 
active, (neutral, activity 1; particle size, 0.06 - 0.2 mm) were from MP Biomedicals 
(Eschwege, Germany). PMEApp was supplied by Gilead Sciences (Foster City, CA). 
The catalytic domain of Bacillus pertussis AC protein (CyaA, amino acids 1–373) was 
purified as described previouslyD16D. [α-32P]ATP (800 Ci/mmol) was purchased from 
PerkinElmer, Rodgau Jügesheim, Germany. Lyophilized calmodulin from bovine 
brain was from Calbiochem (Darmstadt, Germany). Forskolin was supplied by LC 
Laboratories (Woburn, MA). For all experiments double-distilled water was used. 
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Fig. 2. General reaction scheme for the synthesis of mono- and bis-substituted (M)ANT-nucleotides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The principle of the one step synthesis of mono- and bis-substituted (M)ANT-nucleotides is shown. The conversion of nucleotide and diversified isatoic anhydride 
lead to the corresponding acylated nucleotide. 32 compounds were synthesized by variation of phosphate chain length, nucleobase, and anthraniloyl residue 
(details shown in Experimental section). 
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8B2.2 Synthesis of bis-substituted (M)ANT-nucleotides 
(M)ANT-nucleotides were synthesized according to Hiratsuka X43 X with modifications 
(details shown in Experimental section). Surprisingly, during the synthesis of MANT-
IMP we observed for the first time an intensive new peak at later retention time, when 
the crude reaction mixture was analyzed by reversed-phase HPLC (Fig. 3). Due to 
the long retention time of the unknown peak, a more lipophilic compound with 
additional unpolar groups was expected. From our previous studies X14 X, X15 X degradation 
of MANT-NTPs to MANT-NDPs under the basic reaction conditions was known, but a 
decomposition of inosine 5’-monophosphate was obviously not reasonable. Thus, a 
further substitution of a second MANT-group was hypothesized. The analysis of 
LC/MS online coupling corroborated the hypothesis. The esterfication of an additional 
MANT-group was identified by the mass per charge ratio of 613.2 Da for the negative 
ESI measurement. The chromatogram of the crude reaction mixture displayed the 
typical two peak system for the expected N-methyl-2’- and 3’-O-anthraniloyl 
nucleotide isomers at a retention time of 21.4 and 22.0 min. Seven minutes later the 
peak for Bis-MANT-ITP appeared (Rt = 29 min). The high polarity of non-reacted IMP 
resulted in a fast elution directly after the dead time (minor peak at Rt < 2 min). 
Further peaks are identified for the excess of methylisatoic anhydride (Rt ~17 min) 
and decomposition product of the nucleoside of hypoxanthine (Rt ~23 min). The 
assignment of all signals was achieved by LC/MS online coupling. For the  
Fig. 3. Analysis of the synthesis of MANT-IMP by HPLC 
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Chromatograms of MANT-IMP of the crude reaction mixture (A), after purification (B), and Bis-MANT-
IMP after purification (C) were recorded by analytical HPLC analysis. The conditions are described 
under “Experimental section”. Purification by size exclusion chromatography revealed high purity 
(> 99 %) for MANT-IMP and Bis-MANT-IMP. The retention times were 21.4/22.0 min for MANT-IMP 
and 29 min for Bis-MANT-IMP. mAU, milli absorbance unit. 
purification of monophosphate derivatives only size-exclusion chromatography was 
required yielding MANT-nucleotides of high purity of approximately 99 %. 
The obvious constitution of bis-substituted MANT-nucleotides is represented by a 2-
fold acylated IMP derivative of the two hydroxyl groups of the ribosyl ring. A 
convincing conformation for this assumption was delivered by the NMR 
spectroscopy. By one- and two-dimensional NMR measurements structure 
determination of Bis-MANT-IMP confirmed our suggestion of the second acylatated 
free hydroxyl group. Thus, proton spectrum showed two sets of signals for the two 
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methyl anthraniloyl groups (Fig. 4). Furthermore, HMBC spectrum definitely identified 
3J correlation between protons and quaternary carbons to ensure no substitution in 
the purine system of the nucleobase (data not shown).  
However, NMR spectroscopy is a less sensitive method and requires relatively high 
amount of compound, compared to HPLC and LC/MS analysis. Because of the time-
consuming and costly preparative HPLC purification of (M)ANT-NTPs, NMR 
spectroscopic data was performed only for the monophosphate derivative of Bis-
MANT-IMP. Moreover, newly synthesized compounds displayed similar properties in 
analytical and preparative HPLC and were clearly identified by LC/MS online 
coupling. The small amounts of (M)ANT-nucleotides were valuable for 
pharmacological analysis and also demanded in other important projects.  
Fig. 4. Proton spectrum of Bis-MANT-IMP 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure determination of Bis-MANT-IMP was solved by NMR spectroscopy (details shown in 
Experimental section). The proton spectrum with the assignment of proton peaks is shown. The two 
anthraniloyl groups are represented by two signals for the methyl group of carbon 14 and according 
peaks of the phenyl group at position 15, 16, 17, and 18. The preserved purine base is indicated by 
the two protons of carbon 6 and 9. 
At the beginning of our MANT-NTP synthesis X14 X, X15 X we never observed the forming of 
bis-substituted MANT-nucleotides. After the discovery of Bis-MANT-IMP we 
addressed the question, why Bis-MANT-nucleotides did not arise for triphosphate 
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chromatography for separation of starting materials. Non-reacted nucleotide and 
isatoic anhydride were removed by this method as a form of pre-cleaning. 
Unfortunately, bis-substituted MANT-nucleotides were lost by this separation as well. 
When we performed HPLC analysis of the crude reaction mixture without the pre-
cleaning, similar peaks as for Bis-MANT-IMP appeared in the chromatogram (Fig. 5). 
Diode array detection and fluorescence detection for HPLC analysis supported the 
assignment of bis-substituted (M)ANT-nucleotide signals, because of similarity of 
spectroscopic properties to mono-substituted (M)ANT-nucleotides, especially of UV 
absorption. 
Furthermore, the assignment of Bis-MANT-nucleotides was also confirmed by LC/MS 
online coupling. Under the basic reaction conditions degradation of the labile γ-
phosphate always occurred for mono- and bis-substituted (M)ANT-nucleotides. Thus, 
preparative HPLC was applied for the separation of (M)ANT-NTPs and (M)ANT-
NDPs. In general, the purification by this method offered the possibility to obtain four 
putative inhibitors simultaneously. However, due to the small retention time 
differences, the separation of diphosphate derivatives was more sensitive and the 
preparative HPLC conditions had to be chosen carefully to reach separation. 
Moreover, the (M)ANT-NDPs exhibited lower potencies in AC activity assay 
compared to (M)ANT-NTPs. Thus, purification of diphosphate derivatives were not 
carried out for all compounds. MANT-ATP and Bis-MANT-ATP displayed 
representative chromatograms for the preparative HPLC purification of mono- and 
bis-substituted (M)ANT-nucleotides in high purity (Fig. 5). 
Fig. 5. Analysis of the synthesis of MANT-ATP/Bis-MANT-ATP 
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HPLC chromatograms of the crude reaction mixture of the synthesis of MANT-ATP/Bis-MANT-ATP 
(A), after preparative HPLC purification for MANT-ATP (B) and Bis-MANT-ATP (C) are shown. The 
typical peak system of MANT-ATP occurred at the retention times of 20.2 and 20.4 min and the signal 
for Bis-MANT-ATP appeared at later retention time of 27 min. The corresponding diphosphate 
derivatives followed shortly after (A). The crude reaction mixture contained still starting material of ATP 
(Rt < 2 min), methylisatoic anhydride (Rt ~17.3 min), and nucleoside (Rt ~23.1 min) (A). The 
chromatograms after purification by preparative HPLC are displayed for MANT-ATP (B) and Bis-
MANT-ATP (C) as a representative result for mono- and bis-substituted (M)ANT-nucleotide 
separation. Both compounds were obtained simultaneously in high purity of 98 to 99 %. mAU, milli 
absorption units. 
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9B2.3 Cell culture and membrane preparation 
Cell culture and membrane preparation were performed as previously describedD17D. In 
brief, Sf9 cells were cultured in SF 900 II medium supplemented with 5 % (vol/vol) 
fetal bovine serum and 0.1 mg/ml gentamicin. High-titer baculoviruses for ACs 1, 2 
and 5 were generated through two sequential amplification steps as previously 
described X17 X,D18D. In each amplification step the supernatant fluid was harvested and 
stored under light protection at 4 °C. For membrane preparation Sf9 cells (3.0 x 
106 cells/ml) were infected with corresponding baculovirus encoding different 
mammalian ACs (1:100 dilutions of high-titer virus) and cultured for 48 hours. 
Membranes expressing each construct and membranes from uninfected Sf9 cells 
were prepared as described X17 X. Cells were harvested and cell suspensions were 
centrifuged for 10 min at 1,000 x g at 4 °C. Pellets were resuspended in 10 ml of lysis 
buffer (1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptine and 
10 μg/ml benzamide, pH 7.4). Thereafter, cells were lyzed with 20 – 25 strokes using 
a Dounce homogenizer. The resultant cell fragment suspension was centrifuged for 5 
min at 500 x g and 4 °C to sediment nuclei. The cell membrane-containing 
supernatant suspension was transferred into 30 ml tubes and centrifuged for 20 min 
at 30,000 x g and 4 °C. The supernatant fluid was discarded and cell pellets were 
resuspended in buffer consisting of 75 mM Tris/HCl, 12.5 mM MgCl2, and 1 mM 
EDTA, pH 7.4. Membrane aliquots of 1 ml were prepared, stored at -80 °C and 
protein concentration for each membrane preparation was determined using the Bio-
Rad DC protein assay kit (Bio-Rad, Hercules, CA).  
10B2.4 AC activity assay 
AC activity in Sf9 membranes expressing ACs 1, 2 or 5 was determined essentially 
as described in the literatureX18 X. Before starting experiments, membranes were 
sedimented by a 15 min centrifugation at 4 °C and 15,000 x g and resuspended in 
75 mM Tris/HCl, pH 7.4. Reaction mixtures (50 μl, final volume) contained 20 - 40 μg 
of membrane protein, 40 μM ATP/Mn2+ plus 5 mM MnCl2, 100 μM FS, 10 μM GTPγS 
and (M)ANT-nucleotides at concentrations from 0.1 nM to 1 mM as appropriate to 
obtain saturated inhibition curves. Following a 2 min pre-incubation at 37 °C, 
reactions were initiated by adding 20 μl of reaction mixture containing (final) 1.0 -
 1.5 μCi/tube [α-32P]ATP and 0.1 mM cAMP. AC assays were conducted in the 
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absence of an NTP-regenerating system to allow for the analysis of (M)ANT-NDPs 
that could otherwise be phosphorylated to the corresponding (M)ANT-NTPs X18 X. 
Reactions were conducted for 20 min at 37 °C and were terminated by adding 20 μl 
of 2.2 N HCl. 
For the determination of CyaA inhibitionX15 X, assay tubes contained 10 µl of inhibitor at 
final concentrations from 1 nM to 100 µM and 20 µl of CyaA protein (final 
concentration, 10 pM) in 75 mM HEPES/NaOH, pH 7.4, containing 0.1 % (m/v) 
bovine serum albumin. After a 2 min pre-incubation at 25 °C reactions were initiated 
by the addition of 20 µl of reaction mixture consisting of the following components to 
yield the given final concentrations: 100 mM KCl, 10 µM free Ca2+, 5 mM free Mn2+, 
100 µM EGTA, 100 µM cAMP and 100 nM calmodulin. ATP was added as 
nonlabeled substrate at a final concentration of 40 µM and as radioactive tracer [α-
32P]ATP (0.2 µCi/tube). For the determination of Km and Vmax values in kinetic 
studies, 10 µM to 2 mM ATP/Mn2+ were added, plus 5 mM free Mn2+. To ensure 
linear reaction progress, tubes were incubated for 10 min at 25 °C and reactions 
were stopped by the addition of 20 µl of 2.2 N HCl. Denatured protein was 
precipitated by a 1 min centrifugation at 25 °C and 15,000 x g. Sixty μl of the 
supernatant fluid were applied onto disposable columns filled with 1.3 g neutral 
alumina. [32P]cAMP was separated from [α-32P]ATP by elution of [32P]cAMP with 4 ml 
of 0.1 M ammonium acetate, pH 7.0. Recovery of [32P]cAMP was ~80 % as assessed 
with [3H]cAMP as standard. Blank values were approximately 0.02 % of the total 
added amount of [α-32P]ATP; substrate turnover was < 3 % of the total added [α-
32P]ATP. Samples collected in scintillation vials were filled up with 10 ml of double-
distilled water and Čerenkov radiation was measured in a Tri-Carb 2800TR liquid 
scintillation analyzer (PerkinElmer Life and Analytical Sciences).  
Free concentrations of divalent cations were calculated with Win-MaxC 
(http://www.stanford.edu/_cpatton/maxc.html). Competition isotherms were analyzed 
by non-linear regression using the Prism 4.0 software (GraphPad, San Diego, CA). 
Km; values were 120 µM (AC1), 100 µM (AC2), 70µM (AC5) and were taken from 
Gille et al. X18 X for mAC. Km value for bacterial toxin CyaA was 45 µM and was 
determined in our previous studiesX15 X. 
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11B2.5 Fluorescence spectroscopy 
Experiments were conducted using a quartz UV ultra-micro cuvette from Hellma 
(Müllheim, Germany) (light path length, 3 mm; center, 15 mm; total volume, 70 µl; 
type 105.251-QS). Measurements were carried out in a Cary Eclipse fluorescence 
spectrometer (Varian, Inc., Palo Alto, CA, USA) at a constant temperature of 25 °C 
(scan rate, 120 nm/min; averaging time, 0.5 s; PMT voltage, 700 V, data interval, 1 
nm; slit width, 5 nm). Initially, the cuvette contained 64 µl of 75 mM HEPES/NaOH 
buffer, 100 µM CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Next, nucleotide, CyaA 
and CaM were added successively. The cuvette content was mixed after each 
addition to end up with a total volume of 70 µl. In direct fluorescence experiments, 
(M)ANT nucleotides were excited at 350 nm and steady-state emission spectra were 
recorded from 380 to 550 nm at low speed. For CyaA and CaM final concentrations 
of 2.4 µM were necessary to obtain sufficiently large increase in direct fluorescence. 
Basal fluorescence, consisting of buffer alone, was subtracted. (M)ANT-nucleotides 
were finally displaced from CyaA by 9-[2-(phosphonomethoxy)ethyl]adenine 
diphosphate (PMEApp) in concentrations of 100 nM to 3 µM. For an estimation of the 
hydrophobic properties of the binding site interacting with the MANT-group, direct 
fluorescence of mono- and bis-(M)ANT-nucleotides was determined with dimethyl 
sulfoxide ranging from 0 – 100 % (vol/vol). Fluorescence recordings were analyzed 
with the spectrum package of the Cary Eclipse software (Varian). Fluorescence 
polarization spectroscopy was conducted by a multifrequency luminescence 
spectrometer K2 from ISS using a quartz UV micro cuvette (Hellma, 10 x 2 mm). 
12B .6 Modeling of the nucleotide binding mode to CyaA 
Docking studies were performed with the molecular modeling package SYBYL 7.3 
(Tripos Inc., St. Louis, MO) on an Octane workstation (SGI, Mountain View, CA). An 
initial computer model of CyaA in complex with PMEApp was generated from the 
PDB crystal structure 1zot X29 X. Hydrogens were added and AMBER_FF99 charges 
were assigned to the protein and the water molecules, followed by a rough 
preoptimization of the model (100 cycles) with the AMBER_FF99 force fieldD19D and 
fixed PMEApp. The three Mg2+ ions received formal charges of 2. Starting 
conformations of 3’-MANT-2’d-ATP and Bis-Br-ANT-ATP were derived from 
complexes of 3’-MANT-ATP and TNP-ATP with mammalian AC (PDB structures 2gvz 
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and 2gvd, respectively) X27 X, X28 X. PMEApp and the ligands 3’-MANT-2’d-ATP and Bis-Br-
ANT-ATP were provided with Gasteiger-Hueckel charges. Initial docking positions 
resulted from superposition of roughly optimized conformations with PMEApp, 
allowing the modification of rotatable bonds, and from consideration of the 
fluorescence data (interaction of the MANT-group with Phe306). Water molecules in 
the catalytic site were removed. Each complex was refined in a stepwise approach. 
First, ~50 minimization cycles with fixed ligand (AMBER_FF99 force field, steepest 
descent method) were performed; second, ~100 minimization cycles of the ligand 
and the surrounding (distance up to 6 Å) protein residues (Tripos force field)D20D , and, 
third, ~100 minimization cycles with fixed ligand (AMBER_FF99 force field, Powell 
conjugate gradient). The second and third steps were repeated with larger number of 
cycles until an root-mean-square force of 0.05 kcal/mol × Å-1 was approached. To 
avoid overestimation of electrostatic interactions, a distance-dependent dielectric 
constant of 4 was applied. Molecular surfaces and lipophilic potentials [protein variant 
with the new Crippen parameter tableD21D,D22D] were calculated and visualized by the 
program MOLCAD (MOLCAD, Darmstadt, Germany) contained within SYBYL. 
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3B .  Results and Discussion 
13B .1 Overview on nucleotide structures 
We examined the inhibitory effect of 32 nucleotides on the catalytic activity of 
mammalian ACs 1, 2, 5 and bacterial CyaA toxin (Table 1). Nucleotides differed from 
each other in base of adenine, hypoxanthine, cytosine and in phosphate chain length 
of mono-, di- or triphosphate. Furthermore, nucleotides varied in mono- and bis-
substitution at the 2’, 3’ position of the ribosyl ring by anthranilic acid groups. Mono-
substituted compounds (1 – 16) undergo spontaneous isomerization under 
physiological pH between the 2’- and 3’- ribosyl positionD23D,D24D. For bis-substituted 
nucleotides (17 – 32) both hydroxyl groups of the ribosyl cycle are replaced by 
anthranilic acid groups. The anthraniloyl (ANT) moiety differed by hydrogen, 
halogens of chlorine and bromine, and acetylated amino residue in 5 position of the 
phenyl ring system (Fig. 2:R1). Moreover, substitution at the amino function of the 
ANT-group lead to methyl (MANT) and propyl (Pr-ANT) derivatives (Fig. 2:R2). The 
potencies of the different nucleotides were determined in the AC activity assay in the 
presence of the cation Mn2+. 
14B3.2 Structure – activity relationships of mono-substituted (M)ANT-nucleotides 
for mAC 
Recombinant ACs 1, 2, 5 showed different sensitivity to inhibition by (M)ANT-
nucleotides (Table 1). In accordance with previous studies X18 X,D25D,D26D AC2 constitutes the 
AC isoform with the lowest inhibitor affinity due to the exchange of Ala409Pro and 
Val1108Ile in AC1 and AC5 versus AC2D27D. (M)ANT-NTPs of the purine base 
hypoxanthine had the highest impact, especially MANT-ITP is the most potent 
inhibitor known so far for AC1 and AC5 with Ki values of 1 – 3 nM. The exchange of 
nucleobase adenine with cytosine displayed only marginal differences in potency (1 
and 3). The halogenated ANT-ATP derivatives (4 and 6) showed in comparison to 
MANT-ATP (1) slightly more potent inhibition effect for mACs, but the corresponding 
inosine compounds (5 and 7) exhibited lower potency on a still high level. 
Substitution of bromine with chlorine of anthraniloyl inosine triphosphates induced 2-
fold more potent inhibition for mAC (7→5). Elongation of the alkyl residue from N-
methylated to N-propylated ANT-nucleotides lowered Ki values 3- to 8-fold (1→8, 
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 Table 1. Inhibition of catalytic activity of recombinant ACs 1, 2, 5 and bacterial AC toxin CyaA by (M)ANT-nucleotides 
 (M)ANT-nucleotide AC 1 (nM) AC 2 (nM) AC 5 (nM) CyaA (nM) 
1 MANT-ATP  150 ± 40  330 ± 100  100 ± 30  4,300 ± 400 
2 MANT-ITP  2.8 ± 0.9  13.5 ± 0.5  1.2 ± 0.1  600 ± 100 
3 MANT-CTP  150 ± 30  690 ± 20  150 ± 30  1,100 ± 100 
4 Cl-ANT-ATP  80 ± 4  490 ± 20  45 ± 1  350 ± 40 
5 Cl-ANT-ITP  3.3 ± 0.3  8 ± 1  2.0 ± 0.2  700 ± 200 
6 Br-ANT-ATP  120 ± 20  450 ± 40  70 ± 20  330 ± 30 
7 Br-ANT-ITP  7.0 ± 0.1  22 ± 4  4.6 ± 0.4  920 ± 50 
8 Pr-ANT-ATP  440 ± 20  1,100 ± 100  360 ± 60  820 ± 250 
9 Pr-ANT-ITP  22 ± 1  68 ± 12  10 ± 2  3,800 ± 500 
10 Ac-NH-ANT-ATP  6,800 ± 200  11,000 ± 1,000  3,400 ± 40  710 ± 40 
11 Ac-NH-ANT-ITP  140 ± 30  390 ± 80  37 ± 7  4,800 ± 900 
12 MANT-ADP  1,300 ± 200  2,900 ± 500  800 ± 200  12,000 ± 2,000 
13 MANT-IDP   39 ± 12  86 ± 9  31 ± 12  11,000 ± 3,000 
14 Br-ANT-ADP  560 ± 10   1,700 ± 100   280 ± 20  8,700 ± 1,300 
15 MANT-IMP  4,600 ± 400  8,200 ± 800  3,400 ± 200 > 100,000 
16 ANT-IMP  7,400 ± 1,200  7,500 ± 1,400  4,300 ± 600 > 100,000 
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17 Bis-MANT-ATP  700 ± 200  2,100 ± 600  430 ± 50  360 ± 10 
18 Bis-MANT-ITP  310 ± 20  1,100 ± 200  140 ± 40  3,000 ± 400 
19 Bis-MANT-CTP  620 ± 40  7,800 ± 100  750 ± 40  2,500 ± 500 
20 Bis-Cl-ANT-ATP  1,700 ± 100  2,400 ± 100  1,600 ± 100  16 ± 1 
21 Bis-Cl-ANT-ITP  66 ± 1  200 ± 10  65 ± 3  15 ± 1 
22 Bis-Br-ANT-ATP  670 ± 50  1,100 ± 100  900 ± 90  12.6 ± 0.3 
23 Bis-Br-ANT-ITP  21 ± 1  71 ± 2  15 ± 2  20 ± 2 
24 Bis-Pr-ANT-ATP  18,000 ± 3,000  36,000 ± 3,000   18,000 ± 5,000  700 ± 200 
25 Bis-Pr-ANT-ITP  440 ± 10  1,400 ± 100  250 ± 20  2,100 ± 100 
26 Bis-Ac-NH-ANT-ATP  22,000 ± 1,000  7,000 ± 1,000  6,100 ± 1,300  280 ± 20 
27 Bis-Ac-NH-ANT-ITP  1,700 ± 100  5,600 ± 300  480 ± 30  7,500 ± 100 
28 Bis-MANT-ADP  700 ± 300   1,600 ± 300   510 ± 70  6,500 ± 800 
29 Bis-MANT-IDP   1,000 ± 100  1,400 ± 100  700 ± 200  6,600 ± 900 
30 Bis-Br-ANT-ADP  1,600 ± 300  3,300 ± 200  1,800 ± 200  91 ± 5 
31 Bis-MANT-IMP > 100,000 > 100,000 > 100,000  20,000 ± 3,000 
32 Bis-ANT-IMP > 100,000 > 100,000 > 100,000  12,000 ± 3,000 
 
AC activity of bacterial toxin CyaA and in Sf9 membranes were determined as described in “Materials and Methods”. Non-linear regression analysis was used 
for calculation of Ki values from IC50 values. Data are given in nanomolar and are the mean values ± SD of 4 – 5 independent experiments performed in 
triplicates with at least two different membrane preparations (for mACs). 
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2→9). A further decrease in potency was observed for the acetylated amino 
anthraniloyl nucleotides. The inhibition effect for Ac-NH-ANT-ATP (10) dropped into 
micromolar range and the corresponding inosine derivative (11) was 30- to 50-fold 
less potent than MANT-ITP (2). Interestingly, Ac-NH-ANT-ITP (11) displayed a 4-fold 
higher selectivity for AC5 than for AC1. Deletion of the γ-phosphate reduced inhibitor 
affinity 3- to 26-fold (1→12, 2→13, 6→14) and is in accordance with previous data. 
Mou et al. explained by crystallographic studies that the Mn2+ ion in the B-site 
coordinates with the γ-phosphate of MANT-nucleotides. The lack of this phosphate 
group destabilizes the polyphosphate chain in its binding site X27 X,D28D. The deletion of the 
β-phosphate group of the MANT-NMP reduced inhibitor potency 120-fold (13→15). 
Exchange of the MANT-group with an ANT-group had only little effect on inhibitor 
affinity (15→16). 
15B3.3 Structure – activity relationships of mono-substituted (M)ANT-nucleotides 
for CyaA 
In principle, the inhibitor affinity of bacterial CyaA toxin for mono-substituted (M)ANT-
NTPs was lower in comparison to mAC or reached maximally the affinity range of 
AC2. The general preference for a nucleobase was also less pronounced. MANT-
ATP (1) was less potent than MANT-ITP (2), but at all other combinations of 
adenosine and inosine derivatives the corresponding ANT-ATPs exhibited higher 
inhibition potency (4→5, 6→7, 8→9, 10→11). Recent studies from our laboratory 
showed that MANT-CTP (3) is the most potent MANT-nucleotide inhibitor of edema 
factor (EF) of the spore-forming bacterium Bacillus anthracis with the Ki value of 
100 nM X14 X. This preference for the nucleobase cytosine was not observed for CyaAX15 X. 
Insertion of halogens in ANT-ATPs lead to a reduction of Ki values by 12- to 13-fold 
(1→4, 1→6). However, the Ki values of the corresponding inosine derivatives 
remained almost constant (2→5, 2→7). Pr-ANT-ATP (8) and Ac-NH-ANT-ATP (10) 
revealed still stable inhibition potency, but Pr-ANT-ITP (9) and Ac-NH-ANT-ITP (11) 
lost 6- to 8-fold inhibitor affinity compared to MANT-ITP (1). Deletion of γ-phosphate 
reduced inhibitor potency 3- to 20-fold and omission of γ- and β-phosphate reduced 
the inhibitory potency to the high micromolar range. Due to limitations of available 
material, the exact determination of low inhibition effects in millimolar range was 
avoided. 
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16B3.4 Structure – activity relationships of bis-substituted (M)ANT-nucleotides for 
mAC 
Overall, bis-substituted (M)ANT-nucleotides exhibited lower inhibition potency for 
ACs 1, 2 and 5 than the corresponding mono-substituted derivatives. For the highest 
inhibition affinities of Bis-(M)ANT-NTPs the nucleotide inosine is still required. Bis-
MANT-ATP (18) and Bis-MANT-CTP (19) inhibited AC1 and AC5 with almost equal 
potency. The preference for AC2 of this pair of compounds was 4-fold less 
pronounced by Bis-MANT-CTP (19). Bis-halogen-ANT-ITPs (21 and 23) showed 
impressive Ki values between 15 – 66 nM for AC1 and AC5, but the corresponding 
adenine nucleotides (20 and 22) exhibited 25- to 60-fold lower potency. N-propylated 
instead of N-methylated ANT-nucleotides lost affinity dramatically only for Bis-Pr-
ANT-ATP (24) (17- to 42- fold) but not for Bis-Pr-ANT-ITP (25). Bis-Ac-NH-ANT-ATP 
(26) exhibited a low inhibition potency, but possessed 3-fold higher sensitivity for AC2 
and AC5. Usually, the remaining inhibitors showed higher potencies at ACs 1 and 5 
than AC2. Interestingly, Bis-MANT-ADP (28) was as potent as Bis-MANT-ATP (17) 
and Bis-MANT-IDP (29), Bis-Br-ANT-ADP (30) were only 1.3- to 5-fold less potent 
than the corresponding (M)ANT-NTPs. Bis-MANT-IMP (31) and Bis-ANT-IMP (32) 
showed almost no affinity for mACs. 
17B3.5 Structure – activity relationships of bis-substituted (M)ANT-nucleotides for 
CyaA 
Bis-substituted (M)ANT-NTPs exhibited a broad variety in potency by showing Ki 
values from the low nanomolar up to the micromolar range. In general, inhibition 
effects of compounds possessing the nucleobase adenine were more pronounced. 
Bis-MANT-CTP (19) and Bis-MANT-ITP (18) exhibited 7- and 8-fold lower inhibition 
potency than Bis-MANT-ATP (17). Interestingly, halogenated ANT-nucleotide 
derivatives (20 – 23) increased the inhibition affinity 20- to 240-fold compared to Bis-
MANT-nucleotides (16 – 19). Most strikingly, Bis-Br-ANT-ATP (22) showed the 
lowest Ki value of 12.6 nM for CyaA. So far, the most potent inhibitor for bacterial 
CyaA toxin is PMEApp (Ki value: 1 – 25 nM)X15 X,D29D. Thus, we found an inhibitor 
displaying similar potency. The remaining halogen-ANT-NTPs differed only slightly 
with Ki values between 15 – 20 nM. For the chlorine compounds (20 and 21) no 
preference of nucleobase was observable. The affinity of Bis-Pr-ANT-ATP (24) was 
decreased 2-fold compared to Bis-MANT-ATP (17). However, the corresponding 
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propylated inosine derivative (25) exhibited an increase in potency regarding Bis-
MANT-ITP (18). The bulky acylated amino substituent afforded relatively stable 
inhibition affinities for Bis-Ac-NH-ANT-ATP and Bis-Ac-NH-ITP (26 and 27). Again, 
deletion of the γ-phosphate reduced potency of Bis-(M)ANT-NDPs (28 – 30). 
Although, Bis-(M)ANT-NMPs (31 and 32) constitute the end in rank order of affinity 
we paid, for the first time, attention to the couple MANT-IMP (15) and Bis-MANT-IMP 
(31) because of the significant increase in potency by connectivity of a second 
MANT-group X15 X. Afterwards, we observed this phenomenon for most combinations of 
mono- and bis-substituted (M)ANT-NTPs and for all (M)ANT-NDPs. For our high 
potent halogen ANT-nucleotides esterification of the second hydroxyl group of the 
ribosyl residue exhibited 18- to 73-fold (4 – 7→20 – 23) increase in affinity. Bis-
propylated ANT-nucleotides and Bis-Ac-NH-ANT-ATP displayed slight enhancement 
in potency (8 – 10→24 – 26). Exceptions of the rule were Bis-MANT-ITP (17), Bis-Ac-
NH-ANT-ATP (27), and Bis-MANT-CTP (19) exhibiting lower affinity in comparison 
with the corresponding mono-substituted derivatives. 
18B3.6 Selectivity aspects for bacterial CyaA  
In previous studies X18 X potent MANT-nucleotide inhibition for mAC was observed, but 
with lower affinity for bacterial CyaA toxin. In this study we found, for the first time, 
not only high potent (M)ANT nucleotide derivatives for CyaA inhibition, but also 
inhibitors with selectivity for CyaA versus ACs 1, 2, and 5. Bis-substituted 
halogenated ANT-nucleotides of adenosine demonstrated the best selectivity ratio. 
Bis-Cl-ANT-ATP (20) is the most interesting compound with a preference of 100- to 
150-fold for CyaA. The most potent inhibitor Bis-Br-ANT-ATP (22) exhibited high 
selectivity as well (50- to 90-fold). However, Bis-halogen-ANT-ITPs (21 and 23) 
displayed similar potency for bacterial AC, but marginal selectivity. Interestingly, the 
more space filling propyl and acetylated amino group of ANT-ATPs implemented also 
selectivity aspects. Bis-Propyl-ANT-ATP (24) was 26- to 52-fold more selective for 
CyaA compared to mAC and Bis-Ac-NH-ANT-ATP (26) 20- to 80-fold. For acylated 
amino ANT-nucleotides even the mono-substituted derivative (10) yielded a 5- to 15-
fold selectivity. 
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19B3.7 Analysis of the enzyme kinetics of CyaA 
Historically, two classes of AC inhibitors are known, i.e. so-called P-site inhibitors: 
that are non-competitive (or uncompetitive) inhibitors and competitive inhibitors. P-
site inhibitors are adenosine and adenine nucleotide analogues including an intact 
purine ringD30D,D31D. Most P-site inhibitors require a pyrophosphate (PPi) as a cofactor 
and capture an AC-PPi conformationD32D,D33D. 2’-Deoxyadenosine or 2’-deoxy-3’-AMP, 
exhibited uncompetitive inhibition in presence of Gsα and Mg2+, and non-competitive 
kinetics with Mn2+ X31 X. However, β-L-2’,3’-dd-5’-ATP including the triphosphate group in 
5’-position leads to a competitive inhibition process X33 X. Moreover, various nucleotides 
are competitive inhibitors for ACsD34D like ATPαS (Rp-diastereoisomer)D35D,D36D. The kinetic 
pattern of MANT-substituted nucleotides is also well understood. Specifically, MANT-
nucleotides were observed as competitive AC inhibitors in S49 lymphoma cell 
membranesD37D. A validation for the competitive antagonism was achieved by further 
studies of the catalytical subunits C1/C2 of mACsX18 X. 
Therefore, we expected for our newly synthesized mono- and bis-substituted 
(M)ANT-nucleotides identical behavior as for mono-substituted MANT-nucleotides. 
To prove our hypothesis enzyme kinetics of CyaA were conducted with two pairs of 
compounds: MANT-ATP (1) / Bis-MANT-ATP (17) and Br-ANT-ATP (6) / Bis-Br-ANT-
ATP (22) (Fig. 6). Lineweaver-Burk double-reciprocal plotting of CyaA inhibition 
kinetics displayed competitive inhibition pattern for both types of substituted (M)ANT-
nucleotides. The linear regression lines intersected at the y-axis, i.e. Vmax remained 
constant, whereas Km increased with rising inhibitor concentrations. These 
investigations are in accordance with recent literature data X14 X according to which the 
bacterial AC toxin edema factor (EF) from Bacillus anthracis was inhibited 
competitively by MANT-nucleotides. 
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Fig. 6. Enzyme kinetics with mono- and bis-substituted (M)ANT-nucleotides 
AC activity of bacterial CyaA toxin was determined as described under “Material and Methods” with 
the indicated concentrations of MANT-ATP (0 µM, 2 µM, 10 µM, 20 µM) (A) and Bis-MANT-ATP (0 
nM, 0.5 µM, 2.5 µM, 5.0 µM) (B). Reaction mixtures contained 10 pM CyaA, 100 mM KCl, 10 µM free 
Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 100 nM calmodulin, 0.2 µCi/tube [α-32P]ATP and 
unlabeled ATP/Mn2+ concentrations indicated in the graph. Data were plotted double reciprocally and 
analyzed by linear regression according to Lineweaver-Burk. The r2 values of the regression lines 
were 0.97 – 0.99. Shown are the results of a representative experiment performed in triplicates. 
Similar results were obtained in at least two different experiments. 
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AC activity of bacterial CyaA toxin was determined as described under “Materials and Methods” with 
the indicated concentrations of Br-ANT-ATP (0 µM, 1 µM, 2.5 µM, 5 µM) (C) and Bis-Br-ANT-ATP (0 
nM, 100 nM, 250 nM, 500 nM) (D). Reaction mixtures contained 10 pM CyaA, 100 mM KCl, 10 µM 
free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 100 nM calmodulin, 0.2 µCi/tube [α-32P]ATP 
and unlabeled ATP/Mn2+ concentrations indicated in the graph. Data were plotted double-reciprocally 
and analyzed by linear regression according to Lineweaver-Burk. The r2 values of the regression lines 
were 0.96 – 0.99. Shown are the results of a representative experiment performed in triplicates. 
Similar results were obtained in at least two different experiments. 
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20B3.8 Fluorescence spectroscopy  
FRET experiments 
For fluorescence spectroscopic investigations of MANT-nucleotides two principal 
methods are under consideration X15 X, X27 X, X28 X,D38D, i.e. fluorescence resonance energy 
transfer (FRET) experiments and direct fluorescence spectroscopy. FRET 
experiments are an important tool for investigations of structure-response 
relationships of the catalytical AC binding site. 
The approach of FRET analysis includes advantages compared to direct 
fluorescence studies X15 X. For sufficient FRET recordings the final enzyme 
concentration for CyaA was reduced to 300 nM (direct fluorescence: 2.4 µM). 
Moreover, FRET can only occur directly in the catalytic binding pocket, because of 
the two tryptophan residues, Trp69 and Trp242, located 21 and 38 Å away from the 
catalytic siteX29 X. These distances allow FRETX38 X from tryptophan (excitation 
wavelength, 280 nm; emission wavelength, 350 nm) to MANT (excitation wavelength, 
350 nm; emission wavelength, ~450 nm). In previous studies X15 X deoxygenated MANT-
nucleotides like 2’-MANT-3’d-ATP exhibited significant FRET for CyaA, but for 2’,(3’) 
isomeric MANT-nucleotides the transfer of energy was absent or only minimal in 
fluorescence recordings. Thus, the isomerization of the MANT-group may impede 
energy capture of the fluorophore from tryptophan and tyrosine residues. Moreover, 
in this study newly synthesized mono-2’,(3’) isomeric (M)ANT-nucleotides revealed 
no significant energy transfer in fluorescence analysis, as well. Furthermore, addition 
of the second (M)ANT-group in bis-substituted (M)ANT-nucleotides did not change 
these fluorescence properties and exhibited no FRET, as well (Fig. 7). The labeled 
nucleotide was added first to the buffer and weak autofluorescence occurred without 
a maximum as a result of excitation at 280 nm (brown line). When CyaA was added, 
tryptophan and tyrosine fluorescence was detected at 350 nm (blue line). Upon 
addition of CaM, decrease in emission at 350 nm occurred clearly, but increase in 
emission at 430 nm did not arise significantly over the CyaA level (FRET; red line → 
blue line). Although, Bis-MANT-ATP was abounded (1 µM concentration) and CyaA 
saturation by the fluorophore is assumable, the FRET signal was weak and not 
significant over signal to noise ratio. Thus, we focused our measurements on direct 
fluorescence analysis. 
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Fig. 7. FRET analysis of Bis-MANT-ATP 
Monitoring of FRET with Bis-MANT-ATP as a representative bis-substituted (M)ANT-nucleotide 
binding to the catalytic site of CyaA. The assay buffer contained 75 mM HEPES/NaOH, 100 µM CaCl2, 
100 mM KCl, and 5 mM MnCl2, pH 7.4. Bis-MANT-ATP was added to the buffer to yield a final 
concentration of 1 µM and emission was scanned from 300 nm to 550 nm at an excitation wavelength 
of 280 nm. CyaA and CaM were added successively to yield a final concentration of 300 nM. Shown 
are superimposed recordings of a representative experiment. Similar data were obtained with other 
bis-substituted (M)ANT-nucleotides. a.u., arbitrary unit. 
Direct fluorescence experiments 
In direct fluorescence experiments we observed important differences in the intrinsic 
fluorescence between mono- and bis-substituted (M)ANT-nucleotides. Although, 
nucleotides differ in mono-/bis-substiution and in diversified anthraniloyl groups 
wavelengths of absorption and emission spectra were similar. Nucleotides were 
excited at 350 nm and emission was scanned from 380 to 550 nm. As a 
representative experiment the pair of MANT-ATP and Bis-MANT-ATP was compared 
(Fig. 8). MANT-ATP was added first to the buffer, displaying high autofluorescence at 
λem= 449 nm (brown line). Addition of CyaA did not change the intrinsic fluorescence 
significantly (blue line). However, upon addition of CaM, fluorescence increased by 
approximately 36 % in accordance to our previous studiesX15 X. 
Interestingly, Bis-MANT-ATP revealed a nearly 20-fold lower autofluorescence 
(brown line) compared to MANT-ATP. The addition of CyaA into the cuvette 
containing Bis-MANT-ATP increased fluorescence by 4-fold. Moreover, emission 
maximum was shifted to shorter wavelength (blue shift). Thus, binding of MANT-
nucleotides to CyaA transferred the MANT-group into a hydrophobic environment, 
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Fig. 8. Fluorescence emission of MANT-ATP (A) and Bis-MANT-ATP (B) 
Monitoring of MANT-nucleotide binding to the catytic site of CyaA using direct fluorescence. The assay 
buffer contained 75 mM HEPES/NaOH, 100 µM CaCl2, 100 mM KCl, and 5 mM MnCl2, pH 7.4. MANT-
ATP (A) and Bis-MANT-ATP (B) were added to the buffer to yield a final concentration of 2 µM and 
emission was scanned at an excitation wavelength of 350 nm. CyaA and CaM were added 
successively to yield a final concentration of 2.4 µM. Shown are superimposed recordings of a 
representative experiment. Similar data were obtained in three independent experiments. 
Fluorescence intensities are given in a.u. (arbitrary unit). 
Fig. 9. Fluorescence changes of MANT-ATP and Bis-MANT-ATP in an hydrophobic
 environment 
MANT-ATP (A) and Bis-MANT-ATP (B) were added to water-DMSO mixtures ranging from 0 – 100 % 
(vol/vol) to yield a final concentration of 2 µM. Nucleotides were directly excited at λex= 350 nm to 
mimic binding of the MANT-group to a hydrophobic binding pocket. Shown are superimposed 
recordings of a representative experiment. Similar data were obtained in two independent 
experiments. a.u., arbitrary unit. 
probably facilitating interaction with Phe306 X15 X, X29 X, but without the activator CaM. Upon 
addition of CaM, Bis-MANT-ATP displayed full signal of fluorescence increase (6-fold 
higher compared to basal nucleotide fluorescence). For binding of mono-substituted 
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MANT-nucleotides to CyaA, binding of CaM is required. However, Bis-MANT-
nucleotides revealed binding to CyaA without the activator CaM. In analogy, TNP-
nucleotides are reported to display similar protein interaction with CyaA aloneX15 X.  
In comparison, direct fluorescence was determined in a gradient hydrophobic 
environment (Fig. 9). Experiments were conducted for MANT-ATP and Bis-MANT-
ATP with dimethyl sulfoxide (DMSO) ranging from 0 – 100 % (vol/vol). Fluorescence 
of MANT-ATP increased from water environment to pure DMSO by only 5-fold. On 
the contrary, Bis-MANT-ATP exhibited fluorescence increase by ~40-fold. Thus, 
independently from a 12-fold higher potency for CyaA, Bis-MANT-ATP displayed an 
excellent signal to noise ratio for the fluorescence analysis of CyaA. Blue shifts were 
significantly detected for both classes of compounds (MANT-ATP: λmax= 448 nm → 
426 nm, Bis-MANT-ATP: λmax= 445 nm → 429 nm). It should be noted, that the 
fluorescence intensities were 3- to 4-fold lower for Bis-MANT-ATP compared to 
MANT-ATP. 
In kinetic experiments fluorescence was inhibited by the non-fluorescent nucleotide 
analog PMEAppD39D in a concentration dependent manner (Fig. 10). Due to the higher 
potency of PMEApp half-maximal displacement of 2 µM Bis-MANT-ATP occurred
Fig. 10. Competitive kinetic experiment with PMEApp  
Time-resolved activation of CyaA by CaM and stepwise abolishment of direct fluorescence by 
PMEApp. Excitation wavelength was 350 nm and emission was detected at 440 nm over time. 2 µM 
Bis-MANT-ATP (1), 2.4 µM CyaA (2), 2.4 µM CaM (3), and PMEApp in the given concentrations 
(addition steps 4, 100 nM; 5, 500 nM; 6, 1 µM; 7, 2 µM; 8, 3 µM) were added in sequence. A recording 
of a representative experiment is shown. Similar data were obtained in three independent 
experiments. a.u., arbitrary unit. 
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at a PMEApp concentration of approximately 1 µM. Fluorescence change of CyaA 
stimulated by CaM and inhibition by PMEApp occurred within mixing time (a few 
seconds). These data show that direct fluorescence analysis was rapid, specific, and 
reversible. Because fluorescent nucleotides, e.g. Bis-MANT-ATP, were competitively 
displaced from CyaA by PMEApp, the affinity of nonlabeled inhibitors may also be 
estimated using this approach. Furthermore, the production of CyaA can be 
accomplished at large scale X16 X, and kinetics occur within seconds. Thus, fluorimetric 
high-throughput screening of potential novel inhibitors is feasible, avoiding the use of 
radioactive AC assays. 
Experiments with two additional compound pairs, i.e. MANT-ITP/Bis-MANT-ITP and 
Br-ANT-ATP/Bis-Br-ANT-ATP showed similar fluorescence properties as with MANT-
ATP/Bis-MANT-ATP. Control experiments were conducted to rule out false-positive 
fluorescence signals (data not shown): e.g. combination of CaM and fluorophore 
without CyaA caused no signal and denatured CyaA (10 min at 95 °C) reduced 
fluorescence to basal response. 
Saturation experiments by direct fluorescence analysis 
By determination of direct fluorescence with mono- and bis-MANT-derivatives at 
increasing concentrations after addition of CaM, saturation curves were obtained 
(Fig. 11). Final concentrations of nucleotide varied from 100 nM to 10 µM. Although 
saturation was not completely accomplished, higher inhibitor concentration 
measurements (>10 µM) were avoided to prevent intrinsic quenching of the 
fluorophore. KD values were estimated to 6.4 µM for Bis-MANT-ITP and 4.5 µM for 
Bis-Br-ANT-ATP. Due to the high concentration of CyaA (protein concentration 2.4 
µM) needed, saturation could not achieved for e.g. Bis-Br-ANT-ATP (Ki = 12 nM) in 
nanomolar range. Thus, Kd values exhibited only similarity for Bis-MANT-ITP, which 
showed also in AC activity assays only low potencies in the micromolar range. 
Exceptionally, MANT-ITP displayed similar fluorescence properties according to 
mono-substituted MANT-nucleotides, but with increasing concentrations of MANT-
ITP the increase in direct fluorescence was not substantially different; thus, a 
recording of saturation was not possible (data not shown).  
To address the issue of high protein concentration, we employed fluorescence 
polarization spectroscopyD40D. 
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Fig. 11. Saturation curves of Bis-MANT-ATP and Bis-Br-ANT-ATP 
Representative saturation curves of Bis-MANT-ITP (A) and Bis-Br-ANT-ATP (B) binding to activated 
CyaA are shown. Each data point was determined in an independent experiment as described under 
“Materials and Methods”. Final concentration of CyaA and CaM were 2.4 µM each. The fluorescence 
increase at 450 nm was calculated by subtraction of the autofluorescence at 450 nm from the maximal 
fluorescence at 450 nm after the addition of CyaA/CaM. Data were analyzed by nonlinear regression 
using the Prism 4.02 software. Similar data were obtained in three independent experiments. a.u., 
arbitrary unit. 
Fluorescence polarization 
The setup for fluorescence polarization measurements was similar to direct 
fluorescence analysis (details shown in Materials and Methods). In our previous 
observations bis-substituted (M)ANT-nucleotides exhibited low intensities in 
autofluorescence (Fig. 8.). For direct fluorescence spectroscopy the low intrinsic 
fluorescence was favorable due to an excellent signal to noise ratio, but for 
fluorescence polarization it was the exclusion criterion, because polarization values 
did not overcome signal to noise ratio for bis-substituted (M)ANT-nucleotides. Thus, 
only mono-substituted MANT-nucleotides were investigated for this type of analysis. 
First, (M)ANT-nucleotide at concentrations between 200 nM and 3.3 µM were added 
to the buffer and the basal polarization of free fluorophore in solution was 
determined. Second, addition of CyaA exhibited similar signals in polarization 
compared to fluorophore alone. Third, upon addition of CaM the polarization signal 
increased indicating bound fluorophore to the enzyme. CyaA and CaM were applied 
at a final concentration of 280 nM. By determination of fluorescence polarization at 
increasing concentrations of mono-substituted (M)ANT-nucleotides after addition of 
CaM, saturation curves were obtained (Fig. 12). Apparent Kd values were estimated 
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to be 300 nM for Br-ANT-ATP and 400 nM for MANT-ITP. Although, the change in 
polarization was low, saturation was clearly obtained in comparison to the direct 
fluorescence approach. Thus, by the use of fluorescence polarization we found a 
new alternative for the estimation of binding constants at least for one class of 
(M)ANT-derivatives. In future studies, this methodology should be considered for the 
characterization of new fluorophore labeled CyaA inhibitors. 
Fig. 12. Saturation curves by fluorescence polarization 
Saturation curves of MANT-ITP (A) and Br-ANT-ATP (B) binding to activated CyaA are shown. Each 
data point was determined in an independent experiment. Final concentrations of CyaA and CaM were 
280 nM each. The fluorescence polarization increase was calculated by subtracting the fluorescence 
polarization of fluorophore from the fluorescence polarization after addition of CyaA/CaM. Data were 
analyzed by nonlinear regression using the Prism 4.02 software. Similar data were obtained in three 
independent experiments. 
Comparison of binding constants by fluorescence analysis and AC assay 
The high protein concentration of 2.4 µM for direct fluorescence analysis induced 
comparable results to AC assay only for inhibitors with affinity in the micromolar 
range (Table 2). Apparent Kd values for MANT-ATP and Bis-MANT-ITP from direct 
fluorescence were similar to Ki values of the functional AC assay (Kd 0.4 – 2 fold > 
Ki), but for more potent inhibitors, e.g. Bis-Br-ANT-ATP, the estimation by 
fluorescence spectroscopy produced higher Kd values due to the late saturation of 
the enzyme. Thus, we wished to address this issue by fluorescence polarization 
spectroscopy. In contrast to direct fluorescence, CyaA concentration was reduced by 
9-fold for polarization measurements. The estimated Kd values for MANT-ITP and Br-
ANT-ATP are in good agreement to the corresponding Ki values determined in AC 
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activity assay and reached nanomolar range. Overall, all types of fluorescence 
approaches showed limitations for determining of binding constants. FRET 
experiments are selected for deoxygenated MANT-nucleotides X15 X; direct fluorescence 
analysis exhibited consistence with mono- and bis-substituted (M)ANT-nucleotides of 
low affinity, and fluorescence polarization is in agreement for mono-(M)ANT-
nucleotides. 
Table 2. Overview of spectroscopic data in comparison to AC assay 
Comparison of determined Kd values by direct fluorescence and fluorescence polarization, and Ki 
values by AC activity assay. The CyaA concentration is given for each method. Due to low signal 
changes of activated CyaA at increasing nucleotide concentrations, the saturation curve for MANT-ITP 
could not be arranged. In fluorescence polarization experiments bis-substituted (M)ANT-nucleotides 
did not overcome signal to noise ration, because of the weak intrinsic fluorescence of these 
compounds. n.d., not determined. 
 
 
 Direct  fluorescence 
Fluorescence 
polarization AC assay 
c (CyaA) 2.4 µM 280 nM 10 pM 
 Kd [nM] Kd [nM] Ki [nM] 
MANT-ATP 5,800 n.d. 4,300 
Bis-MANT-ATP 7,400 - 360 
MANT-ITP - 400 600 
Bis-MANT-ITP 6,400 - 3,000 
Br-ANT-ATP 2,400 300 330 
Bis-Br-ANT-ATP 4,500 - 12.6 
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21B3.9 Modeling of binding modes 
The crystal structure of CyaA in complex with CaM and PMEAppX29 X offered us the 
possibility of predicting the binding mode of mono- and bis-substituted (M)ANT-
nucleotides. The AC domain of CyaA includes the catalytic site at the interface of two 
structural domains, CA (Met1–Gly61, Ala187–Ala364) and CB (Val62–Thr186). 
Compared with PMEApp, the substrate ATP and the fluorescent nucleotides are 
conformationally constrained because of the semirigid ribosyl moiety. However, the 
spacious cavity between CA and CB may accommodate the different scaffolds so that 
an alignment of the adenine base and the terminal phosphates is possible (Fig. 6A). 
Hydrophobic interactions, especially of the 3’-MANT-group with Phe306, significantly 
contribute to the binding of the mono-substitiuted MANT-nucleotide of adenine to 
CyaA. In fact, the mutant CyaA-Phe306Ala failed to increase the fluorescence signal 
of 3’-ANT-2’d-ATPX29 X.  
How is the high affinity of PMEApp explained, compared to the potency of most 
MANT-NTPs, although the alignment of both indicates similar interactions? A 
reasonable superposition of the phosphates and the adenine bases is only possible if 
the conformation of the nucleotide moiety retains a certain strain of approximately 
3 kcal/mol. A complete minimization would displace the adenine base and, in 
particular, the phosphate groups from their optimal positions. Therefore, the “true” fit 
must be a balance between conformational strain and binding energy. Moreover, the 
ethoxy oxygen of PMEApp strongly interacts with Glu301 and Asn304 via a water 
molecule, and the ethylene bridge is also in close contact with the edge of Phe306. 
The docking of 3’-MANT-2’-d-ATP into CyaA is represented in more detail by a stick 
model (Fig.6B). The desoxyribosyl ring adopts a 3’-exo conformation like the ribosyl 
moiety of MANT-ATP in complex with mammalian AC X28 X. The three Mg2+ ions are in 
positions similar to those in the CyaA-PMEApp complex and form the same 
interactions. Two of them are coordinated with Asp188 and Asp190, one additionally 
with His298, and the third with the α- and β-phosphate. The imidazolyl-NH of His298 
may be H-bonded with an oxygen of the α-phosphate. The γ-phosphate contacts the 
lysine residues Lys65 and Lys58 (O-N distances, ~2.8 Å). These interactions account 
for the higher inhibitory potencies of the triphosphates compared with the 
diphosphate and monophosphate analogs (Table 1). The adenine moiety is 
sandwiched between the side chains of Leu60, His298 and Asn304 whose amide 
NH2 group may form an additional hydrogen bond with the desoxyribosyl ring oxygen. 
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The 6-amino substituent of the nucleobase is in proximity to the backbone oxygens of 
Val271, Gly299, and Thr300. However, the loop between Gly299 and Asn304 may 
align all of the nucleobases in similar position. In case of ITP derivatives backbone 
NH functions of, e.g. Gly299 and Val271, may serve as hydrogen donors for the 
carbonyl oxygens in 6 position, respectively. This diversity of possible interactions 
may account for inconsistent potency differences of nucleobase substitution. In 
addition, the affinity of each nucleotide may be affected by a specific arrangement of 
water molecules that cannot be simply transferred from the PMEApp-bound CyaA 
structure. 
In our previous study X15 X we observed high inhibition potency of 3’-MANT-2’-d-ATP and 
2’-MANT-3’-d-ATP for CyaA. 3’-MANT-2’d-ATP adopted an ideal position for π-
stacking of the phenyl rings of the inhibitor and Phe306. This stacking also accounts 
for the efficient fluorescence analysis. The axial position of the hydrogen atom 
corresponding to the 2’-OH group in 3’-MANT-ATP suggests that even the 2’,3’ bis-
substituted MANT-ATP derivative will be potent because the 2’-MANT moiety may fit 
into a hydrophobic site consisting of Pro305 and Phe261. This site would also be 
occupied by the 2’-MANT group in 2’-MANT-3’-d-ATP if the desoxyribosyl ring adopts 
a 3’-exo conformation. However, similar potencies in AC assay of the positional 
isomers as well as similar magnitudes of fluorescence properties rather indicate 
analogous interactions between the MANT group and Phe306 in the complexes of 
CyaA with 2’-MANT-3’-d-ATP and 3’-MANT-3’-d-ATP, respectively. The docking of 2’-
MANT-3’-d-ATP reproduced indeed the interaction pattern of 3’-MANT-2’-d-ATP. The 
only difference is a 3’-endo conformation of the desoxyribosyl moiety as is present, 
e.g., in A-DNA.  
In our present study the docking of Bis-Br-ANT-ATP was based on the 3’-MANT-2’-d-
ATP, since the position of the hydrogen atom corresponding to the 2’-OH group 
enables the second Br-ANT moiety to be accommodated outside of the active site 
and to form additional specific interactions with CyaA. The 3’-endo binding mode of 
2’-MANT-3’-d-ATP does not provide the degree of freedom for an equatorial 3’-Br-
ANT substituent. The previous guess that the second ANT-group may interact with 
Phe261 was not confirmed due to conformational restrictions of the ester moiety 
(clash with the adenine base) X15 X. Instead of that, an energetically favorable 
conformation of Bis-Br-ANT-ATP is possible where the 2’-Br-ANT substituent can 
easily expand to Phe306 and where the binding mode of the rest of the molecule is 
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largely the same as in the case of 3’-MANT-2’-d-ATP. The bromo-anthraniloyl 
moieties enclose Phe306 from both sides (Fig. 6C). Obviously, bromine and chlorine 
substituents increase the hydrophobic interactions with Phe306, thus accounting for 
the high inhibitory activity of Bis-halogen-ANT-ATPs compared to their 
dehalogenated derivatives. Additional hydrophobic contacts are formed between the 
2’-Br-ANT phenyl ring and the side chain of Leu60. 
The stick model presents the putative binding mode of Bis-Br-ANT-ATP in more 
detail (Fig. 6D). The adenine base, the desoxyribosyl nucleus and the phosphate 
groups form the same interactions as described for 3’-MANT-2’-d-ATP (see above). 
The 3’-Br-ANT moiety is completely aligned with the phenyl ring of Phe306, whereas 
in the case of the 2’-Br-ANT-group only the bromine substituent contacts this residue. 
Not only the side chain, but also the backbone oxygen of Leu60 may interact with the 
2’-Br-ANT group by forming a hydrogen bond with the amine. In the case of the 3’-
substituents, generally an outer and an inner orientation of the free or substituted 
amino group is possible. An inner position like in Fig. 6D should be favorable due to a 
charge assisted hydrogen bond with the carboxylate of Glu308, but may be 
impossible when more bulky substituents are present. This may explain subtle 
activity differences between ANT, MANT, Pr-ANT and Ac-NH-ANT derivatives. 
The lower substrate Km and Vmax values as well as the generally 5- to 40-fold higher 
activity of the inhibitors under Mn2+ conditions clearly point to considerably tighter 
binding when compared with the Mg2+ enzyme. This increase in the free energy of 
binding of up to ca. 2 kcal mol-1 should be mainly due to stronger Mn2+-phosphate 
binding. No further conclusions can be drawn from the docking approaches based on 
force field methods and without a CyaA structure with Mn2+ instead of Mg2+. 
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Fig. 13. Docking of mono- and bis-substituted (M)ANT-nucleotides 
 
 
Docking of PMEApp (carbon atoms in magenta); 3’-MANT-2’d-ATP (carbon and hydrogen atoms in 
yellow) to CyaA (A). Overview of the binding site, represented by the lipophilic potential mapped onto 
a MOLCAD Connolly surface (brown, hydrophobic areas; green and blue, polar areas).The models are 
based on the crystal structure of CyaA in complex with PMEApp, PDB 1zot X29X. Colors of atoms, unless 
otherwise indicated: orange, phosphorus; red, oxygen; blue, nitrogen; white, carbon; gray, hydrogen; 
green spheres, magnesium. Docking of 3’-MANT-2’d-ATPX15X in the stick model (B). Amino acids within 
a sphere of ~3 Å around the ligand are labeled. The protein backbone is schematically represented by 
a tube. Carbon atoms of the backbone are colored in dark cyan; carbon atoms of the side chains are 
in light cyan. 
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Docking of Bis-Br-ANT-ATP (C and D) to CyaA. The models are based on the crystal structure of 
CyaA in complex with PMEApp, PDB 1zotX29X. Colors of atoms, unless otherwise indicated: orange, 
phosphorus; red, oxygen; green, bromine; blue, nitrogen; white, carbon; gray, hydrogen; green 
spheres, magnesium. Overview of the binding site (C), represented by the lipophilic potential mapped 
onto a MOLCAD Connolly surface (brown, hydrophobic areas; green and blue, polar areas). Docked 
ligand: Bis-Br-ANT-ATP (carbon and hydrogen atoms in yellow; second Br-ANT group: carbon atoms 
in orange). D, docking of Bis-Br-ANT-ATP. Amino acids within a sphere of ~3 Å around the ligand are 
labeled. The protein backbone is schematically represented by a tube. Carbon atoms of the backbone 
are colored in dark cyan; carbon atoms of the side chains are in light cyan. For clarity, some labels are 
omitted (see B).  
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4B . Conclusion 
In our present study, we have shown that our newly synthesized (M)ANT-substituted 
nucleotides, especially the bis-substituted (M)ANT-nucleotides, exhibit unique 
pharmacological applications for bacterial CyaA with respect to inhibition potency, 
selectivity, and fluorescence spectroscopy.  
For the first time we found inhibitors combining high inhibition potency for CyaA toxin 
with selectivity towards mammalian ACs. Bis-substituted halogen anthraniloyl-derived 
purine nucleotides inhibited CyaA in the nanomolar range in a competitive manner 
(20 – 23, Ki = 13 – 20 nM). Our prediction of accommodation bulky bis-substituted 
(M)ANT-nucleotides in the large cavity of the catalytic CyaA binding site, causing an 
increase in affinity, was confirmed experimentally. Moreover, bis-substituted halogen 
anthraniloyl-derived nucleotides of adenine (20 and 22) displayed not only high 
affinity to the bacterial AC, but also revealed high selectivity by 50- to 150-fold 
depending on the chosen mAC 1, 2 or 5 and purine derivative. In times of falling 
vaccine rates for whooping coughD41D and ineffective conventional antibiotic treatment 
due to toxemia or antibiotic-resistant strains, more effective drugs for the prophylaxis 
of whooping cough are needed. Thus, these nucleotide derivatives could serve as 
pharmacophores for finding new drugs against Bordetella pertussis broadening. For 
in vivo applications enzymatic degradation and high bioavailability of AC inhibitors 
may be achieved by recent prodrug strategiesD42D. In analogy to antiviral drugs like 
PMEA, the lipophilic nucleotide prodrug is activated first by cleavage with esterases 
and then phosphorylated by specific kinases to obtain the active nucleoside 5’-
triphosphate derivative.  
Moreover, the expansion of pharmacological analysis with our nucleotide analogs 
may offer new potentials investigating other bacterial ACs. Thus, our newly 
synthesized compound library is analyzed for Bacillus anthracis AC toxin edema 
factor (EF) and AC of Mycobacterium tuberculosis in parallel projects. 
In recent studies X14 X EF displayed several structural homologies to CyaA. The Bacillus 
anthracis bears a phenylalanine residue close to the catalytic site. In comparison to 
Phe306 of CyaA, edema factor bears Phe586, resulting in fluorescence increases 
with MANT-nucleotides, as well. Nonetheless, the inhibitory profile of EF differs 
considerably from CyaA. In particular, MANT-ATP and MANT-CTP inhibit catalytic 
activity of CyaA with about 10-fold lower potency than catalysis by EF, 
respectivelyX14 X, X15 X. Based on these differences it is also reasonable to assume that the 
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enzymological analysis of EF with our new compound library will give different results 
than the analysis of CyaA. The knowledge about AC inhibition of Mycobacterium 
tuberculosis by MANT-nucleotides is very limited. Thus, the analysis of other ACs is 
feasible, but the success is not predictable. 
Bis-substituted (M)ANT-nucleotides offered the advantage of excellent signal to noise 
ratio in fluorescence spectroscopy, compared to mono-substituted (M)ANT-
nucleotides, with applications in HTS for assessment of non-fluorescent inhibitor 
potencies like PMEApp. The increase of direct fluorescence for Bis-(M)ANT-NTPs 
upon interaction with CyaA in the absence of the activator CaM indicates that the 
nucleotide binding site of CyaA is already functional in the catalytically inactive toxin. 
Similar results were obtained for TNP nucleotides with CyaAX15 X and for MANT-
nucleotides in combination with the catalytical subunits C1/C2 of mammalian AC in 
the absence of the activator forskolin X27 X, X28 X. The identification of the precise nature of 
this conformational change requires crystallization of CyaA complex with Bis-
(M)ANT-nucleotide in the absence and presence of CaM. Another implication of the 
CaM-independent binding of bis-substituted (M)ANT-nucleotides to CyaA is that the 
catalytic site of CyaA possesses different binding properties than the site in the 
presence of CaM, offering additional possibilities for inhibitor design and increasing 
inhibitor selectivity. Comparison of inhibition profiles of non-fluorescent inhibitors on 
Bis-(M)ANT-NTP fluorescence bound to CyaA in the absence and presence of CaM 
is a feasible approach. With respect to catalysis, such comparison is impossible 
because enzymatic activity obligatorily depends on CaM X5 X, X16 X. 
Our present modeling study demonstrate an impression for the obvious alignment of 
the (M)ANT-nucleotide binding mode to CyaA. The docking of bis-substituted 
halogen anthraniloyl derivatives exposed additional hydrophobic interactions 
between enzyme and inhibitor causing higher potency for this class of compounds. 
Mammalian ACs offer a limitation in accommodation of the second bulky (M)ANT-
substituent. Further dockings of the less potent binding of Bis-(M)ANT-NTPs to the 
catalytic site of C1/C2 for mACs are needed to explain its selectivity for CyaA. 
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5B . Experimental section 
22B5.1 Synthesis procedures 
General protocol of mono- and bis-(M)ANT-nucleotide synthesis 
(M)ANT-nucleotides were synthesized according to HiratsukaD43D with modifications. In 
general, mono- and bis-substituted (M)ANT-nucleotides could be achieved both in an 
one pot synthesis procedure. The nucleotide (0.33 mmol, 1 eq) was propounded in a 
small two-neck round flask and dissolved in a minimum amount of water (3 ml). 
Under continuous stirring a crystalline preparation of the appropriate isatoic 
anhydride derivative (0.5 mmol, 1.5 eq) was added. After heating to 38 °C the pH-
value was adjusted to 8.6 and maintained by titration of 1 N NaOH solution for 2 
hours. The reaction mixture was extracted three times by 20 ml chloroform (only for 
MANT-nucleotides). The aqueous phase was dry-frozen. The received foam showed 
white to brown color. The crude reaction mixture was purified by preparative reversed 
phase high pressure liquid chromatography. Especially for the sensitive separation of 
mono- and Bis-(M)ANT-NTPs from mono- and Bis-(M)ANT-NDPs this purification 
strategy was required. In case of monophosphate derivatives only size-exclusion 
chromatography with a long Sephadex® LH-20 column (85 x 2 cm) and subsequently 
elution with double-distilled water was applied. The desired product could be 
detected directly by its blue fluorescence in the collection tubes at λex of 366 nm and 
by TLC. After final dry-freezing white to brown solid compounds (purity > 98 %) were 
obtained. For all derivatives yields were determined by analytical HPLC 
measurements of crude reaction mixtures and correlate with the maximal accessible 
yield. Because of the time consuming and costly preparative HPLC purification 
separation was stopped after obtaining approximate 5 mg pure compound. 
Synthesis of isatoic anhydride precursors 
For the propyl (8, 9, 24, 25) and acetylated amino (10, 11, 26, 27) ANT-nucleotide 
derivatives the corresponding isatoic anhydrides (33, 34) were easily accessible by 
nucleophilic substitutionD44D with propyliodide and for acetylation with acetic acid 
anhydride by standard protocolD45D, respectively. 
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23B5.2 Analytical procedures 
HPLC analysis of (M)ANT-nucleotides 
The samples were filtered using a PTFE filter (Chromafil, O-20/15, organic, pore size 
0.2 mm; Machery-Nagel, Düren, Germany). A 10 μL sample was analyzed using a 
HPLC model 1100 (Agilent Technologies, Waldbronn, Germany) fitted with a C18 
analytical column (Phenomenex Luna, particle size 3 μm, 150 x 4.60 mm, 
Aschaffenburg, Germany) and DAD. Data were analyzed using a HPLC-3D 
ChemStation Rev. A.10.01 [1635]. Gradient elution was performed with 0.05 M 
ammonium acetate (solvent A) and acetonitrile (solvent B) at a constant flow rate of 
1.0 ml/min. A gradient profile with the following proportions of solvent B was applied [t 
(min), % B]: [0, 5], [10, 5], [30, 45], [40, 80]. The chromatograms were monitored at 
220 nm and 254 nm. In addition, a fluorescence detector was used for the analysis of 
the fluorescent anthraniloylic compounds at λex of 350 nm and λem of 450 nm. 
LC/MS online coupling 
All samples were filtered using a PTFE filter and injected into a HPLC model 1100 
(Hewlett-Packard, Waldbronn, Germany). The compound to be analyzed was 
separated by a C18 column (Phenomenex luna, particle size 3 μm, 150 x 2 mm, 
Aschaffenburg, Germany). A binary eluent mixture consisting of water (10 mM 
ammonium acetate) (eluent A) and acetonitrile (eluent B) was pumped with a 
constant flow of 0.3 ml/min. The following gradient profile was used t [min], % B: [0, 
5], [10, 5], [30, 45], [40, 80]. The injected volume was 3 μl. The mass of the 
respective compound was determined using a triple stage mass spectrometer 
(Finnigan TSQ 7000; Thermo Fisher Scientific, Waltham, MA). 
Preparative HPLC 
Compound mixtures were dissolved in water (concentration: 30 - 50 mg/ml) and 
filtered using a PTFE filter. Compounds were separated using a HPLC model 1100 
(Agilent Technologies, Waldbronn, Germany) fitted with a C18 preparative column 
(Phenomenex Luna, particle size 10 μm, 250 x 21.2 mm). Gradient elution was 
performed with 0.05 M ammonium acetate (solvent A) and acetonitrile (solvent B) at 
a constant flow rate of 21 ml/min. Due to the efficiency of separation injection 
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volumes differed from 10 µl to 60 µl for a run. The chromatograms were monitored at 
220 nm and 254 nm.  
NMR spectrometry 
Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, 31P-NMR: 161.9 MHz, T = 
300 K), Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical 
shifts are reported in δ [ppm] relative to external standards (solvent residual peak). 
The spectra were analyzed by first order, the coupling constants are given in Hertz 
[Hz]. Characterization of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, 
dd = double doublet, ddd = double double doublet. Integration is determined as the 
relative number of atoms. Assignment of signals in 13C-spectra was determined with 
DEPT-technique (pulse angle: 135 °) and given as (+) for CH or CH3, (-) for CH2 and 
(Cquat) for quaternary C. Error of reported values: chemical shift: 0.01 ppm for 1H-
NMR, 0.1 ppm for 13C-NMR and 0.1 Hz for coupling constants. The solvent used is 
reported for each spectrum. 
Spectroscopy 
Absorption spectroscopy was performed using a Varian Cary BIO 50 UV/VIS/NIR 
spectrometer with a 1 cm quartz cuvette (Hellma) and Uvasol solvents (Merck or 
Baker). IR spectra were recorded by a Bio-Rad FTS 2000 MX FT-IR. Further mass 
spectrometry measurements with electron ionization technique were applied by a 
Varian CH-5.  
Miscellaneous 
Melting Points were determined by a Tottoli micro melting point apparatus and are 
uncorrected. TLC analyses were conducted on silica gel 60 F-254 with a 0.2 mm 
layer thickness. 
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24B5.3 Newly synthesized compounds 
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Cl-ANT-ATP (2’(3’)-O-5-chloroanthraniloyl-adenosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-chlorobenzoate (4). 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded 61 mg (92 μmol, 51 %) pure product after purification. Rf = 0.26 
(1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 21.35 min; k = 12.91; 
LC/MS (ESI, H2O/CH3CN): m/z = 678.0 [M+NH4+] (Rt = 18.89 min, 100 %), 660.8 
[M+H+] (Rt = 18.89 min, 10 %); (-ESI, H2O/CH3CN): m/z = 659.1 [M-H-] 
(Rt = 18.89 min, 100 %); HPLC (preparative), gradient (t [min], % B: U[ U0, 14], [6, 14], 
U[ U11, 37], [15, 40], [20, 80]): Rt = 10.15 min; UV/Vis (H2O) λmax (log ε) = 255 nm 
(16,000), 343 nm (3,500); empirical formula: C17H20ClN6O14P3; MW = 660.75 
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Cl-ANT-ITP (2’(3’)-O-5-chloroanthraniloyl-inosine-5’-triphosphate) or [(2R,3S, 
4R,5R)- 5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-phosphonooxy- 
 Cl-ANT-ATP 
Cl-ANT-ITP 
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phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-chlorobenzoate (5). 
For the procedure see general prescription. 100 mg (0.17 mmol) introduced disodium 
salt of ITP yielded 47 mg (71 μmol, 42 %) pure product after purification. Rf = 0.27 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 20.59 min, 20.84 min; 
k = 13.24, 13.39; LC/MS (ESI, H2O/CH3CN): m/z = 696.0 [M+NH3NH4+] 
(Rt = 16.77 min, 100 %), 679.0 [M+NH4+] (Rt = 16.77 min, 90 %), 662.1 [M+H+] 
(Rt = 16.77 min, 5 %); (-ESI, H2O/CH3CN): m/z = 660.1 [M-H-] (Rt = 16.77 min, 
100 %); HPLC (preparative), gradient (t [min], % B: U[ U0, 14], [6, 14], [15, 38], [20, 80]): 
Rt = 7.71 min, 8.44 min; UV/Vis (H2O) λmax (log ε) = 255 nm (14,600), 348 nm 
(4,500); empirical formula: C17H19ClN5O15P3; MW = 661.73 
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Br-ANT-ATP (2’(3’)-O-5-bromoanthraniloyl-adenosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-bromobenzoate (6).  
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP led to 36 mg (50 μmol, 28 %) pure product after purification. Rf = 0.24 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 20.24 min, 20.39 min; 
k = 12.18, 12.28; LC/MS (ESI, H2O/CH3CN): m/z = 724.1 [M+NH4+] (Rt = 21.21 min, 
100 %), 741.2 [M+NH3+NH4+] (Rt = 21.21 min, 40 %); (-ESI, H2O/CH3CN): m/z = 
705.1 [M-H-] (Rt = 21.21 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 
17], [8, 17], [10, 25], [15, 38], [20, 80]): Rt = 6.32 min; UV/Vis (H2O) λmax (log ε) = 
256 nm (16,400), 332 nm (3,300); empirical formula: C17H20BrN6O14P3; MW = 705.20 
Br-ANT-ATP 
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Br-ANT-ITP (2’(3’)-O-5-bromoanthraniloyl-inosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-bromobenzoate (7). 
For the procedure see general prescription. 100 mg (0.17 mmol) introduced disodium 
salt of ITP yielded 48 mg (68 μmol, 40 %) pure product after purification. Rf = 0.25 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 21.16 min, 21.45 min; 
k = 13.63, 13.83; LC/MS (ESI, H2O/CH3CN): m/z = 725.1 [M+NH4+] (Rt = 18.81 min, 
100 %), 742.2 [M+NH3+NH4+] (Rt = 18.81 min, 35 %); (-ESI, H2O/CH3CN): 
m/z = 706.1 [M-H-] (Rt = 18.81 min, 100 %); HPLC (preparative), gradient (t [min], % 
B: U[ U0, 18], [15, 38], [20, 80]): Rt = 4.27 min, 4.53 min; UV/Vis (H2O) λmax (log ε) = 
248 nm (15,000), 328 nm (4,300); empirical formula: C17H19BrN5O15P3; MW = 706.18 
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Pr-ANT-ATP (N-propyl-2’(3’)-O-anthraniloyl-adenosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-propylaminobenzoate (8). 
Br-ANT-ITP 
Pr-ANT-ATP 
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For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded 29 mg (43 μmol, 24 %) pure product after purification. Rf = 0.31 
(1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 24.93 min, 25.67 min; 
k = 15.29, 15.78; LC/MS (ESI, H2O/CH3CN): m/z = 669.0 [M+H+] (Rt = 23.12 min, 
100 %), 686.0 [M+NH4+] (Rt = 23.12 min, 15 %); (-ESI, H2O/CH3CN): m/z = 667.0 [M-
H-] (Rt = 23.12 min, 100 %); HPLC (preparative), gradient (t [min], % B: U[U0, 5], [20, 
45], [25, 80]): Rt = 13.33 min; UV/Vis (H2O) λmax (log ε) = 257 nm (17,500), 359 nm 
(4,600); empirical formula: C20H27N6O14P3; MW = 668.38 
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Pr-ANT-ITP (N-propyl-2’(3’)-O-anthraniloyl-inosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-propylaminobenzoate (9). 
For the procedure see general prescription. 100 mg (0.17 mmol) introduced disodium 
salt of ITP yielded 25 mg (37 μmol, 22 %) pure product after purification. Rf = 0.32 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 24.73 min, 25.16 min; 
k = 16.10, 16.40; LC/MS (ESI, H2O/CH3CN): m/z = 687.0 [M+NH4+] (Rt = 22.87 min, 
100 %), 669.8 [M+H+] (Rt = 22.87 min, 20 %); (-ESI, H2O/CH3CN): m/z = 668.0 [M-H-] 
(Rt = 22.87 min, 100 %); HPLC (preparative), gradient (t [min], % B: U[ U0, 5], [20, 45], 
[25, 80]): Rt = 13.12 min; UV/Vis (H2O) λmax (log ε) = 257 nm (17,500), 359 nm 
(4,600); empirical formula: C20H26N5O15P3; MW = 669.37 
Pr-ANT-ITP 
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Ac-NH-ANT-ATP (2’(3’)-O-5-acetylaminoanthraniloyl-adenosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-phosphono-
oxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-acetylamino-
benzoate (10). 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded 57 mg (84 μmol, 46 %) pure product after purification. Rf = 0.21 
(1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 8.39 min, 8.75 min; 
k = 4.48, 4.72; LC/MS (ESI, H2O/CH3CN): m/z = 683.9 [M+H+] (Rt = 3.34 min, 
100 %), 701.0 [M+NH4+] (Rt = 3.34 min, 70 %); (-ESI, H2O/CH3CN): m/z = 682.0 [M-
H-] (Rt = 3.34 min, 100 %); HPLC (preparative), gradient (t [min], % B: U[ U0, 6], [5, 7], 
[23, 14], [24, 80], [29, 80]): Rt = 12.06 min; UV/Vis (H2O) λmax (log ε) = 259 nm 
(17,200), 349 nm (3,100); empirical formula: C19H24N7O15P3; MW = 683.35 
Ac-NH-ANT-ATP 
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Ac-NH-ANT-ITP (2’(3’)-O-5-acetylaminoanthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-acetyl-
aminobenzoate (11). 
For the procedure see general prescription. 100 mg (0.17 mmol) introduced disodium 
salt of ITP yielded 60 mg (88 μmol, 52 %) pure product after purification. Rf = 0.22 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 7.63 min, 7.99 min; k = 4.28, 
4.53; LC/MS (ESI, H2O/CH3CN): m/z = 702.0 [M+NH4+] (Rt = 1.91 min, 100 %), 719.0 
[M+NH3+NH4+] (Rt = 1.91 min, 40 %), 684.9 [M+H+] (Rt = 1.91 min, 25 %); (-ESI, 
H2O/CH3CN): m/z = 683.0 [M-H-] (Rt = 1.91 min, 100 %); HPLC (preparative), 
gradient (t [min], % B: U[U0, 5.8], [11, 5.8], [12, 10], [18, 13], [20, 80]): Rt = 9.50 min; 
UV/Vis (H2O) λmax (log ε) = 248 nm (11,400; shoulder), 345 nm (2,500); empirical 
formula: C19H23N6O16P3; MW = 684.34 
Ac-NH-ANT-ITP 
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Br-ANT-ADP (2’(3’)-O-5-bromoanthraniloyl-adenosine-5’-diphosphate) or [(2R,3S, 
4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[(hydroxy-phosphonooxyphosphoryl) 
oxymethyl]oxolan-3(4)-yl]2-amino-5-bromobenzoate (14). 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded 9 mg (14 μmol, 8 %) pure product after purification. Rf = 0.27 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 20.86 min, 21.16 min; 
k = 12.59, 12.79; LC/MS (ESI, H2O/CH3CN): m/z = 644.1 [M+NH4+] (Rt = 22.09 min, 
100 %), 627.2 [M+H+] (Rt = 22.09 min, 80 %); (-ESI, H2O/CH3CN): m/z = 625.1 [M-H-] 
(Rt = 22.09 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 16], [10, 16], 
[15, 50], [17, 51.5], [20, 80]): Rt = 9.94 min, 10.99 min; UV/Vis (H2O) λmax (log ε) = 
255 nm (12,700), 328 nm (3,400); empirical formula: C17H19BrN6O11P2; MW = 625.25 
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Bis-MANT-ATP (N-methyl-2’,3’-bis-O-anthraniloyl-adenosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-methylaminobenzoate (17). 
Br-ANT-ADP
Bis-MANT-ATP
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For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP led over all purification steps to 21 mg (27 μmol, 15 %) pure product. 
Rf = 0.32 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 26.95 min; 
k = 16.61; LC/MS (ESI, H2O/CH3CN): m/z = 791.2 [M+NH4+] (Rt = 28.58 min, 100 %), 
774.2 [M+H+] (Rt = 28.58 min, 40 %); (-ESI, H2O/CH3CN): m/z = 772.3 [M-H-] 
(Rt = 28.58 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 11], [2, 11],   
[5, 30], [15, 31.5], [18, 80]): Rt = 9.91 min; UV/Vis (H2O) λmax (log ε) = 255 nm 
(18,000), 359 nm (7,300); empirical formula: C26H30N7O15P3; MW = 773.48 
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Bis-MANT-ITP (N-methyl-2’,3’-bis-O-anthraniloyl-inosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxyphosphoryl) 
oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-methylaminobenzoate (18). 
For the procedure see general prescription. 100 mg introduced disodium salt of ITP 
(0.17 mmol) yielded over all purification steps 18 mg (23 μmol, 14 %) pure product. 
Rf = 0.33 (1-propanol:H2O: NH3 (32 %) = 2:1:1) HPLC (analytic): Rt = 26.74 min; 
k = 16.52; LC/MS (ESI, H2O/CH3CN): m/z = 792.3 [M+NH4+] (Rt = 28.02 min, 100 %), 
775.2 [M+H+] (Rt = 28.58 min, 15 %); (-ESI, H2O/CH3CN): m/z = 773.3 [M-H-] 
(Rt = 28.08 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 11], [2, 11], 
[5, 30], [15, 31.5], [18, 80]): Rt = 9.72 min; UV/Vis (H2O) λmax (log ε) = 251 nm 
(16,400), 358 nm (6,400); empirical formula: C26H29N6O16P3; MW = 774.46 
Bis-MANT-ITP
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Bis-MANT-CTP (N-methyl-2’,3’-bis-O-anthraniloyl-cytosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-(hydroxy-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-methylaminobenzoate (19).  
100 mg introduced trisodium salt of CTP (0.18 mmol) yielded 35 mg (46 μmol, 26 %) 
pure product. Rf = 0.29 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): 
Rt = 26.83 min; k = 16.60; LC/MS (ESI, H2O/CH3CN): m/z = 750.0 [M+H+] 
(Rt = 25.37 min, 100 %), 767.1 [M+NH4+] (Rt = 25.37 min, 10 %); (-ESI, H2O/CH3CN): 
m/z = 748.0 [M-H-] (Rt = 25.37 min, 100 %); HPLC (preparative), gradient (t [min], % 
B: [0, 14], [6, 14], [11, 35], [15, 40], [20, 80]): UV/Vis (H2O) λmax (log ε) = 253 nm 
(14,500), 359 nm (6,600); Rt = 13.19 min; empirical formula: C25H30N5O16P3; 
MW = 749.45 
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Bis-Cl-ANT-ATP (2’,3’-bis-O-5-chloroanthraniloyl-adenosine-5’-triphosphate) or [(2R, 
3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxyphosphoryl) 
oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-amino-5-chlorobenzoate (20). 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded 31 mg (38 μmol, 21 %) pure product after purification. Rf = 0.32 
Bis-MANT-CTP
Bis-Cl-ANT-ATP
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(1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 27.79 min; k = 17.10; 
LC/MS (ESI, H2O/CH3CN): m/z = 831.0 [M+NH4+] (Rt = 26.24 min, 100 %), 814.1 
[M+H+] (Rt = 26.24 min, 10 %); (-ESI, H2O/CH3CN): m/z = 812.0 [M-H-] (Rt = 
26.24 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 14], [6, 14], [11, 
37], [15, 40], [20, 80]): Rt = 13.26 min; UV/Vis (H2O) λmax (log ε) = 255 nm (16,900), 
350 nm (5,100); empirical formula: C24H24Cl2N7O15P3; MW = 814.31 
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Bis-Cl-ANT-ITP (2’,3’-bis-O-5-chloroanthraniloyl-inosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxyphosphoryl) 
oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-methyl-5-chloroaminobenzoate (21). 
For the procedure see general prescription. 100 mg introduced disodium salt of ITP 
(0.17 mmol) yielded over all purification steps 30 mg (37 μmol, 22 %) pure product. 
Rf = 0.35 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 27.46 min; 
k = 17.99; LC/MS (ESI, H2O/CH3CN): m/z = 849.1 [M+NH4+] (Rt = 25.90 min, 100 %), 
832.0 [M+H+] (Rt = 25.90 min, 90 %); (-ESI, H2O/CH3CN): m/z = 830.0 [M-H-] 
(Rt = 25.90 min, 100 %); HPLC (preparative), gradient (t [min], % B: U[ U0, 14], [6, 14], 
[15, 38], [20, 80]): Rt = 15.65 min; UV/Vis (H2O) λmax (log ε) = 249 nm (19,700), 350 
nm (6,200); empirical formula: C24H23Cl2N6O16P3; MW = 815.30 
Bis-Cl-ANT-ITP
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Bis-Br-ANT-ATP (2’,3’-bis-O-5-bromoanthraniloyl-adenosine-5’-triphosphate) or (2R, 
3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxyphosphoryl) 
oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-amino-5-bromobenzoate (22). 
For the procedure see general prescription. 100 mg introduced disodium salt of ATP 
yielded 18 mg (20 μmol, 11 %) pure product after purification. Rf = 0.31 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 26.72 min; k = 16.41; 
LC/MS (ESI, H2O/CH3CN): m/z = 920.9 [M+NH4+] (Rt = 26.24 min, 100 %), 904.0 
[M+H+] (Rt = 26.24 min, 10 %); (-ESI, H2O/CH3CN): m/z = 901.9 [M-H-] 
(Rt = 26.24 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 17], [8, 17], 
[10, 25], [15, 38], [20, 80]): Rt = 16.14 min; UV/Vis (H2O) λmax (log ε) = 255 nm 
(14,600), 348 nm (4,500); empirical formula: C24H24Br2N7O15P3; MW = 903.21 
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Bis-Br-ANT-ITP (2’,3’-bis-O-5-bromoanthraniloyl-inosine-5’-triphosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxyphosphoryl) 
oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-methyl-5-bromoaminobenzoate (23). 
For the procedure see general prescription. 100 mg introduced disodium salt of ITP 
(0.17 mmol) yielded over all purification steps 32 mg (36 μmol, 21 %) pure product. 
Bis-Br-ANT-ATP
Bis-Br-ANT-ITP
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Rf = 0.33 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 28.16 min; 
k = 18.47; LC/MS (ESI, H2O/CH3CN): m/z = 921.9 [M+NH4+] (Rt = 25.89 min, 100 %), 
905.0 [M+H+] (Rt = 25.89 min, 15 %); (-ESI, H2O/CH3CN): m/z = 903.0 [M-H-] 
(Rt = 25.89 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 18], [15, 38], 
[20, 80]: Rt = 12.39 min; UV/Vis (H2O) λmax (log ε) = 249 nm (19,000), 348 nm 
(5,600); empirical formula: C24H23Br2N6O16P3; MW = 904.20 
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Bis-Pr-ANT-ATP (N-propyl-2’,3’-bis-O-anthraniloyl-adenosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxy 
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-propylaminobenzoate (24). 
For the procedure see general prescription. 100 mg introduced disodium salt of ATP 
(0.18 mmol) yielded over all purification steps 21 mg (25 μmol, 14 %) pure product. 
Rf = 0.34 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 33.04 min; 
k = 20.59; LC/MS (ESI, H2O/CH3CN): m/z = 830.2 [M+H+] (Rt = 30.63 min, 100 %), 
847.2 [M+NH4+] (Rt = 30.63 min, 30 %); (-ESI, H2O/CH3CN): m/z = 828.1 [M-H-] 
(Rt = 30.63 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 5], [20, 45], 
[25, 80]): Rt = 20.14 min; UV/Vis (H2O) λmax (log ε) = 255 nm (16,800), 359 nm 
(5,800); empirical formula: C30H37N6O16P3; MW = 829.58 
Bis-Pr-ANT-ATP
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Bis-Pr-ANT-ITP (N-propyl-2’,3’-bis-O-anthraniloyl-inosine-5’-triphosphate) or [(2R, 
3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxyphosphoryl) 
oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-propylaminobenzoate (25). 
For the procedure see general prescription. 100 mg introduced disodium salt of ITP 
(0.17 mmol) yielded over all purification steps 15 mg (19 μmol, 11 %) pure product. 
Rf = 0.35 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 30.57 min; 
k = 20.14; LC/MS (ESI, H2O/CH3CN): m/z = 848.1 [M+NH4+] (Rt = 30.60 min, 100 %), 
831.1 [M+H+] (Rt = 30.60 min, 20 %); (-ESI, H2O/CH3CN): m/z = 829.1 [M-H-] 
(Rt = 30.60 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 5], [20, 45], 
[25, 80]): Rt = 19.58 min; UV/Vis (H2O) λmax (log ε) = 255 nm (14,600), 359 nm 
(5,300); empirical formula: C30H37N6O16P3; MW = 830.57 
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Bis-Ac-NH-ANT-ATP (2’,3’-bis-O-5-acetylaminoanthraniloyl-adenosine-5’- 
triphosphate) or [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-amino-5-
acetylaminobenzoate (26). 
Bis-Pr-ANT-ITP
Bis-Ac-NH-ANT-ATP 
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For the procedure see general prescription. 100 mg introduced disodium salt of ATP 
(0.18 mmol) yielded over all purification steps 27 mg (32 μmol, 18 %) pure product. 
Rf = 0.27 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 20.05 min; 
k = 12.10; LC/MS (ESI, H2O/CH3CN): m/z = 860.1 [M+H+] (Rt = 16.79 min, 100 %), 
877.2 [M+NH4+] (Rt = 16.79 min, 30 %); (-ESI, H2O/CH3CN): m/z = 858.1 [M-H-] 
(Rt = 16.79 min, 100 %); HPLC (preparative), gradient (t [min], % B: U[ U0, 6], [5, 7], [23, 
14], [24, 80], [29, 80]): Rt = 21.49 min; UV/Vis (H2O) λmax (log ε) = 261 nm (23,500), 
350 nm (5,700); empirical formula: C28H32N9O17P3; MW = 859.53 
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Bis-Ac-NH-ANT-ITP (2’,3’-bis-O-5-acetylaminoanthraniloyl-inosine-5’-triphosphate) 
or [(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxy-
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-amino-5-acetylamino-
benzoate (27). 
For the procedure see general prescription. 100 mg introduced trisodium salt of ITP 
(0.17 mmol) yielded over all purification steps 16 mg (19 μmol, 11 %) pure product. 
Rf = 0.29 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 18.80 min; 
k = 12.00; LC/MS (ESI, H2O/CH3CN): m/z = 878.1 [M+NH4+] (Rt = 8.85 min, 100 %), 
895.1 [M+NH3+NH4+] (Rt = 8.85 min, 35 %), 861.1 [M+H+] (Rt = 8.85 min, 30 %);       
(-ESI, H2O/CH3CN): m/z = 859.1 [M-H-] (Rt = 8.85 min, 100 %); HPLC (preparative), 
gradient (t [min], % B: U[ U0, 5.8], [11, 5.8], [12, 10], [18, 13], [20, 80]): Rt = 18.43 min; 
UV/Vis (H2O) λmax (log ε) = 259 nm (14,300; shoulder), 348 nm (5,200); empirical 
formula: C28H31N8O18P3; MW = 860.51 
Bis-Ac-NH-ANT-ITP 
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Bis-MANT-ADP (N-methyl-2’,3’-bis-O-anthraniloyl-adenosine-5’-diphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[(hydroxy-phosphonooxyphosphoryl) 
oxymethyl]oxolan-3,4-bis-yl]2-methylaminobenzoate (28). 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded over all purification steps 7 mg (11 μmol, 6 %) pure product. 
Rf = 0.35 (1-propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 27.10 min; 
k = 16.78; LC/MS (ESI, H2O/CH3CN): m/z = 711.3 [M+NH4+] (Rt = 28.85 min, 100 %), 
694.3 [M+H+] (Rt = 28.85 min, 90 %); (-ESI, H2O/CH3CN): m/z = 692.2 [M-H-] 
(Rt = 28.83 min, 100 %); HPLC (preparative),  gradient (t [min], % B: [0, 11],  [2, 11], 
[5, 30], [15, 31.5], [18, 80]): Rt = 11.71 min; UV/Vis (H2O) λmax (log ε) = 255 nm 
(16,000), 359 nm (6,200); empirical formula: C26H29N7O12P2; MW = 693.50 
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Bis-MANT-IDP (N-methyl-2’,3’-bis-O-anthraniloyl-inosine-5’-diphosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[(hydroxy-phosphonooxyphosphoryl)oxymethyl] 
oxolan-3,4-bis-yl]2-methylaminobenzoate (29). 
For the procedure see general prescription. 100 mg (0.17 mmol) trisodium salt of ITP 
yielded 6 mg (9 μmol, 5 %) pure product. Rf = 0.36 (1-propanol:H2O:NH3 (32 %) = 
Bis-MANT-ADP 
Bis-MANT-IDP 
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Bis-Br-ANT-ADP 
2:1:1). HPLC (analytic): Rt = 27.48 min; k = 16.94; LC/MS (ESI, H2O/CH3CN): 
m/z = 712.3 [M+NH4+] (Rt = 28.76 min, 100 %), 695.4 [M+H+] (Rt = 28.76 min, 10 %); 
(-ESI, H2O/CH3CN): m/z = 693.3 [M-H-] (Rt = 28.76 min, 100 %); HPLC (preparative),  
gradient (t [min], % B: [0, 11],  [2, 11], [5, 30], [15, 31.5], [18, 80]): Rt = 11.24 min; 
UV/Vis (H2O) λmax (log ε) = 252 nm (15,800), 359 nm (6,000); empirical formula: 
C26H28N7O13P2; MW = 694.48 
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Bis-Br-ANT-ADP (2’,3’-bis-O-5-bromoanthraniloyl-adenosine-5’-diphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[(hydroxy-phosphonooxyphosphoryl) 
oxymethyl]oxolan-3(4)-yl]2-amino-5-bromobenzoate (30). 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced disodium 
salt of ATP yielded 6 mg (7 μmol, 4 %) pure product after purification. Rf = 0.35 (1-
propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 27.39 min; k = 16.85; 
LC/MS (ESI, H2O/CH3CN): m/z = 823.9 [M+H+] (Rt = 27.73 min, 100 %), 840.9 
[M+NH4+] (Rt = 27.73 min, 20 %); (-ESI, H2O/CH3CN): m/z = 821.9 [M-H-] 
(Rt = 27.73 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 17], [8, 17], 
[10, 25], [15, 38], [20, 80]): Rt = 16.68 min; UV/Vis (H2O) λmax (log ε) = 255 nm 
(14,100), 348 nm (4,000); empirical formula: C24H23Br2N7O12P2; MW = 823.23 
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Bis-MANT-IMP (N-methyl-2’,3’-bis-O-anthraniloyl-inosine-5’-monophosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[phosphonooxymethyl]oxolan-
3,4-bis-yl]2-methylaminobenzoate (31). 
The disodium salt of IMP (100 mg, 0.26 mmol) yielded 80 mg (130 μmol, 50 %) pure 
product after size-exclusion chromatography. Rf = 0.28 (1-propanol:H2O:NH3 (32 %) 
= 2:1:1). HPLC (analytic): Rt = 28.95 min, k = 17.56; LC/MS (ESI, H2O/CH3CN): 
m/z = 632.2 [M+NH4+] (Rt = 30.28 min,100 %); (-ESI, H2O/CH3CN): m/z = 613.2 [M-
H-] (Rt = 30.28 min, 100 %), 673.2 [M+CH3COO-] (Rt = 30.28 min, 70 %); 1H-NMR 
(400 MHz, D2O): δ = 2.16 (s, 3 H, HMBC: 14a-H), 2.25 (s, 3 H, HMBC: 14b-H), 4.09 
(s, 2 H, COSY: 1-H), 4.58 (s, 1 H, COSY: 2-H), 5.67 (t, 1 H, COSY, HSQC: 17a-H), 
5.75 (d, 3J = 8.35 Hz, 1 H, COSY, HSQC: 15a-H), 5.81 (s, 1 H, COSY, HSQC: 3-H), 
5.96 (d, 3J = 8.38 Hz, 1 H, COSY, HSQC: 15b-H), 6.08 (m, 2 H, COSY, HSQC: 4-H, 
17b-H), 6.16 (d, 3J = 6.21 Hz, 1 H, COSY, HMBC: 5-H), 6.47 (s, 1 H, COSY: 16a-H), 
6.77 (s, 1 H, COSY: 16b-H), 7.22 (d, 3J = 7.52 Hz, 1 H, COSY, HSQC: 18a-H), 7.63 
(d, 3J = 7.49 Hz, 1 H, COSY, HSQC: 18b-H), 7.72 (s, 1 H, HSQC: 9-H), 8.51 (s, 1 H, 
HMBC: 6-H); 13C-NMR (100.6 MHz, D2O): δ [ppm] = 28.6 (1 C, HSQC, HMBC: 14-C), 
28.8 (1 C, HSQC, HMBC: 14-C), 64.0 (1 C, HSQC: 1-C), 72.1 (1 C, HSQC: 3-C), 
73.8 (1 C, HSQC: 4-C), 84.4 (1 C, HSQC: 2-C), 85.2 (1 C, HSQC, HMBC: 5-C), 
107.5 (1 C, HMBC: 12a-C), 108.1 (1 C, HMBC: 12b-C), 110.54 (1 C, HSQC, HMBC: 
15a/b-C),113.7 (1 C, HSQC, HMBC: 17a-C), 114.1 (1 C, HSQC, HMBC: 17b-C), 
123.3 (1 C, HMBC: 10-C), 131.0 (1 C, HSQC: 18a-C), 131.3 (1 C, HSQC: 18b-C), 
134.9 (2 C, HSQC, HMBC: 16a/b-C), 139.7 (1 C, HMBC: 6-C), 146.0 (1 C, HSQC, 
HMBC: 9-C), 148.9 (1 C, HMBC: 7-C), 151.7 (1 C, HMBC: 13a-C), 151.8 (1 C, 
HMBC: 13b-C), 158.1 (1 C, HMBC: 8-C), 166.7 (1 C, HMBC: 11a-C), 167.2 (1 C, 
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HMBC: 11b-C); 31P-NMR (161.9 MHz, D2O): δ = 3.3; UV/Vis (H2O) λmax (log ε) = 250 
nm (16,200), 359 nm (6,500); empirical formula: C26H27N6O10P3; MW = 614.50 
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Bis-ANT-IMP (2’,3’-bis-O-anthraniloyl-inosine-5’-monophosphate) or [(2R,3S, 
4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[phosphonooxymethyl]oxolan-3,4-bis-yl]2-amino-
benzoate (32). 
The disodium salt of IMP (100 mg, 0.26 mmol) yielded 82 mg (140 μmol, 54 %) pure 
product after size-exclusion chromatography. Rf = 0.28 (1-propanol:H2O:NH3 (32 %) 
= 2:1:1). HPLC (analytic): Rt = 25.03 min, k = 15.41; LC/MS (ESI, H2O/CH3CN): 
m/z = 604.3 [M+NH4+] (Rt = 26.15 min, 100 %); (-ESI, H2O/CH3CN): m/z = 585.3 [M-
H-] (Rt = 26.15 min, 80 %), 645.3 [M+CH3COO-] (Rt = 26.15 min, 100 %); UV/Vis 
(H2O) λmax (log ε) = 250 nm (23,600), 333 nm (7,600); empirical formula: 
C24H23N6O10P; MW = 586.45 
N
O
O
O
 
N-propylisatoic anhydride or 1-propyl-1,3-benzoxazine-2,4-dione (33). 
Isatoic anhydride (1.0 g, 6.1 mmol) was dissolved in a minimum amount of dry 
dimethylformamide (10 ml) and 177 mg (7.35 mmol, 1.2 eq) sodiumhydrid (60 %) 
was added stepwise in small portions accompanied by vigorous gas evolution. After 
five minutes of stirring 1.2 g iodopropane (6.74 mmol, 1.1 eq) were added dropwise 
to the pacified solution. The reaction mixture was stirred for 24 h and then 
Bis-ANT-IMP 
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precipitated in 100 ml cold water to give a white powder. After filtration and washing 
the product was dried over phosphorpentoxide under vacuum to yield 988 mg 
(4.8 mmol, 79 %). 
1H-NMR (300 MHz, CDCl3): δ = 1.04 (t, 3J = 8.1 Hz, 3 H, CH3), 1.78 (m, 2 H, CH2), 
4.02 (t, 3J = 7.7 Hz, 2 H, CH2), 7.16 (d, 3J = 8.5 Hz, 1 H, C8-H), 7.28 (ddd, 3J = 7.9 
Hz, 3J = 7.4 Hz, 4J = 1.0 Hz, 1 H, C6-H), 7.76 (ddd, 3J = 8.6 Hz, 3J = 7.4 Hz., 4J = 
1.7 Hz, 1 H, C7-H), 8.13 (dd, 3J = 7.9 Hz, 4J = 1.7 Hz, 1 H, C5-H); 13C-NMR 
(75.5 MHz, CDCl3): δ = 11.0 (+), 20.2 (–), 46.4 (–),111.7 (Cquat, phenyl), 114.0 (+), 
123.9 (+), 130.9 (+), 137.3 (+), 141.4 (Cquat, phenyl), 147.8 (Cquat, anhydride), 158.6 
(Cquat, anhydride); MS (EIMS, 70 eV): m/z = 205.0 [M+•] (100 %), 161.1 [M+•-CO2] 
(20 %); IR (KBr): [cm-1] = 3094, 2964, 2936, 2875, 1770, 1724, 1603, 1477, 1326, 
1022, 766; Mp: 94 °C; UV/Vis (ACN) λmax (log ε) = 245 (8,500), 320 nm (4,000); 
empirical formula: C11H11NO3; MW = 205.21 
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5-acetylaminoisatoic anhydride or N-(2,4-dioxo-1,4-dihydro-benzo[1,3] oxazin-6yl)-
acetamide (34). 
Acetic acid (2 ml) and acetic anhydride (63 mg, 0.61 mmol, 1.1 eq) was propounded 
in a small flask. Under stirring 5-aminoisatoic anhydride (100 mg, 0.56 mmol) was 
added and heated to 60 °C for 4 hours. After cooling to room temperature; 10 ml 
water was added dropwise. The brown colored product was precipitated by ice-
cooling followed by filtration and washing with ice-cold water. The precipitate was 
dried over phosphorpentoxide under vacuum to yield 110 mg (0.5 mmol, 90 %).  
1H-NMR (300 MHz, CDCl3): δ = 2.05 (s, 3 H, CH3), 7.10 (d, 3J = 8.8 Hz, 1 H, C8-H), 
7.80 (dd, 3J = 8.8 Hz, 4J = 2.5 Hz, 1 H, C7-H), 8.24 (d, 4J = 2.5 Hz, 1 H, C5-H), 10.17 
(s, 1 H, N-H), 11.66 (s, 1 H, N-H); 13C-NMR (75.5 MHz, CDCl3): δ = 23.8 (+), 110.1 
(Cquat, phenyl), 115.7 (+), 117.5 (+), 128.1 (+), 134.9 (Cquat, phenyl), 136.7 (Cquat, 
phenyl), 146.9 (Cquat, anhydride), 159.8 (Cquat, anhydride), 168.4 (Cquat, acetyl); MS 
(EIMS, 70 eV): m/z = 176.0 [M+•-CO2] (100 %), 161.1 [M+•] (80 %); IR (KBr): [cm-1] = 
3117, 2843, 2936, 2735, 1788, 1725, 1645, 1510, 1336, 1264, 911; Mp: 259 °C; 
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UV/Vis (MeOH) λmax (log ε) = 270 nm (15,500), 350 nm (5,600); empirical formula: 
C10H8N2O4; MW = 220.18 
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Chapter IV.  Review Azamacrocycles 
IV. Transition metal complexes of some azamacrocycles 
and their use in molecular recognitionωφ 
1. Introduction 
The field of coordination chemistry of polyazamacrocycles has undergone immense 
growth since the publication of seminal articles by Curtis1 and Thompson and Busch2 
in the early 1960s. Especially two cyclic tetraamines have played a key role in this 
field, namely 1,4,7,10-tetraaza-cyclododecane ([12]aneN4 or cyclen) and 1,4,8,11-
tetraaza-cyclotetradecane ([14]aneN4 or cyclam). The fit between the size of the 
metal ion and the cavity provided by the macrocycle is crucial for the design of metal 
complexes. On complexation with transition metals, the stereo-electronic 
requirements must also be taken into account3-4. As the cavity of the 12-membered 
cyclen is smaller than that of 14-membered cyclam, the macrocycle tends to fold 
around metal ions with octahedral coordination geometry adopting a cis 
conformation4-6. In general, tetraazamacrocycles exhibit high basicity in the first two 
protonation steps and rather low basicity in the last two steps. The critical protonation 
constants (log KHi) for cyclen and cyclam and stability constants (log KMmHhLl) of their 
complexes with several metal ions are reported in Table 1.  
Table 1.  Protonation constants (log KHi) for cyclen and cyclam and stability constants (log KMmHhLl)
 of their complexes with selected metal ions. T = 25 °C. 
Ion Equilibrium constant Cyclam Cyclen 
H+ [HL]/[L] x [H] 11.58,a 11.3b 10.97h 
 [H2L]/[HL] x [H] 10.62,a 10.23b 9.87h 
 [H3L]/[H2L] x [H] 1.61,a 1.43b 1.6i 
 [H4L]/[H3L] x [H] 2.42,a 2.27b 0.8i 
 [H4L]/[L] x [H]4 26.23,a 25.23b 23.24h,i 
Ni2+ [ML]/[M] x [L] 22.2,c 20.1d 16.4j 
Cu2+ [ML]/[M] x [L] 26.5,b 27.2e 23.29,b 24.8e 
Zn2+ [ML]/[M] x [L] 15.0,e 15.5f 16.2f 
 [ML(H2O)]/[ML(OH)] x [H] 9.77g 8.02g 
                                                          
ω This chapter was published in Curr. Org. Synth. 2007, 4, 390 – 412  
φ  The chapter deals with a review about azamacrocycles. Such compounds were synthesized in an ongoing side
 project for transmembrane channeling of AC inhibitors. The review was the by-product of this unfinished work. 
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Cd2+ [ML]/[M] x [L] 11.23b 14.3f 
Pb2+ [ML]/[M] x [L] 10.83b 15.9f 
Co2+ [ML]/[M] x [L] 12.7i  
Hg2+ [ML]/[M] x [L] 23.0k 25.5k 
a I = 0.5 mol dm-3 KNO3 7; b I = 0.1 mol dm-3 NaNO38; c I = 0.1 mol dm-3 NaOH9; d I = 0.5 mol dm-3 
NaCl10; e I = 0.2 mol dm-3 KNO311,12; f I = 0.2 mol dm-3 NaClO413; g I = 0.2 mol dm-3 KNO314; h I = 
0.5 mol dm-3 KNO315; i I = 0.2 mol dm-3 NaClO416; j I = 0.1 mol dm-3 NaNO317; k I = 0.2 mol dm-3 KNO318 
In this review the role of metal complexes of 1,4,7-triaza-cyclononane ([9]aneN3 or 
TACN), 1,5,9-triaza-cyclododecane ([12]aneN3), 1,4,7,10-tetraaza-cyclododecane 
([12]aneN4 or cyclen) and 1,4,8,11-tetraaza-cyclotetradecane ([14]aneN4 or cyclam) 
as molecular binding sites is discussed (Fig. 1). Many metal complexes of 
azamacrocycles have in addition to the azamacrocycle ligand additional reversibly 
coordinated ligands. Their binding and exchange can be used in molecular 
recognition, if reversible and rapid. In the following review we discuss the current 
literature available for such binding situations. Reported X-ray structure analyses of 
TACN, cyclen and cyclam metal complexes which coordinate additional ligands and 
the literature on solution studies involving coordination to [9]aneN3, [12]aneN3, cyclen 
and cyclam are summarized and discussed. 
Fig. 1. The parent structure [9]aneN3, [12]aneN3, cyclen and cyclam. 
In order to be considered, the parent structure needs to complex a metal, thereby 
HNNH
NH HN
NH HN
HNNH
N
H
HNNH
N
H
HNNH
1
[9]aneN3
2
[12]aneN3
3
[12]aneN4
cyclen
4
[14]aneN4
cyclam
coordinating to all nitrogens (3 in the case of [9]aneN3 and 4 in the case of [12]aneN4 
and [14]aneN4) in the azamacrocycle. Alkyl, phenyl and aryl substitution at any 
position (carbon or nitrogen substitution) is allowed provided such substitution does 
not affect the geometry of the parent structure nor introduce additional ligands which
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coordinate to the metal and thus induce a change in the coordination geometry. Such 
metal complexes needed to undergo an intermolecular coordination with another 
molecule. Only metal coordination to halogens, sulfates, perchlorates, cyanides, 
isothiocyanides, azides, nitrates, nitrites, carbonates and solvent molecules (DMF, 
DMSO, H2O) are excluded. In general the guest molecule should be an organic entity 
which can coordinate to the host, ideally under physiological conditions.  
2.  Structures of 1,4,7,10-tetraaza-cyclododecane ([12]aneN4 or 
cyclen) complexes in solid state 
2.1. Co(III) complexes  
[Co(cyclen)-(X)Y]n+ species exhibit exclusive cis stereochemistry, but exist as various 
isomeric forms depending on the orientation (syn or anti) of the sec-NH protons at the 
two equatorial sites19. The X-ray structure analysis of [Co(cyclen)(O2C2O2)]+ (Fig. 2) 
shows the oxalate coordinated with a cis stereochemistry with the Co(III) atom 
adopting a distorted octahedral geometry which is typical for Co(III) cyclen 
complexes20-23. Similar complexes such as [Co(cyclen)-(O2CCH2CO2)]+ 19, show the 
same geometry.  
Fig. 2. Structure of syn,anti-[Co(cyclen)(O2C2O2)]+ in the crystal. Thermal ellipsoids are drawn at the
 50 % probability level. 
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On coordination with a monodentate ligand such as a phosphite anion, Co(III) cyclen 
maintains its octahedral geometry by also coordinating a water molecule (Fig. 3)24. 
Fig. 3. Structure of syn(OP(H)(O)2),anti(OH2)-[Co(cyclen)(OH2){OP(H)(O)2}]+ in the solid state.
 Thermal ellipsoids are drawn at the 50 % probability level. 
 
 
 
 
 
 
 
 
 
 
Co(III) complexes of cyclen also coordinate diamines, such as ethylenediamine, 
2-(aminomethyl)pyridine, (R)-1,2-propanediamine, (R,R)-1,2,-diaminocyclohexane, 
trimethylenediamine or 2-methyl-1,3-diaminopropane25,26. In addition the coordination 
of amino acids such alanine to Co(III) complexes have been reported20,27. The X-ray 
structure of the Co(III) complex of (2R,5R,8R,11R)-2,5,8,11-tetraethyl-1,4,7,10-
tetraaza-cyclododecane bound to (S)-alanine is shown in Fig. 4. The macrocycle 
coordinated in a folded manner leaves space available for the coordination of the 
bidentate ligand. The stereochemistry of the amino acid is maintained upon 
coordination to Co(III) ion28. 
Fig. 4. The crystal structure of the Co(III) complex of (2R,5R,8R,11R)-2,5,8,11- tetraethyl-1,4,7,10-
 tetraaza-cyclododecane bound to (S)-alanine.  
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2.2 Cu(II) complexes 
Several structures of Cu(II) complexes of cyclen have been reported29,30. X-ray 
analyses show that copper is coordinated in a square pyramidal geometry with the 
four nitrogens of cyclen31. However no relevant molecular recognition of such 
complexes has been reported.  
2.3 Ni(II) complexes 
Ni(II) cyclen complexes have an octahedral coordination sphere by coordinating two 
water molecules in a cis orientation that only slowly exchange with other ligands32,33. 
An N-methylated Ni(II) cyclen derivative leads to the [Ni2(Me2-cyclen)2ox]2+ binuclear 
cation (where ox = oxalate anion)34. The oxalate dianion acts a tetradentate bridging 
ligand between two Ni(II) cyclen complexes. 
A Ni(II) cyclen complex containing imidazole has also been reported. The X-ray 
structure analysis shows the Ni(II) ion in a distorted octahedral coordination geometry 
consisting of four nitrogen atoms from cyclen as donor atoms, one nitrogen atom 
from the imidazole and one oxygen atom from one of the perchlorate ions35. The 
same distorted octahedral geometry is also illustrated in the following example where 
a Ni(II) cyclen complex binds an acetate anion (Fig. 5)36. 
Fig. 5. Structure of [Ni(cyclen)(η2-CH3CO2)]+ cation in the solid state. Hydrogen atoms are omitted for
 clarity. Probability ellipsoids are 30%. 
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Ni(II) cyclen complexes also coordinate phenanthroline (phen) (Fig. 6)37 and 
7,7,8,8-tetracyanoquino-dimethane (TCNQ)30 as additional ligands giving distorted 
octahedral coordination geometry consisting of four nitrogen atoms from cyclen and 
two nitrogens atoms from the heteroaromatic ligand. 
Fig. 6. Molecular structure of [Ni(cyclen)(phen)](ClO4)2. 
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2 ClO4-  
2.4 Zn(II) complexes 
Zn(II) cyclen complexes interact with uridine (U) and thymidine (T) nucleotides by 
specific Zn(II)-imide N- coordination (Fig. 7)38. Additional stabilization of this structure 
by hydrogen bonds between amine N-H of the cyclen ligand and the carbonyl groups 
of the heterocycle have been proposed, but solid evidence is missing.  
Fig. 7. Zn(II) cyclen complexes selectively coordinate the imide group in nucleosides, such as 3’-
 azido-3’-deoxythymidine (AZT). 
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The X-ray structure analysis of [Zn(cyclen)(AZT)](ClO4)⋅2H2O reveals a distorted 
square pyramidal N5-coordination geometry for the Zn(II) ion (Fig. 8)38.  
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Fig. 8. Structure of [Zn(cyclen)(AZT)](ClO4)⋅2H2O, (AZT = 3’-azido-3’-deoxythymidine) in the crystal.
 A perchlorate anion and two water molecules are omitted for clarity (ellipsoids are 50%). 
 
A further example for such an imide recognition repetitiving the distorted square 
pyramidal geometry is the coordination of the important metabolite creatinine to the 
Zn(II) cyclen39. In general the binding affinity of imides correlates with the decreasing 
of the pka value of the imide nitrogen.  
Zn(II) cyclen complexes coordinated with phosphate anions as additional ligands 
have been described and characterized by X-ray analysis (Fig. 9)40. The para-nitro 
phenyl ester of phosphate (NPP2-) forms a complex with three Zn(II) cyclen moieties. 
The three oxygen atoms of the phosphate anion act as the fifth ligand for the Zn(II) 
ions coordinated by the cyclen ligand. 
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Fig. 9. Structure of Zn(cyclen)]3-NPP2- in the solid state. All hydrogen atoms, perchlorate anions and
 water molecules are omitted for clarity. Probability ellipsoids are 30%. 
 
 
 
 
 
 
 
 
 
 
An imidazolate anion can act as a bridging ligand for two Zn(II) cyclen units. The 
X-ray structure analysis (Fig. 10) shows the two Zn(II) ions with distorted square 
pyramidal coordination geometry composed of four nitrogen atoms from cyclen ligand 
and one nitrogen atom from the bridging imidazolate ion35.  
Fig. 10. Structure of [Zn(cyclen)]2-im (im = imidazolate) in the solid state.  
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Bis-Zn(II) cyclen complexes coordinate barbital41 as well as thymidine and uridine 
nucleosides, such as thymidine 5’-monophosphate (5’-dTMP)42. The aggregates 
have a 2:2 stoichiometry and consist of a macrocyclic arrangement. Tris-Zn(II) cyclen 
variations have also been reported to coordinate organic phosphate dianions40. 
3. Structures of 1,4,7,10-tetraaza-cyclododecane([12]aneN4 or 
cyclen) complexes in solid state (tabulated) 
Table 2 summarizes all X-ray structures registered at the Cambridge 
Crystallographic Database according to the selection criteria previously mentioned.  
Table 2. Structurally characterized metal complexes of 1,4,7,10-tetraaza-cyclododecane ([12ane]N4
 or cyclen) with additional ligand coordinated to the metal ion in solid state. 
Structure of the Metal ions 
additional ligand Zn2+ Ni2+ Co3+ Rh3+ Ru2+ 
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 (1) Substitution – n-aryl; R1 = aryl; (2) a) Substitution – none; R2 = p-nitrophenolate; (2) b) Substitution – 
n-alkyl; R2 = O; (3) Substitution – none; (4) Substitution – none; (5) Substitution – n-alkyl (cage); R8 = 
CH3, R9 = H; (6) a) Substitution – none; R8 = CH3, R9 = H; (6) b) Substitution – none; R8 = CH3, R9 = 
Br; (7) Substitution – none; (8) Substitution – none; (9) Substitution – none; (10) Substitution – none; (11) 
Substitution – none; (12) Substitution – n-aryl; R2 = CH3; (13) Substitution – none; R2 = metal; (14) 
Substitution – none; R2 = H; (15) Substitution – n-aryl; (16) Substitution – none; (17) Substitution – none; 
(18) Substitution – none; (19) Substitution – none; (20) Substitution – none; (21) Substitution – n-alkyl; (22) 
Substitution – n-alkyl; R5 = H, R6 = CH3 (alanine); (23) a) Substitution – c-alkyl; R5 = H, R6 = CH3 
(alanine); (23) b) Substitution – c-alkyl; R5 = COOH, R6 = CH3; (23) c) Substitution – c-alkyl; R5 = H, R6 
= CH2OH (serine); (23) d) Substitution – c-alkyl; R5 = CH3, R6 = CH2OH (methylserine); (23) e) 
Substitution – c-alkyl; R5 = H, R6 = H (glycine); (23) f) Substitution – c-alkyl; R5 = H, R6 = -
CH2CH2SCH3; (23) g) Substitution – c-alkyl; R5 = H, R6 = CH(OH)CH3 (threonine); (23) h) Substitution – 
c-alkyl; R5 = CH3, R6 = CH2PhOH(methyltyrosine); (24) Substitution – none; (25) Substitution – none; (26) 
Substitution – none.  
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4. Molecular recognition of 1,4,7,10-tetraaza-cyclododecane 
([12]aneN4 or cyclen) complexes in solution 
4.1 Co(III) complexes 
The optically active Co(III) complex of (2R,5R,8R,11R)-2,5,8,11-tetraethyl-1,4,7,10-
tetraaza-cyclododecane was found to react with several neutral amino acids at pH 8 
to form the corresponding amino acidato complexes56. The stereochemistry of the 
amino acid was retained on complexation with the macrocycle.  
4.2 Cd(II) complexes 
The Cd(II) complex of cyclen containing 7-amino-4-trifluoromethylcoumarin, 5 was 
designed as a fluorescent reporter69. Particular phosphate and citrate anions are 
bound by the metal complex, thus displacing the aromatic amino group of the 
coumarin and causing a change of the excitation spectrum (Fig. 11).  
Fig. 11. Sensoric principle of phosphate ion sensing with 5. 
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N N
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O
n+
:
5 (M = Cd2+)  
The metal complex detects pyrophosphate and citrate with high selectivity, whilst no 
response was shown for fluoride or perchlorate. Organic anions such as ATP and 
ADP also gave strong signals whilst cAMP showed little response (Table 3). The 
sensing mechanism was shown to be reversible.  
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Table 3. Apparent dissociation constants (Kd) of sensor 5 for anions in 100 mM HEPES Buffer (pH
 7.4). 
Anion Kd (M) 
Pyrophosphate 7.5 x 10-5 
Citrate 9.0 x 10-5 
Phosphate 1.5 x 10-2 
ATP 1.4 x 10-5 
ADP 2.6 x 10-5 
GMP 4.8 x 10-5 
AMP 4.4 x 10-4 
UMP 1.7 x 10-3 
UMP 1.7 x 10-3 
cAMP a 
a Kd is too large to be calculated. 
4.3 Zn(II) complexes 
The prevalence of Zn(II) ions in biological systems has led to a large number of Zn(II) 
complexes as models for such systems. A comprehensive review on the molecular 
interactions of Zn(II) cyclen and its derivatives was recently published70. On 
complexation with cyclen, the acidity of the Zn(II) ion is reinforced, which results in a 
lowering of the pKa value of the Zn(II)-bound water from 9.0 to 7.9 at 25 °C38. Zn(II) 
cyclen also forms 1:1 complexes with deprotonated sulfonamides at neutral pH, 
despite the weak acidity of sulfonamides with pKa values of 7-10 (Fig. 12)71, 72. 
Fig. 12. Reversible coordination of sulfonamide anions to Zn(II) cyclen. 
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Following a similar principle Zn(II) cyclen complexes have been applied to the 
molecular recognition of nucleobases, thymine (dT) and uracil (U), which possess 
similarly weak acidic (pKa around 10) protons at their ‘imide’ groups73. The 
centrosymmetric linear arrangement of the three-point functional groups in 8 
comprises the acidic Zn(II) acting to yield the ‘imide’ anion to form a stable Zn(II)-
N(3)- bond and the two hydrogens attached to cyclen nitrogens to form two 
complementary hydrogen bonds with each of the ‘imide’ carbonyls. This specific 
Zn2+-imide N- coordination allows the reversible coordination of flavin derivates, 
which are important cofactors of flavoproteins74-76 and photolyases77. These 
electronic and structural fittings also permit formation of extremely strong 1:1 
complexes of 8 with dT, AZT, U, Ff (5-fulorouracil) and riboflavin (Fig. 13). Zn(II) 
cyclen complexes appended with polyaromatic rings were shown to selectively bind 
to T- or U-rich sequences in double stranded DNA (or RNA) to denature them50,78. It 
does not interact with the other DNA nucleosides (i.e. dG, dA and dC), making the 
reversible coordination highly selective. 
UV radiation leads to the formation of photolesions in DNA, which compromise the 
genetic information and can induce cell death or skin cancer. Especially dimeric Zn(II) 
cyclen complexes containing xylyl spacers inhibit efficiently photo[2+2]cycloaddition 
of thymidilyl(3´-5´)thymidine (d(TpT)) and promote the photosplitting of the 
corresponding photoproduct cis-syn-cyclobutane thymine dimer (T[c,s]T)77,78. 
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Fig. 13. Zn(II) cyclen complex coordination to molecules bearing acidic imide groups. 
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Zn(II) cyclen complexes reversibly coordinate phosphate dianions such as HPO42-, 
phenyl phosphate (PP2-) and 4-nitrophenyl phosphate (NPP2-) as monodentate 
ligands to yield 1:1 complexes 9 in solution (Fig. 14). The observed binding affinities 
in neutral aqueous solution are in the millimolar range. Furthermore metal cyclen 
complexes added with fluorescent ligands are used for sensing anions by twisted 
intramolecular charge transfer (TICT)79. 
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Fig. 14. Zn(II) cyclen coordinating monodentate phosphate dianions. 
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The dianions of phosphate monoesters, RPO32- are potential bidentate donors and 
bridge two Zn(II) ions (Fig. 15). A bis-Zn(II) cyclen complex linked with a meta-xylene 
spacer forms a stable complex with NPP2- with log Ks of 4.0 in aqueous solution (I = 
0.1 NaClO4 at 25 °C)41. 
Fig. 15. Bis-Zn(II) cyclen complexes bind phosphate monoesters in a bidentate fashion. 
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Fig. 16. The C3-symmetric tris-Zn(II) cyclen complex 12. 
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A yet higher binding constant could be achieved for tris-Zn(II) cyclen complexes 
(Fig. 16)40. A summary of the phosphate affinity constants of Zn(II) cyclen, bis-Zn(II) 
cyclen and tris-Zn(II) cyclen is shown in Table 4. 
Table 4. Phosphate (phosphonate) affinity constants (log Ks)2 of Zn(II) cyclen 9, m-bis(Zn(II) cyclen)
 10 and tris(Zn(II) cyclen) 12, for NPP-, PP2-, phenyl phosphonate (PhP2-), and α-D-glucose
 1-phosphate (α-Glu-P2-) at 25 °C and I = 0.10 (NaNO3)80. 
Phosphate (pK2’b)  Log Ksa  
(phosphonate)  9 10 12 
NPP2- (5.2) 3.1 4.0 5.8 
PP2- (5.9) 3.5 4.6 6.6 
α-Glu-P2- (6.1)   7.0 
PhP2- (7.0)   7.9 
aKs = [ZnL1-RPO32- complex] / [ZnL1][RPO32-] (M-1) for 9, [Zn2L3-RPO32- complex] / [Zn2L3][RPO32-]
 (M-1) for 10, or [Zn3L5-RPO32- complex] / [Zn3L5][RPO32-] (M-1) for 12. 
bK2’ = - log ([RPO32-]aH + / [RPO3H-]) obtained by pH titration at 25 °C with I = 0.10 (NaNO3). 
The bis-[Zn(II) cyclen] complexes 10 and 14 (Fig. 17 and 18) can bind imide-
containing nucleotides. Table 5 compares the apparent complexation constants of 
13, 10 and 1480. Recent investigations have shown a dramatical acceleration of 
plasmid DNA cleavage by derivatives of bis[Zn(II) cyclen] complexes81. 
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Fig. 17. Zn(II) benzylcyclen 13 and p-xylyl-bis-[Zn(II) cyclen] 14. 
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Fig. 18. The binding of 14 to 5’-dTMP and 5’-dTDP respectively, showing the NOE interactions. 
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Table 5. Apparent complexation constants (log Kapp) for imide-containing nucleotides with Zn(II)
 cyclen complexes at pH 7.6 and 25 °C. 
 13 10 14 
dT 3.2a (5.7)d 3.2, 3.2b  
 3.4c (10:dT = 1:2)  
c-dTMP 3.3c 3.5, 3.5b  
  (10:c-dTMP = 1:2)  
5’-CMP 3.3a (3.7)d 3.2a (4.3)d  
 3.3b 3.4b  
3’-dTMP  5.2a (8.6)d 5.9a (8.9)d 
  5.3b 5.8b,e 
 127
Chapter IV.  Review Azamacrocycles 
  5.4c,f 5.8c,f 
5’-dTMP 3.4, 3.4b 5.5a (9.3)d 6.4a (9.6)d 
 (13:5’-dTMP = 2:1) 5.5b > 6b,e 
  5.7c,f > 6c,f 
2’-UMP  5.7b  
3’-UMP  4.8a (7.8)d 5.5a (8.5)d 
  5.2c,f 5.7c,f 
5’-UMP  5.4a (8.3)d 6.2a (8.8)d 
  5.5c,f > 6b 
   > 6c,f 
5’-dTDP  5.6b > 6b 
  5.5c,f > 6c,f 
5’-dTTP  5.0b 5.6b 
5’-AZTMP  5.5b > 6b,e 
  5.7c,f > 6c,f 
5’-AZTDP  5.3b 5.9b 
  5.5c > 6c,f 
a Determined by potentiometric pH titration. 
b Determined by isothermal titration calorimetry (50 mM HEPES buffer). 
c Determined by UV titration in 50 mM HEPES buffer with I = 0.1 (NaNO3). 
d For the intrinsic complexation constants Ks, see reference. 
e Titrations were carried out at [5’-dTMP] = 0.2 mM and 0.1 mM and the average values were listed. 
f  Titrations were carried out at [nucleotide] = 0.1 mM and 50 µM and the average values were listed. 
A recent publication has exposed a further approach of recognition with the tris-
[Zn(II)cyclen] 1282. The (Zn3L3)3 forms a stable 1:1 complex with cis,cis-1,3,5-
cyclohexanetriol triphosphate (CTP3), a model compound for inositol 1,4,5-
triphospate (IP3) (Fig. 19). IP3 is an important second messenger in the intracellular 
signaling pathway released by a phospholipase C (PLC), which induces an increase 
of Ca2+ concentrations in living cells. CTP3 has a similar Ca2+-releasing activity, but it 
is readily available. A luminescent chemical sensing system can be achieved by a 
ruthenium(II)-templated assembly of three molecules of a bis-[Zn(II)cyclen] complex 
containing a bipyridyl linker82. 
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Fig. 19. 1:1 complex of tris-[Zn(II)cyclen] and CTP3. 
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The search for small molecules that interact with RNA is currently attracting great 
interest for drug discovery in AIDS therapeutics83. The transcription of HIV-1 genome 
is facilitated by a HIV-1 regulatory protein Tat which activates the synthesis of full-
length HIV-1 mRNA by its binding to a TAR (trans-activation responsive) element 
RNA84. The TAR element comprising the first 59 nucleotides of the HIV-1 primary 
transcript adopts a hairpin structure with a uracil (U)-rich bulge (UUU or UCU), which 
is the Tat binding site. Linear tris-[Zn(II) cyclen] complexes inhibit HIV-1 TAR RNA-
Tat peptide binding due to its strong binding to the UUU bulge83,85. Fig. 20 shows the 
coordination of dT- pdT- pdT- with a linear tris-[Zn(II) cyclen] complex 15. 
Fig. 20. The binding of tris-[Zn(cyclen)] 15 to dT-pdT-pdT-. 
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5. Immobilized 1,4,7,10-tetraaza-cyclododecane ([12]aneN4 or 
cyclen) complexes in solid state 
Zn(II) complexes 
Zn(II) cyclen complexes have been bound to polymers and used to extract riboflavin 
from aqueous solutions. The reversible recognition of Zn(II) cyclen complexes to 
flavin imide moieties allowed the quantitative and selective extraction (and release 
from the polymer) of vitamin B2 (riboflavin) from a mixture of compounds at 
physiological pH (Fig. 21)86. 
Fig. 21. Binding equilibrium of Zn(II) cyclen polymer with riboflavin (R = ribityl) or its tetraacetate [R =
 CH2CH(OAc)CH(OAc)CH(OAc)CH2OAc]. 
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A molecular imprinted polymer (MIP) from polymerizable Zn(II) cyclen complexes and 
ethylene glycol dimethyl acrylate has been prepared39. Creatinine was used as the 
template molecule which was reversibly coordinated to the Zn(II) complex (Fig. 22). 
The imprinted polymer reverses the binding selectivity of Zn(II) cyclen for creatinine 
and thymine from 1:34 in homogenous solution to 3.5:1 in the MIP.  
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Fig. 22. Preparation of a stoichiometric template Zn(II) cyclen-creatinine monomer salt and
 copolymerization of 17 with ethylene glycol dimethyl acrylate (EDGMA). 
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A similar MIP polymer was prepared for the selective recognition and separation of 
phosphates87. Here again a polymerizable Zn(II) cyclen complex (ZnL2) was 
copolymerized with ethylene glycol dimethyl acrylate. The polymer interacts 
selectively with phosphomonoester dianions such as deoxyadenosine 5’-
monophosphate (5’-dAMP) and 4-nitrophenyl phosphate (4-NPP) over 
deoxyadenosine (dA) and adenosine 3’,5’-cyclic-monophosphate (3’,5’-cAMP). The 
apparent complexation constants for the 1:1 complex of ZnL2 on the MIP and 5’dAMP 
and 4-NPP, log Kapp(ZnL-S2-) (S2- = phosphomonoester dianion), at pH 7.0 and 25 °C 
were determined as 4.1. 
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6. Structures of 1,4,8,11-tetraaza-cyclotetradecane ([14]aneN4 or 
cyclam) complexes in solid state 
6.1 Zn(II) complexes 
Zn(II) cyclam complexes can coordinate carboxylates as additional ligand. The X-ray 
structure of a Zn2-xylyl-bicyclam with an acetate anion is shown (Fig. 23)88. Both 
cyclam units adopt the cis-V configuration (according to the nomenclature of 
Bosnich89) with chelation by acetate on one cyclam face and twofold H-bonding on 
the other. 
Fig. 23. X-ray crystal structure of [Zn2-xylyl-bicyclam(OAc)2](OAc)2·2CH3OH. CH3OH is not shown for
 clarity. 
 
 
 
 
 
 
 
 
The Zn(II) complex of 1,4,8,11-tetraazacyclotridecane-5-one, a closely related cyclam 
derivative, can coordinate glycine by glycine amine-Zn(II) coordination90. The X-ray 
structure (Fig. 24) shows a distorted square pyramidal geometry. The Zn atom has 
an irregular five-coordinate geometry, with the donors being three nitrogen atoms and 
one oxygen atom from the azamacrocycle and one coordinated chloride. 
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Fig. 24. Structure of Zn(II) complex of 1,4,8,11-tetraazacyclotridecane-5-one in the crystal. 
 
6.2 Ni(II) complexes 
Cyclam forms compared to zinc the thermodynamically and kinetically more stable 
complexes with copper and nickel, where the cyclic amine is arranged in a strain-free 
conformation with the metal atom located in the plane defined by the four nitrogen 
atoms of the cyclam4-6. There is some evidence that Ni(II)-cyclam can bind 
benzoates and that the metal free cyclams preorganize the ligands. The X-ray 
structure (Fig. 25) of Ni(O-benzoato)2(cyclam) quite closely parallels that of nickel 
free (4-t-butylbenzoato)2(cyclamH2). The X-ray structure of the Ni(II) cyclam distinctly 
shows that a Ni-O bond is formed in the case of Ni(O-benzoato)2(cyclam). 
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Fig. 25. Structure of (4-t-butylbenzoato)2(cyclamH2) and Ni(O-benzoato)2(cyclam) respectively, in the
 solid state. 
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Similar geometries were found for the corresponding Cu(II) complexes. However in 
the case of copper, the two carboxylate anions remain hydrogen bound to the 
(coordinated) cyclam ligand, and do not take part in the metal’s inner coordination 
sphere and no Cu-O bond is formed91.  
The Ni(II) complex of 1,4,7,10-tetraazacyclododecane-2,9-dione coordinates the 
dipeptide glycine-glycine92. The X-ray structure of [Ni(DOTA)2](ClO4)2 (Fig. 26) 
shows a octahedral coordination geometry. The Ni(II) has a regular six-coordinate 
geometry, with the donors being four nitrogen atoms and two oxygen atoms from two 
macrocyclic ligands. 
Fig. 26. Structure of Ni(II) complex of 1,4,7,10-tetraazacyclododecane-2,9-dione) in the crystal. 
 
 
 
 
 
 
 
7. Structure of 1,4,8,11-tetraaza-cyclotetradecane ([14]aneN4 or 
cyclam) complexes in solid state (tabulated) 
Table 6 summarizes all X-ray structures registered at the Cambridge 
Crystallographic Database according to the selection criteria previously mentioned.  
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Table 6. Structurally characterized metal complexes of 1,4,8,11-tetraaza-cyclotetradecane ([14ane]N4 or cyclam) with additional ligand coordinated to the  
 metal ion in solid state. 
Structure of the Metal ions 
additional ligand Ga3+ Zn2+ Cd2+ Cu2+ Ni2+ Co3+ Fe2+ Ru2+ Mn3+ Cr3+ 
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(14)See ref. 
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 (1) Substitution – n-alkyl; R1 = CH3; (2) a) Substitution – none; R2 = Ga3+; (3) Substitution – none; R2 = Ga3+; (4) Substitution – c-alkyl; R2 = Al3+; (5) a) Substitution – 
none; R3 = Ar; (5) b) Substitution – none; R3 = OMe; (6) a) Substitution – none; R3 = Ar; (6) b) Substitution – none; R3 = OMe; (7) a) Substitution – none; R3 = Ar; (7) 
b) Substitution – none; R3 = cyclohexane; (8) Substitution – none; R3 = pyridine; (9) Substitution – none; R4 = H; (10) Substitution – none; (11) Substitution – none; (12) 
Substitution – none; (13) Substitution – c-alkyl; (14) Substitution – none; (15) a) Substitution – c-alkyl; R3 = aryl; (15) b) Substitution – c-alkyl; R3 = pyridine; (16) 
Substitution – c-alkyl; R3 = aryl; (17) Substitution – c-alkyl; R7 = alkyl or aryl; (18) Substitution – c-alkyl; (19) a) Substitution – none; (19) b) Substitution – c-alkyl; (20) a) 
Substitution – c-alkyl; (21) Substitution – c-alkyl; (22) a) Substitution – n-alkyl (caged); R8 = CH3; (22) b) Substitution – c-phenyl; R8 = CH3; (23) Substitution – none; R8 
= CH3; (24) Substitution – n-alkyl; R6 = R7 = CH3; (25) a) Substitution – c-alkyl; R6 = R7 = H, (25) b) Substitution – n-alkyl; R6 = H, R7 = CH3; (25) c) Substitution – c-
alkyl; R6 = R7 = CH2CH3; (26) Substitution – none; R1 = quinonedi-imine; (27) Substitution – n-alkyl; R1 = 2-cyanoethene-1,2-dithiolate; (28) Substitution – none; (29) 
Substitution – none; (30) Substitution – none; (31) Substitution – none; (32) Substitution – none; (33) Substitution – none; (34) Substitution – none; (35) Substitution – c-
alkyl; R9 = O, R10 = NH-alkyl;  (36) a)Substitution – c-alkyl; R11 = Ar; (36) b) Substitution – c-alkyl; R11 = -SCH2COO-; (36) c) Substitution – c-alkyl; R11 = -
SCH2CH2COO-; (37) Substitution – c-alkyl; (38) Substitution – c-alkyl; R12 = R13 = CH2CH2-Ph; (39) Substitution – c-alkyl; R12 = R13 = CH2CH2-Ph; 
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8. Structures of 1,4,8,11-tetraaza-cyclotetradecane ([14]aneN4 or 
cyclam) complexes in solution 
8.1 Zn(II) complexes 
The bicyclam 18 (Fig. 27) is a very potent anti-HIV agent146. Entry of T-lymphotropic 
HIV-1 and HIV-2 strains is blocked by specific binding to the CXCR4 coreceptor147. 
Based on the strong propensity of the cyclam to bind carboxylic acid groups, receptor 
mutagenesis identified Asp171 and Asp262 as being essential for the ability of 18 to 
block the binding of the chemokine ligand stromal cell-derived factor (SDF)-1α and 
the binding of the receptor antibody 12G5149. Since the level of free Zn(II) in plasma 
is ca. 1 nM and cyclam and its alkylated derivates strongly bind Zn(II), it is 
reasonable to expect that the active compound in vivo is the Zn(II) complex88. 
Fig. 27. Molecular structure of xylyl-bicyclam 18, 1,1'-[1,4-phenylenebis(methylene)]-bis(1,4,8,11-
 tetraazacyclotetradecane). The octa-HCl salt of the compound is registered as the anti-HIV
 drug AMD3100. 
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The interaction of the Zn(II) complex of xylyl-bis-cyclam, which is 10 times more 
active than 18 in its interaction with the CXCR4 receptor148, with acetate was studied. 
In solution, acetate binds149 to the Zn(II) bicyclam complex with a binding constant of 
log K = 2.75 ± 0.15, assuming the formation of 1:1 complexes of acetate with Zn-
cyclam units and that the two Zn-cyclam units are independent88. Both in solution and 
in the solid phase the complex adopts a cis-V configuration (according to the 
nomenclature of Bosnich89) via chelation and second coordination sphere double 
H-bonding88. It was shown that only Zn(II) cyclams could bind acetates. Pd(II) 
cyclams do not coordinate acetates, as the acetate does not induce configurational 
changes of Pd(II) cyclam nor Pd(II)2-xylyl-bicyclam, and Pd(II) cyclams can readily 
adopt a cis-V configuration88,148.  
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Although Co(III) cyclams are known to bind strongly to carboxylates, and are capable 
of undergoing isomerizations from cis to trans configurations150, Co(III)2-xylyl-
bicyclam has a very low activity towards CXCR4148. This is most likely attributable to 
the kinetic inertness of Co(III) cyclams151. 
The Zn(II) complex of 1,4,8,11-tetraaza-cyclotridecane-5-one was found to be 
extremely efficient in the recognition of glycine in aqueous solution (Fig. 28)90. 
Fig. 28. Zn(II) complex of 1,4,8,11-tetraaza-cyclotridecane-5-one can bind glycine. 
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The carboxylate group is capable of forming a coordinative bond to the Zn(II) ion, 
while the H-atom of the amide on the macrocycle may also favor aggregate 
formation. Table 7 shows the stability constants for the Zn(II) 1,4,8,11-
tetraazacyclotridecane-5-one glycine complex 19. 
Table 7. Stability constants for Zn(II) 1,4,8,11-tetraaza-cyclotridecane-5-one (L)
 glycine complex 19 (µ = 0.10 M KCl, 25 °C). 
Stoichiometry    Quotient K log K 
(L) Zn Glycine H   
1 1 0 0 [LZn] / [L][Zn] 9.33 
1 1 0 1 [LZnH] / [LZn][H] 6.44 
1 1 0 2 [LZnH2] / [LZn][H]2 6.65 
1 1 1 0 [LZnGly-] / [LZn][Gly-] 12.25 
1 1 1 1 [LZnGlyH] / [LZnH][Gly] 2.58 
1 1 1 -1 [LZnGlyOH] / [LZnOH][Gly] 1.00 
1 1 1 -2 [LZnGlyOH2] / [LZnOH2][Gly] 0.88 
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8.2 Ni(II) complexes 
The Ni(II) complex of 1,4,7,10-tetraaza-cyclododecane-2,9-dione was found to be 
efficient in the recognition of the dipeptide glycine-glycine in aqueous solution 
(Fig. 29)92.  
Fig. 29. Ni(II) complex of 1,4,7,10-tetraaza-cyclododecane-2,9-dione 20 can recognize the dipeptide
 glycine-glycine (GG). 
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The formation of a stable ternary complex, L-Ni(II)-Gly-Gly- leads to a very high 
binding constant of log K = 19.20 (Table 8). The strong recognition may also be 
partially attributed to the formation of an H-bond between the macrocycle and the 
dipeptide. 
Table 8. Stability constants for the Ni(II) 1,4,7,10-tetraaza-cyclododecane-2,9-dione (L) glycine-
 glycine (GG) complex 20 (µ = 0.10 M KCl, 25 °C). 
Stoichiometry    Quotient K log K 
(L) Ni GG H   
1 1 0 0 [LNi] / [L][Ni] 15.51 
1 1 0 1 [LHNi] / [LNi][H] 4.50 
1 1 0 2 [LH2Ni] / [LHNi][H] 4.11 
1 1 0 -1 [LNiOH] / [LNi][H] 6.31 
1 1 0 -2 [LNiOH2] / [LNiOH][OH] -9.64 
1 1 1 0 [LNiGG] / [LNi][GG] 19.20 
1 1 1 -1 [LNiGGOH] / [LNiG][OH] 10.07 
1 1 1 -2 [LNiGGOH2] / [LNiGOH][OH2] 0.29 
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8.3 Hg(II) complexes 
Mallik et al. have shown that the Hg(II)-xylyl-bicyclam 21 (Fig. 30) could bind 
imidazole in DMSO (binding constants >> 100 M-1)152,153. 
Fig. 30. The Hg(II)-xylyl-bis-cyclam 21 bound to two imidazole units. 
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An improvement in imidazole binding is shown with the tris-cyclam ligand 22 which 
when complexed with Hg2+ has recognized a model histidine peptide 23 with a K > 
105 M-1 in DMSO (Fig. 31)154. 
Fig. 31. A tris-cyclam 22 when complexed with Hg(II) recognizes the model tris-histidine peptide 23, 
which is complementary in geometry. 
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9. Immobilised 1,4,8,11-tetraaza-cyclotetradecane ([14]aneN4 or 
cyclam) complexes 
Ni(II) complexes 
A linear polymer containing Ni(II) cyclam and 2,2’-bipyridyl-5,5’-dicarboxylate 
(bpydc2-) was synthesized (Fig. 32). The polymer binds guests in the order of ethanol 
≈ phenol (formation constant, Kf = 42 M-1) > pyridine (Kf = 13 M-1) > benzene 
(Kf = 3 M-1) in isooctane solution155.  
Fig. 32. Structure of the linear polymer containing Ni(II) cyclam and bpydc2-. 
Ni
2+
N
N
N
N
H H
H H
N N O
OO
O
[Ni(cyclam)]2+ bpydc2-  
 
10. Structures of 1,5,9-triaza-cyclododecane ([12]aneN3) complexes 
in solid state 
Zn(II) complexes 
Although the coordination of Zn(II) [12]aneN3 to acetazolamide and sulfonamides has 
been reported in solution14,71, no X-ray structures were found for their coordination in 
solid state. The X-ray structure of [Zn(12aneN3)(OH2)](ClO4)2 shows a zinc atom with 
slightly distorted tetrahedral coordination environment, with a bound water molecule 
(Fig. 33).  
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Fig. 33. Structure of [Zn(12aneN3)(OH2)](ClO4)2 in the crystal. Perchlorate anions and hydrogen atoms
 are omitted for clarity. Probability ellipsoids are 30%. 
 
 
 
 
 
11. Molecular recognition of 1,5,9-triaza-cyclododecane ([12]aneN3) 
complexes in solution 
Zn(II) complexes 
The Zn(II) complex of the 12-membered triamine, [12]aneN3 forms 1:1 complexes 
with acetazolamide and sulfonamides14,71. The intermolecular affinities of aromatic 
sulfonamides to Zn(II) [12]aneN3 (ZnL) are summarized in the Table 9.  
Table 9.  Comparison of critical affinity constants of different inhibitors (I) and inhibitor-ZnL
 complexes, Ki (M-1) and K [Zn(II) [12]aneN3-I-] (M-1)71. 
Inhibitor(I) log Ki log K[Zn(II) [12]aneN3-I-] 
acetazolamide 3.6 4.9 
4-nitrobenzenesulfonamide 2.6 4.8 
p-toluenesulfonamide 2.4 5.7 
Determined by inhibition kinetics at pH 8.4 (50 mM TAPS buffer), I = 0.10 and 25 °C. 
Due to the poor solubility of the sulfonamides, the potentiometric pH titration method 
could not be used to determine the binding constants. The binding constants were 
measured by an inhibition kinetic method in the Zn(II) [12]aneN3 complex promoted 
4-nitrophenyl acetate hydrolysis, which is analogous to the procedure used to 
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determine sulfonamide binding to carbonic anhydrase (CA)156. The apparent binding 
constants are consistent with previous biochemical data reported for CA models 
which makes such Zn(II) [12]aneN3 complexes good models for CA. 
12. Immobilised 1,5,9-triaza-cyclododecane ([12]aneN3) complexes 
No reports on immobilized [12]aneN3 complexes have been appeared in literature so 
far. 
13. Structures of 1,4,7-triaza-cyclononane ([9]aneN3 or TACN) 
complexes in solid state 
Cu(II) complexes 
The smallest azamacrocycle which forms metal complexes is [9]aneN3. Its Cu(II) 
complex binds to the amino acid histidine, forming a square pyramidal Cu(II) 
coordination geometry157. The X-ray structure analysis confirms that the distorted 
square-pyramidal Cu(II) coordination sphere is comprised of three nitrogen donors 
from the [9]aneN3 plus one carboxylate atom and the primary nitrogen from L-
histidine (Fig. 34). 
Fig. 34. The structure of [Cu(TACN)(histidine)]2+(PF6)- in the solid state. 
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14. Structures of 1,4,7-triaza-cyclononane ([9]aneN3 or TACN) 
complexes in solid state (tabulated) 
Table 10 summarizes all X-ray structures registered at the Cambridge 
Crystallographic Database according to the selection criteria previously mentioned.  
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Table 10.  Structurally characterized metal complexes of 1,4,7-triaza-cyclononane ([9ane]N3 or TACN) with additional ligand coordinated to the metal ion in
 solid state. 
Structure of the Metal ions 
additional ligand Zn2+ Cu2+ Ni2+ Co3+ Rh3+ Fe3+ Fe2+ Ru2+ Mn3+ Cr3+ V3+ Zr4+ 
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Substitution – none; R3 = aryl; (4) Substitution – n-alkyl; R4 = CH2Ph; (5) Substitution – n-alkyl; R4 = Ph; (6) Substitution – none; (7) a) Substitution – none; (8) a) 
Substitution – n-CH2Ph; (8) b) Substitution – n-alkyl; (9) Substitution – n-alkyl; (10) Substitution – n-alkyl; (11) Substitution – n-alkyl; (12) Substitution – n-alkyl; R8 = 
CH3; (13) Substitution – n-alkyl; R8 = Ph; (14) Substitution – n-alkyl; R8 = Ph; (15) Substitution – n-alkyl; R8 = CH3; (16) Substitution – n-alkyl; R8 = CH3; (17) 
Substitution – n-alkyl; R8 = CH3; (18) Substitution – n-alkyl; R8 = CH3; (19) Substitution – none; R8 = CH3; (20) Substitution – n-alkyl; (21) Substitution – n-alkyl; (22) 
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alkyl; R7 = H; (30) b) Substitution – none; R7 = CH3; (31) Substitution – none; (32) Substitution – n-alkyl; R7 = Ph, R8 = tert-butyl.  
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15. Molecular recognition of 1,4,7-triaza-cyclononane ([9]aneN3 or 
TACN) complexes in solution 
Cu(II) complexes 
TACN chelates Cu(II) strongly (log K = 15.5 at 25 °C)196. Above pH 8 one of the two 
equatorial coordination sites available on the copper atom is occupied by a hydroxide 
ion197. Above pH 9 glucose readily displaces water and hydroxide to form a ternary 
TACN-Cu(II)-glucose complex, which results in the net release of protons (Fig. 35). 
The measurement of this proton release by pH titration gives apparent binding 
constants of 35 M-1 at pH 10.25 to 1200 M-1 at pH 11.5 for the complexation of Cu(II) 
TACN with glucose198. The Cu(II) TACN complex exhibits considerable selectivity 
depending on the diol. At alkaline pH it can bind cis-diols 1,4-anhydroerythritol and 
glucose, while trans-diol sugar analogue and 1,4-anhydro-L-threitol cannot be 
coordinated.  
Fig. 35. The Cu(II) TACN complex coordinates glucose at alkaline pH. 
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+ 2+
+ H+ + 2 H2O  
In addition recent investigations of a TACN cobalt complexe have shown interactions 
with calf-thymus DNA (CT DNA) by visometric and electrochemical studies199. The 
metal complex binds on the DNA surface with no possibility for partial intercalation 
interaction. 
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16. Immobilised 1,4,7-triaza-cyclononane ([9]aneN3 or TACN) 
complexes 
Cu(II) complexes 
A polymerizable TACN-Cu(II)-glucopyranoside complex has been copolymerized with 
a cross linking monomer to form a porous polymer198. After washing to remove the 
template, a polymer which rebinds glucose and thereby releasing protons in to the 
surrounding solution was created (Fig. 36). The change in pH provides a convenient 
measure of glucose concentration over a clinically relevant range (0-25 mM) 
(Fig. 37). 
Fig. 36. Preparation of a glucose sensing Cu(II) TACN containing polymer. 
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Fig. 37. Titration of methyl-ß-D-glucopyranoside-imprinted polymer (0.034 mmol Cu(II)) with D-
 glucose in 0.15 M NaCl, 25 °C at pH 10.25, 10.75 and 11.25 at constant pH. 
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The high ratio of cross-linker in the polymer generates a microporous polymer which 
allows the small glucose molecules to bind, but hinders larger molecules such as 
glycosylated proteins which may otherwise also bind to the metal complex. The 
polymers ability to sense glucose is not impeded by the many potential competing 
species present in a complex biological sample such as porcine plasma (adjusted to 
pH 11.25)200.  
17. Conclusion 
A variety of transition metal complexes from cyclen, cyclam to TACN reversibly 
coordinate additional donor molecules in the solid state, in solution or immobilized on 
polymer support. In many cases this coordination of an additional ligand is selective 
for a particular functional group. In solution binding affinities in the milli or micromolar 
range are observed, even at physiological conditions. This allows the selective 
molecular recognition of target molecules with high binding strength in biological 
media, a process which is difficult to achive using synthetic receptors based on 
hydrogen bonding. Therefore many transition metal complexes of azamacrocyclic 
ligands are ideally suited as molecular binding sites for analytes, and many 
applications in diagnostics, bioanaytics, biotechnology or material sciences may be 
envisaged. 
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V.  Appendix 
1. ABBREVIATIONS 
AC adenylyl cyclase 
Ac acetyl  
ANT anthraniloyl 
ATP adenosine 5’-triphosphate 
AU arbitrary unit 
CaM Calmodulin 
cAMP adenosine 3’,5’-cyclic 
monophosphate  
CTP cytidine 5’-triphosphate 
CyaA exotoxin AC of Bordetella 
pertussis 
d- deoxy 
DAD diode array detector 
DNA deoxyribonucleic acid 
EDTA ethylene diaminetetraacetic 
acid disodium salt 
EF edema factor 
EGTA  ethylene glycol tetraacetic 
acid  
EI electronic ionisation 
eq equivalents 
ESI electronic spray ionisation 
Fig. figure 
FRET fluorescent resonance 
energy transfer 
FS forskolin 
GPCR G-protein coupled receptor 
GTP guanosine 5’-triphosphate 
GTPγS guanosine 5’-(γ-thio) 
triphosphate 
HEPES 4-(2-hydroxyethyl)-
piperazine-1-ethane 
sulfonic acid 
HMBC heteronuclear multiple 
bond coherence 
HPLC high performance liquid 
chromatography 
HSQC heteronuclear single 
quantum coherence 
IC50 half-maximal inhibition 
concentration 
IR infrared spectroscopy 
IMP inosine 5’-monophosphate 
ITP inosine 5’-triphosphate 
ITPγS inosine 5’-(γ-thio) 
triphosphate 
J coupling constant 
k capacity factor 
Kd dissociation constant 
Ki inhibition constant 
Km Michaelis Menten constant 
KO knockout  
LC liquid chromatography 
LTP long-term potentiation 
mAC membranous adenylyl 
cyclase 
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MANT methyl anthraniloyl 
mAU  milli absorbance unit  
Mp melting point  
mRNA messenger ribonucleic acid 
MS mass spectroscopy 
MW molecular weight 
n. d. not determined 
NDP nucleoside 5’-diphosphate 
NMP nucleoside 5’-mono 
phosphate 
NMR nuclear magnetic 
resonance 
NOE nuclear overhauser effect 
NTP nucleoside 5’-triphosphate 
PDB protein data bank 
PKA protein kinase A 
PKC protein kinase C 
PMEapp 9-[2-(phosphonomethoxy) 
ethyl]adenine diphosphate 
PMT photomultiplier  
PPi pyrophosphate  
Pr propyl 
PTFE polytetrafluorethylene 
Rf retention factor 
Rt retention time 
sAC soluble adenylyl cyclase 
SD standard deviation 
Sf Spodoptera frugiperda 
TNP 2,4,6 trinitrophenyl 
TLC thin layer chromatography 
UTP uridine 5’-triphospate 
UV ultraviolet 
Vis visible 
Vmax maximal velocity 
vol/vol volume/volume 
vs versus 
XTP xanthosine 5’-triphospate
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